

# SENTARA COMMUNITY COMPLETE (HMO D-SNP) PRIOR AUTHORIZATION CRITERIA

(01/01/2026 - 01/31/2026)

Certain covered drugs may have additional requirements or limitations regarding coverage. We have made available documentation that outlines our criteria for Prior Authorization requirements.

PLEASE READ: This document contains information about some of the drugs we cover in this plan.

The Prior Authorization Criteria was updated on 10/15/2025

### **ABIRATERONE ACETATE**

#### **Products Affected**

• abiraterone oral tablet 250 mg, 500 mg • abirtega

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Initial: Approve if the member has a diagnosis of metastatic, castration resistant or castration-sensitive prostate cancer and meets the following (A and B): A) Requested medication will be taken with a gonadotropin-releasing hormone (GnRH) analog concurrently or member had a bilateral orchiectomy, AND B) Medication will be taken with prednisone either once daily or twice daily depending on diagnosis. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation that disease progression has not occurred required.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

# **ACITRETIN**

#### **Products Affected**

• acitretin

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a dermatologist
Coverage Duration	12 months
Other Criteria	Initial: Member must have a diagnosis of psoriasis with a trial and failure or contraindication to methotrexate or cyclosporine prior to approval. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

# **ACTIMMUNE**

#### **Products Affected**

• ACTIMMUNE

PA Criteria	Criteria Details
Exclusion Criteria	Simultaneous administration of requested medication with other heterologous serum protein or immunological preparations (e.g., vaccines)
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Chronic Granulomatous Disease: Prescribed by or in consultation with an immunologist, hematologist, or an infectious diseases specialist. Malignant osteopetrosis: Prescribed by or in consultation with an endocrinologist or hematologist.
Coverage Duration	12 months
Other Criteria	Chronic Granulomatous Disease (CGD)-Initial: Approve if diagnosis has been established by one of the following tests: Nitroblue tetrazolium test (negative), Dihydrorhodamine test (DHR + neutrophils less than 95 percent), a molecular genetic test identifying a gene-related mutation linked to chronic granulomatous disease or immunoblot positive for p22phox, p40phox, p47phox, p67phox, or gp91phox. Must have a trial and failure of trimethoprim/sulfamethoxazole AND itraconazole or an intolerance or contraindication to those therapies. Severe malignant osteopetrosis (SMO)-Initial: Approve if patient has diagnosis has been established by a molecular genetic test identifying a gene-related mutation linked to severe malignant osteopetrosis OR radiographic (X-ray) imaging demonstrating skeletal features related to osteopetrosis. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

# **ACUTE HAE**

#### **Products Affected**

• icatibant

• sajazir

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

### **ADALIMUMAB**

- HADLIMA
- HADLIMA PUSHTOUCH
- HADLIMA(CF)
- HADLIMA(CF) PUSHTOUCH
- SIMLANDI(CF) AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR, KIT 40 MG/0.4 ML, 80 MG/0.8 ML
- SIMLANDI(CF) SUBCUTANEOUS SYRINGE KIT 20 MG/0.2 ML, 40 MG/0.4 ML, 80 MG/0.8 ML

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

### **ADBRY**

#### **Products Affected**

• ADBRY

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with any other monoclonal antibody that can be used to treat the same indication as the requested medication
Required Medical Information	Diagnosis
Age Restrictions	12 years and older
Prescriber Restrictions	Must be prescribed by or in consultation with an allergist, immunologist, or dermatologist.
Coverage Duration	12 months
Other Criteria	Atopic Dermatitis (AD)-Initial: Approve if member has a diagnosis of atopic dermatitis and has tried and failed one prescription strength topical corticosteroid OR tacrolimus ointment. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

# **ADEMPAS**

#### **Products Affected**

• ADEMPAS

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist or a pulmonologist
Coverage Duration	12 months
Other Criteria	Initial: Approve if the member has a diagnosis of pulmonary arterial hypertension (PAH) with chart notes documenting all the following are required: A) mean arterial pressure (mPAP) measured greater than or equal to 20 mmHg at rest, B) pulmonary artery wedge pressure (PAWP) measured less than or equal to 15 mmHg, AND C) pulmonary vascular resistance (PVR) greater than or equal to 2 woods units. Member must meet either A or B: A) Member has PAH WHO Group 1 confirmed by hemodynamic definitions obtained from a right heart catheterization (RHC) (documentation required) AND member has tried and failed or has a contraindication to sildenafil OR B) Member has PAH WHO Group 4, which includes Chronic Thromboembolic Pulmonary Hypertension (CTEPH) with the member meeting BOTH i and ii (documentation required): i) Diagnosis of CTEPH is confirmed by CT pulmonary angiography, pulmonary angiography, or V/Q (ventilation-perfusion) scan. Member must have tried and failed surgical treatment or member has inoperable CTEPH. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	No

# AG EPCLUSA

#### **Products Affected**

• SOFOSBUVIR-VELPATASVIR

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

# **AG HARVONI**

#### **Products Affected**

• LEDIPASVIR-SOFOSBUVIR

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

# **AIMOVIG**

#### **Products Affected**

• AIMOVIG AUTOINJECTOR

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

# **AKEEGA**

#### **Products Affected**

AKEEGA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Prostate cancer-Initial: Approve if the member meets the following (A, B, C, and D): A) Patient has metastatic castration-resistant prostate cancer, AND B) Member has deleterious or suspected deleterious BRCA-mutated (BRCAm) disease as determined by an FDA-approved test, AND C) The medication is used in combination with prednisone, AND D) Patient meets one of the following (i or ii): i. The medication is used concurrently with a gonadotropin-releasing hormone (GnRH) analog OR ii. Member has had a bilateral orchiectomy Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

# **ALECENSA**

### **Products Affected**

• ALECENSA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Non-Small Cell Lung Cancer (NSCLC)-Initial: Approve if the member has anaplastic lymphona kinase (ALK) positive disease as detected by an FDA approved test and meets either A or B: A) Member has metastatic disease OR B) Member will be using medication as adjuvant treatment following tumor resection (tumors greater than or equal to 4 cm or node positive). Provider must attest to monitoring liver laboratory tests every two weeks during the first three months of treatment, then once a month and as clinically indication, with more frequent testing in members who develop transaminase and bilirubin elevations. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

# **ALOSETRON**

#### **Products Affected**

alosetron

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

# **ALPHA 1 PROTEINASE INHIBITORS**

#### **Products Affected**

• PROLASTIN-C INTRAVENOUS SOLUTION

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

### **ALUNBRIG**

- ALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MG
- ALUNBRIG ORAL TABLETS, DOSE PACK

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Non-Small Cell Lung Cancer (NSCLC)-Initial: Approve if the member has metastatic disease that is anaplastic lymphona kinase (ALK) positive as detected by an FDA approved test. Member must have a trial and failure of alectinib (Alecensa) prior to approval or a medical reason as to why it cannot be started or continued. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

# **AMBRISENTAN**

#### **Products Affected**

• ambrisentan

PA Criteria	Criteria Details
Exclusion Criteria	Pregnancy, idiopathic pulmonary fibrosis (IPF)
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist or a pulmonologist.
Coverage Duration	12 months
Other Criteria	Intial: Member must have a diagnosis of pulmonary arterial hypertension (PAH) World Health Organization (WHO) Group 1. PAH must be confirmed by right heart catherterization. Must have chart documentation of right heart catheterization that indicates the following hemodynamic values: mean pulmonary arterial pressure greater than 20 mmHg, pulmonary capillary wedge pressure OR left atrial pressure OR left ventricular end-diastolic pressure less than or equal to 15 mmHg, pulmonary vascular resistance greater than or equal to 3 wood units. Must have baseline negative pregnancy test prior to initiation of therapy if a natal female of reproductive potential. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

### **ANTIDEPRESSANTS**

- AUVELITY
- FETZIMA ORAL CAPSULE,EXT REL 24HR DOSE PACK 20 MG (2)- 40 MG (26)
- FETZIMA ORAL CAPSULE,EXTENDED RELEASE 24 HR
- TRINTELLIX

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Initial: Approve if member has had prior therapy, contraindication, or intolerance in adequate doses (i.e. as determined by the treating provider based on individual patient characteristics) and duration (i.e. at least 8 weeks for each antidepressant) with either A or B: A) two preferred SSRIs or B) one preferred SSRI AND venlafaxine ER. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

# **ANTIFUNGALS (IV)**

- fluconazole in nacl (iso-osm) intravenous voriconazole intravenous piggyback 200 mg/100 ml, 400 mg/200 ml

piggyouck 200 mg/100 mi, 400 mg/200 mi	
PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	3 months
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

### **APTIOM**

#### **Products Affected**

• eslicarbazepine oral tablet 200 mg, 400 mg, 600 mg, 800 mg

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	12 months
Other Criteria	Initial: Approve if member has a diagnosis of partial-onset seizures (i.e. focal seizures). Member must have tried and failed or have a contraindication to two or more generic formulary antiepileptic medications used to treat the same indication: levetiracetam, lamotrigine, carbamazepine, zonisamide, divalproex, gabapentin, or topiramate. Provider must attest the member will not be taking the medication concomitantly with oxcarbazepine.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

# **ARCALYST**

#### **Products Affected**

• ARCALYST

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with biologics
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	CAPS: Prescribed by or in consultation with a rheumatologist, geneticist, allergist/immunologist, or dermatologist. DIRA: Prescribed by or in consultation with a rheumatologist, geneticist, dermatologist, or a physician specializing in the treatment of autoinflammatory disorders. Pericarditis: Prescribed by or on consultation with a cardiologist or rheumologist.
Coverage Duration	12 months
Other Criteria	Cryopyrin-Associated Periodic Syndromes (CAPS)-Initial-Approve if the member is at least 12 years of age and has a confirmed diagnosis of CAPS, including Familial Cold Autoinflammatory Syndrome (FCAS), and Muckle-Wells Syndrome (MWS). Deficiency of Interleukin-1 Receptor Antagonist (DIRA)-Initial: Approve if the member weighs at least 10 kg AND a genetic test confirms a mutation in the IL1RN gene. Must have a trial and failure of anakinra (Kineret) prior to approval. Pericarditis-Initial: Approve if the member is at least 12 years of age and has a diagnosis of recurrent pericarditis (defined as two recurrent episodes that occur a minimum of 4 to 6 weeks apart) and symptoms consist of one of the following: pericarditis chest pain, pericardial rub, pericardial effusion, or ST-segment elevation or PR depression. Member must have a trial and failure or contraindication to colchicine. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

# **ARIKAYCE**

#### **Products Affected**

• ARIKAYCE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by a pulmonologist, infectious disease physician or a physician who specializes in the treatment of MAC lung infections
Coverage Duration	12 months
Other Criteria	Mycobacterium Avium Complex (MAC)-Initial-Approve if the member has a positive sputum culture for mycobacterium avium complex for which the member has limited or no alternative treatment options. Member must have failed to achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy (e.g. macrolide (azithromycin or clarithromycin), ethambutol, and a rifamycin (rifampin or rifabutin)). Member's culture must have been collected after the 6 month multidrug therapy completion. The Mycobacterium avium complex isolate must be susceptible to the requested medication with a minimum inhibitor concentration (MIC) of less than or equal to 64 microgram/mL AND medication will be used in conjunction to a background multidrug regimen. Note-a multidrug regimen typically includes a macrolide (azithromycin or clarithromycin), ethambutol and a rifamycin (rifampin or rifabutin). Reauthorization: Approve if the requested medication will be used in conjunction with a background multidrug regimen AND i. Member meets ONE of the following criteria (A or B): A)Member has not achieved negative sputum cultures for Mycobacterium avium complex OR B) Member has not achieved 3 consecutive negative monthly sputum cultures by month 6.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

# **ARMODAFINIL**

#### **Products Affected**

• armodafinil

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

### **ATYPICAL ANTIPSYCHOTICS**

- CAPLYTA
- FANAPT
- FANAPT TITRATION PACK A
- FANAPT TITRATION PACK B
- FANAPT TITRATION PACK C
- LYBALVI
- REXULTI ORAL TABLET
- SECUADO
- VRAYLAR ORAL CAPSULE

• FANAPI TITRATION PACK C	
PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

# **AUGTYRO**

#### **Products Affected**

• AUGTYRO ORAL CAPSULE 160 MG, 40 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Non-Small Cell Lung Cancer (NSCLC)-Initial: Approve if the member has locally advanced or metastatic disease. Member must have ROS1-positive arrangement mutation as detected by an approved test. Solid Tumors-Initial: Approve if the member has solid tumors meeting all the following A, B, C: A) Tumor has a neurotropic tyrosine receptor kinase (NTRK) gene fusion as detected by an FDA-approved test, B) Tumors are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and C) Tumors have progressed following treatment or have no satisfactory alternative therapy. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

### **AUSTEDO**

#### **Products Affected**

- AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG
- AUSTEDO XR

• AUSTEDO XR TITRATION KT(WK1-4) ORAL TABLET, EXT REL 24HR DOSE PACK 12-18-24-30 MG

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

# **AVMAPKI-FAKZYNJA**

#### **Products Affected**

• AVMAPKI-FAKZYNJA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Initial: Approve if the member has a diagnosis of low-grade serous ovarian cancer (LGSOC) that is KRAS-mutated as determined by an FDA-approved test. Disease must be recurrent after prior systemic therapy. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **AVONEX**

- AVONEX INTRAMUSCULAR PEN INJECTOR KIT
- AVONEX INTRAMUSCULAR SYRINGE KIT

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use of other disease-modifying agent used for multiple sclerosis
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or after consultation with a neurologist or an MS specialist.
Coverage Duration	12 months
Other Criteria	Initial: Approve if member has a diagnosis of relapsing forms of multiple sclerosis (RRMS). Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

### **AYVAKIT**

#### **Products Affected**

• AYVAKIT

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	GIST-Initial: Member must have a confirmed diagnosis of gastrointestinal stromal tumor (GIST) that harbors a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations as detected by an FDA-approved test. Member must have tried and failed two or more of the following prior to request: imatinib, sunitinib, dasatinib, regorafenib, or ripretinib. Systemic Mastocytosis-Initial: Member must have a platelet count greater than or equal to 50,000/mcL. Member has confirmed diagnosis of indolent systemic mastocytosis (ISM) or one of the following subtypes of advanced systemic mastocytosis (AdvSM): aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL). All Indications-Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

### **BALVERSA**

#### **Products Affected**

• BALVERSA ORAL TABLET 3 MG, 4 MG, 5 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Urothelial Carcinoma-Initial: Approve if the member meets A, B, and C: A) Member must have locally advanced or metastatic disease, B) Member has susceptible fibroblast growth factor receptor 3 (FGFR3) genetic alterations, and C) Member's disease has progressed on or after at least one line of prior systemic therapy including a Programmed Cell Death Protein 1 (PD-1) or Programmed Death-Ligand 1 (PD-L1) inhibitor (i.e. avelumab, pembrolizumab), if eligible. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **BENLYSTA**

#### **Products Affected**

• BENLYSTA SUBCUTANEOUS

PA Criteria	Criteria Details
Exclusion Criteria	Severe active central nervous system lupus or concomitant therapy with biologic therapies
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	SLE-Prescribed by or in consultation with a rheumatologist. Lupus Nephritis-Prescribed by or in consultation with a nephrologist or rheumologist.
Coverage Duration	Initial: 6 months, Reauthorization: 12 months
Other Criteria	Systemic Lupus Erythematosus (SLE)-Initial: Approve if the patient has autoantibody-positive SLE with documentation of one of the following: 1) Positive antinuclear antibodies (ANA) titre greater than or equal to 1:80 and/or anti-double-stranded DNA antibody [anti-dsDNA] above the upper limit of normal (based on reference range provided by the laboratory). Must have a trial and failure or contraindication of hydroxychloroquine, azathioprine, methotrexate, or mycophenolate. Must be on concomitant therapy with one of the following: non-steroidal anti-inflammatory drugs (NSAIDs), antimalarials, corticosteroids, or immunosuppressants. SLE-Reauthorization: Documentation from prescriber indicating improvement in condition and continual use of standard therapy (i.e. corticosteroids, antimalarials, NSAIDs, or immunosuppressants). Lupus Nephritis (LN)-Initial: Must have active lupus nephritis confirmed by a kidney biopsy (documenation required). Baseline renal function showing proteinuria must be submitted. Member must be on concomitant standard immunosuppressive therapy (defined as induction therapy with systemic corticosteroids and mycophenolate or cyclophosphamide followed by maintenance therapy with mycophenolate mofetil or azathioprine)). Must not be used in combination with voclosporin (Lupkynis). LN-Reauthorization: Member continues to receive immunosuppressive therapy with mycophenolate mofetil or azathioprine. Provider submits renal

PA Criteria	Criteria Details
	function tests showing improvement from baseline (e.g. decreased proteinuria, improvement in urine creatinine ratio, improved eGFR, etc).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **BESREMI**

#### **Products Affected**

• BESREMI

PA Criteria	Criteria Details
Exclusion Criteria	Existence of, or history of severe psychiatric disorders, particularly severe depression, suicidal ideation or suicide attempt, hepatic impairment (Child-Pugh B or C), history or presence of active serious or untreated autoimmune disease, immunosuppressed transplant recipients
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	12 months
Other Criteria	Polycythemia Vera (PV)-Initial: Member must have confirmed diagnosis based on one the following: 1) Hemoglobin greater than 16.5 g/dL for men or 16.0 g/dL for women, 2) Hematocrit greater than 49% for men or 48% for women, 3) Increased red cell mass based on reference range provided by the laboratory. Member must have a trial and failure or contraindication to hydroxyurea prior to approval.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **BETASERON**

#### **Products Affected**

• BETASERON SUBCUTANEOUS KIT

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with other disease-modifying agent used for multiple sclerosis
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or after consultation with a neurologist or an MS specialist.
Coverage Duration	12 months
Other Criteria	Initial: Approve if member has a diagnosis of relapsing forms of multiple sclerosis (RRMS). Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

# **BEXAROTENE (ORAL)**

#### **Products Affected**

• bexarotene oral

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Cutaneous T-Cell Lymphoma (CTCL)-Initial: Approve if the member has diagnosis AND is refractory to at least one prior systemic therapy. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

# **BEXAROTENE (TOPICAL)**

#### **Products Affected**

• bexarotene topical

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist, hematologist, or dermatologist
Coverage Duration	12 months
Other Criteria	Cutaneous T-Cell Lymphoma (CTCL)-Initial: Approve if the member has diagnosis (Stage IA and IB) AND disease is refractory or persistent after other therapies or who have not tolerated other therapies. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **BOSENTAN**

#### **Products Affected**

• bosentan oral tablet

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist or a pulmonologist.
Coverage Duration	12 months
Other Criteria	Intial: Member must have a diagnosis of pulmonary arterial hypertension (PAH) World Health Organization (WHO) Group 1. PAH must be confirmed by right heart catherterization. Must have chart documentation of right heart catheterization that indicates the following hemodynamic values: mean pulmonary arterial pressure greater than 20 mmHhg, pulmonary capillary wedge pressure OR left atrial pressure OR left ventricular end-diastolic pressure less than or equal to 15 mmHg, pulmonary vascular resistance greater than or equal to 3 wood units. Must have WHO Functional Class II-IV symptoms. Must have baseline liver function tests (AST, ALT), prior to initiation of therapy. Must have baseline negative pregnancy test prior to initiation of therapy if a natal female of reproductive potential. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

### **BOSULIF**

#### **Products Affected**

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Chronic Myelogenous Leukemia (CML)-Initial: Approve if the member meets A or B: A) Member is an adult with accelerated, or blast phase philadelphia chromosome positive (Ph+) CML AND had resistance or intolerance to prior therapy or B) Member has chronic phase CML, newly-diagnosed or resistant or intolerant to prior therapy. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **BOTOX**

#### **Products Affected**

• BOTOX

PA Criteria	Criteria Details
Exclusion Criteria	Use in the management of cosmetic uses (eg, facial rhytides, frown lines, glabellar wrinkling, horizontal neck rhytides, mid and lower face and neck rejuvenation, platsymal bands, rejuvenation of the peri-orbital region)
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Migraine headache prevention-prescribed by, or after consultation with, a neurologist or HA specialist.
Coverage Duration	Authorization will be for 12 months
Other Criteria	Blepharospasm Associated with Dystonia or Strabismus-approve, Cervical Dystonia-approve, Hyperhidrosis, primary axillary-approve, Chronic low back pain after trial with at least 2 other pharmacologic therapies (eg, NSAID, antispasmodics, muscle relaxants, opioids, antidepressants) and if being used as part of a multimodal therapeutic pain management program. Essential tremor after a trial with at least 1 other pharmacologic therapy (eg, primidone, propranolol, benzodiazepines, gabapentin, topiramate), Migraine Headache Prevention-must have 15 or more migraine headache days per month with headache lasting 4 hours per day or longer (prior to initiation of Botox therapy) AND have tried at least two standard prophylactic pharmacologic therapies, each from a different pharmacologic class (e.g., beta-blocker, anticonvulsant, tricyclic antidepressant) and patient has had inadequate efficacy or adverse events. If the patient is currently taking Botox for migraine headache prevention, patient must have had significant clinical benefit. Overactive bladder with symptoms of urge urinary incontinence, urgency and frequency-approve if the patient has tried at least one other pharmacologic therapy. Spasticity, limb-approve. Urinary incontinence associated with a neurological condition-approve if the patient has tried at least one other pharmacologic therapy.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.

PA Criteria	Criteria Details
Off-Label Uses	Achalasia, Anal Fissure, Chronic facial pain/pain associated with TMJ dysfunction, Chronic low back pain, Dystonia, other than cervical, Essential tremor, Hyperhidrosis, gustatory, hyperhidrosis, Palmar/Plantar and facial, Myofascial pain, Ophthalmic disorders, other than blepharospasm or Strabismus, Sialorrhea, chronic, Spasticity, other than limb (i.e., due to cerebral palsy, stroke, brain injury, spinal cord injury, MS, hemifacial spasm)
Part B Prerequisite	No
Prerequisite Therapy Required	No

## **BRAFTOVI**

#### **Products Affected**

• BRAFTOVI

PA Criteria	Criteria Details
Exclusion Criteria	Members with wild-type BRAF melanoma, wild-type BRAF CRC, or wild-type BRAF NSCLC
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Melanoma-Initial: Approve if the member has unresectable, advanced or metastatic melanoma with a BRAF V600E or V600K mutation as detected by an FDA-approved test. Medication must be used in combination with binimetinib (Mektovi). Colorectal Cancer (CRC)-Initial: Approve if the member has metastatic disease with BRAF V600E mutation as detected by an FDA-approved test and meets one of the following criteria A or B: A) The requested medication will be used in combination with cetuximab and mFOLFOX6 or B) Member has history of prior therapy for mCRC AND requested medication will be used in combination with cetuximab. NSCLC-Initial: Approve if member has metastatic disease with a BRAF V600E mutation as detected by an FDA-approved test AND medication will be taken in combination with binimetinib (Mektovi). Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

### **BRIVIACT**

#### **Products Affected**

- BRIVIACT ORAL SOLUTION BRIVIACT ORAL TABLET

DA G '	
PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	12 months
Other Criteria	Initial-Approve if member has a diagnosis of partial-onset seizures.  Member must have a trial and failure or contraindication to two generic formulary antiepileptic drugs (i.e. levetiracetam, topiramate, lamotrigine). Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **BRUKINSA**

#### **Products Affected**

• BRUKINSA ORAL CAPSULE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Mantle Cell Lymphoma (MCL)-Initial: Approve if the member has tried at least one other therapy prior to requested medication. Marginal Zone Lymphoma-Initial: Approve if the member has relapsed or refractory disease after a trial and failure of at least one anti-CD20 based regimen prior to the requested medication. Chronic Lymphocytic Leukemia (CLL)/Small lymphocyctic lymphoma (SLL) or Waldenstrom Macroglobulinemia (WM)- Initial: Approve. Chronic Lymphocytic Leukemia (CLL)/Small lymphocyctic lymphoma (SLL)-Approve. Follicular Lymphoma (FL)-Initial: Approve if member has refractory or relapsed disease after a trial and failure of at least two or more systemic regimens prior to requested medication AND member will be using in combination with obinutuzumab (Gazyva).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

# **BUDESONIDE EC (UCERIS)**

#### **Products Affected**

• budesonide oral tablet, delayed and ext.release

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with a gastroenterologist
Coverage Duration	2 months
Other Criteria	Initial: Approve if member has a diagnosis of mild to moderate active ulcerative colitis and medication will be used to induce remission of active disease. Member must have had previous treatment or intolerance to at least two of the following: sulfasalazine, balsalazide capsules, mesalamine enema or mesalamine 0.375g extended-release prior to approval. Reauthorization: Must have documentation of concurrent maintenance treatment of ulcerative colitis and and either clinical rationale from prescriber for continuation of treatment beyond 8 weeks or documentation that member is experiencing a subsequent flare-up and experienced improvement in the condition as a result of treatment with budesonide during a previous flare-up.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### C1 ESTERASE INHIBITORS

#### **Products Affected**

HAEGARDA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an allergist or immunologist
Coverage Duration	12 months
Other Criteria	Hereditary Angioedema (HAE) due to C1 Inhibitor (C1-INH) Deficiency [Type I or Type II]-Initial: Approve if the member has diagnosis of HAE and confirmatory lab values (documentation with lab reference ranges required). Chart note documentation showing history of previous HAE attacks to demonstrate member is a candidate for prophylactic therapy is required. Medication must be used as prophylactic therapy for prevention of HAE attacks. For Type I: low C4 complement level in mg/dL, normal C1q complement component level in mg/dL (C1q complement component level is not required for members under 18 years of age or if symptoms began before 18 years of age), and either low C1 esterase inhibitor antigenic level in mg/dL or low C1 esterase inhibitor functional level expressed as a percent. For Type II: low C4 complement level in mg/dL, normal C1q complement component level in mg/dL (C1q complement component level is not required for members under 18 years of age or if symptoms began before 18 years of age), and low C1 esterase inhibitor functional level expressed as a percent. Must not be on concurrent therapy with another prophylactic drug for HAE. Reauthorization: Member must not be on concurrent therapy with another prophylactic drug for HAE. Documentation submitted indicating improvement in condition required.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	No

### **CABOMETYX**

#### **Products Affected**

• CABOMETYX

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	DTC-12 years and older, All other indications-18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Renal Cell Carcinoma (RCC)-Initial: Approve if the member has advanced disease and either A or B: A) The member will be using the requested medication as monotherapy OR B) The member will be using the requested medication as a first-line therapy in combination with nivolumab (Opdivo). Hepatocellular Carcinoma (HCC)-Initial: Approve if the member has been previously treated with sorafenib (Nexavar) and medication will be used as monotherapy. Differentiated Thyroid Cancer (DTC)-Initial: Approve if the member will be using medication as monotherapy and meets all the following (A, B, C, and D): A) Member is at least 12 years of age or older, B) Member has locally advanced or metastatic disease, C) Member is ineligible or refractory to radioactive iodine therapy, AND D) Member has tried a vascular endothelial growth factor receptor (VEGFR)-targeted therapy. Pancreatic Neuroendocrine Tumors (pNET)-Initial: Approve if the member is at least 12 years of age with a previously treated, unresectable, locally advanced or metastatic disease and meets either A or B: A) Member has well-differentiated pNET OR B) Member has well-differentiated extrapancreatic neuroendocrine tumors (epNET). Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.

PA Criteria	Criteria Details
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

# **CALQUENCE**

#### **Products Affected**

• CALQUENCE (ACALABRUTINIB MAL)

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Mantle Cell Lymphoma (MCL)-Initial: Approve if the member meets either A or B: A) Member has tried at least one prior therapy and will be using the requested medication as monotherapy OR B) Member is ineligible for autologous hematopoietic stem cell transplant (HSCT) and has previously untreated disease. Medication will be used in combination with bendamustine (Bendeka) and rituximab. Small lymphoplasmacytic lymphoma (SLL)-Initial: Approve. Chronic lymphocytic leukemia (CLL)-Initial: Approve. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **CAPRELSA**

#### **Products Affected**

• CAPRELSA ORAL TABLET 100 MG, 300 MG

PA Criteria	Criteria Details
Exclusion Criteria	Congenital long QT syndrome
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Medullary Thyroid Cancer (MTC)-Initial: Approve if the member has symptomatic or progressive locally advanced or metastatic medllary thyroid cancer that is unresectable. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

## **CARGLUMIC ACID**

#### **Products Affected**

• carglumic acid

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a provider who specializes in the treatment of inherited metabolic disorders
Coverage Duration	NAGs, NAG, or CPS 1-Initial: 90 days, Reauth: 12 months, PA or MA: 7 days
Other Criteria	N-Acetylglutamate Synthase (NAGs)-Initial: Approve if genetic testing confirmed a mutation leading to N-acetylglutamate synthase deficiency or if the patient has hyperammonemia. Propionic Acidemia (PA) or Methylmalonic Acidemia (MA) with Hyperammonemia, Acute Treatment-approve if the patient's plasma ammonia level is greater then or equal to 50 micromol/L and the requested medication will be used in conjunction with other ammonia-lowering therapies.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

### **CAYSTON**

#### **Products Affected**

• CAYSTON

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist, infectious disease specialist, or a physician who specializes in the treatment of cystic fibrosis.
Coverage Duration	12 months
Other Criteria	Approve if the member has a positive culture for Pseudomonas aeruginosa in the airway (e.g., sputum culture, oropharyngeal culture, bronchoalveolar lavage culture). Member must be at least 7 years of age or older. Member must have FEV1 greater than or equal to 25% OR less than or equal to 75% predicted. Provider attests member is not colonized iwth Burkholderia cepacia.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

### **CENOBAMATE**

#### **Products Affected**

- XCOPRI MAINTENANCE PACK
- XCOPRI ORAL TABLET 100 MG, 150 MG, 200 MG, 25 MG, 50 MG

XCOPRI TITRATION PACK

DA Critaria Dataila	
PA Criteria	Criteria Details
Exclusion Criteria	Familial Short QT Syndrome
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	12 months
Other Criteria	Initial-Approve if member has a diagnosis of partial-onset seizures.  Member must have a trial and failure or contraindication to two generic formulary antiepileptic drugs (i.e. levetiracetam, topiramate, lamotrigine). Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **CLOBAZAM**

#### **Products Affected**

- clobazam oral suspension
- clobazam oral tablet

#### SYMPAZAN

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	12 months
Other Criteria	Lennox-Gastaut Syndrome (LGS)-Initial: Approve if member has tried one of the following: lamotrigine, topiramate, rufinamide, felbamate, or Epidiolex. Treatment refractory seizures/epilepsy-Initial: Approved if the member has tried and/or is concomitantly receiving at least two other antiepileptic drugs (e.g., valproic acid, lamotrigine, topiramate, clonazepam, levetiracetam, zonisamide, felbamate). Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **COBENFY**

#### **Products Affected**

• COBENFY

#### • COBENFY STARTER PACK

PA Criteria	Criteria Details
Exclusion Criteria	Urinary or gastric retention, untreated narrow-angle glaucoma, moderate or severe hepatic impairment
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Initial: Approve if the member has a diagnosis of schizophrenia and chart note documentation showing two or more of the following symptoms: 1) delusions 2) hallucinations 3) disorganized speech 4) grossly disorganized or catatonic behavior 5) negative symptoms (i.e reduced emotion expression, lack of motivation, social withdrawal). Member must have an inadequate response or significant side effect/toxicity or have a contraindication to cariprazine (Vraylar) AND brexipiprazole (Rexulti). Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

## **COMETRIQ**

#### **Products Affected**

• COMETRIQ ORAL CAPSULE 100 MG/DAY(80 MG X1-20 MG X1), 140 MG/DAY(80 MG X1-20 MG X3), 60 MG/DAY (20 MG X 3/DAY)

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	MTC-18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Initial: Approve if the member has a diagnosis of progressive metastatic medllary thyroid cancer. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

### **COPIKTRA**

#### **Products Affected**

COPIKTRA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Chronic lymphocytic leukemia (CLL)/Small lymphocytic leukemia (SLL)-Initial: Member must have a confirmed diagnosis of CLL or SLL. Member must have tried and failed ibrutinib (Imbruvica) and one more prior line of systemic therapy for the same indication prior to request. CLL/SLL-Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **CORLANOR**

#### **Products Affected**

- CORLANOR ORAL SOLUTION
- ivabradine

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

### **COSENTYX**

#### **Products Affected**

- COSENTYX (2 SYRINGES)
- COSENTYX PEN
- COSENTYX PEN (2 PENS)
- COSENTYX SUBCUTANEOUS SYRINGE 150 MG/ML, 75 MG/0.5 ML
  - COSENTYX UNOREADY PEN

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with other biologics, targeted synthetic DMARDs, potent immunosuppressants, anti-interleukin monoclonal antibodies, or janus kinase inhibitors.
Required Medical Information	Diagnosis, For all pre-requisite drug trials, members who have already been on biologic therpies not required to step back and try a traditional systemic agent (i.e. conventional systemic DMARDs).
Age Restrictions	HS: 18 years and older
Prescriber Restrictions	All indications must be prescribed by or in consultation with the following: PsO and HS: Dermatologist. PsA: Rheumatologist or dermatologist. AS, nr-axSpA, ERA: Rheumatologist.
Coverage Duration	12 months
Other Criteria	Ankylosing Spondylitis (AS)-Initial: Approve if the member has signs and symptoms of active disease (i.e. back pain and stiffness in the lower back and hips, neck pain and fatigue, skin rashes) and member has tried and failed or have a contraindication to an NSAID at target anti-inflammatory doses or maximally tolerated dose. Non-radiographic Axial Spondyloarthritis (nr-axSpA)-Initial: Approve if the member has at least one documented magnetic resonance imaging (MRI) scan with results showing inflammation OR C-reactive protein (CRP) levels above the upper limit of normal. Member must have tried and failed or have a contraindication to an NSAID at target anti-inflammatory doses or maximally tolerated dose. Psoriatic Arthritis (PsA)/Enthesitis Related Arthritis (ERA)-Initial: Approve if the member has active disease as determined by the presence of at least one of the following (documentation required): actively inflamed joints, dactylitis, enthesitis, axial disease, active skin or nail involvement, or extraarticular manifestations such as uveitis or inflammatory bowel disease (IBD). For ERA only, member must have tried and failed or have a contraindication to an NSAID at target anti-inflammatory doses or maximally tolerated dose. Plaque Psoriasis (PsO)-

PA Criteria	Criteria Details
	Initial: Approve if the member has chronic moderate to severe disease and member has tried and failed or has a contraindication to at least one systemic therapy for 3 months with inadequate results (i.e. phototherapy, methotrexate, acitretin). Hidradenitis Suppurativa (HS)-Initial: Approve if the member has moderate to severe disease defined as Hurley Stage II (i.e. one or more widely separated recurrent abscesses with tract information and scars) or Hurley Stage III (i.e. multiple interconnected tracts and abscesses throughout an entire area). Member must have tried and failed or have a contraindication to at least one other therapy (e.g., intralesional or oral corticosteroids, systemic antibiotics, isotretinoin). Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

## **COTELLIC**

#### **Products Affected**

• COTELLIC

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Melanoma-Initial: Approve if the member has unresectable or metastatic melanoma with a BRAF V600E or V600K mutation as detected by an FDA-approved test. Medication must be used in combination with vemurafenib (Zelboraf). Histiocytic neoplasms-Initial: Approve if the member has diagnosis and will be using the requested medication as monotherapy. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

# **CRESEMBA (ORAL)**

#### **Products Affected**

• CRESEMBA ORAL CAPSULE 186 MG, 74.5 MG

PA Criteria	Criteria Details
Exclusion Criteria	Co-administration of strong CYP3A4 inducers (i.e. rifampin, carbamazepine, St. John's Wort, long-acting barbiturates) and strong CYP3A4 inhibitors (i.e. ketoconazole or high-dose ritonavir [400mg every 12 hours]). Members with familial short QT syndrome.
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	3 months
Other Criteria	Mucormycosis-Initial: Approve if the member has a diagnosis of mucormycosis (laboratory and clinical documentation confirming organism must be submitted). Member must have a trial and failure, intolerance, or contraindication to liposomal amphotericin B AND posaconazole prior to approval. Invasive Aspergillosis-Initial: Approve if the member has a diagnosis of invasive aspergillosis (laboratory and clinical documentation confirming organism must be submitted). Member must have a trial and failure, intolerance, or contraindication to voriconazole prior to approval. Reauthorization: Approve if the member requires secondary prophylaxis to prevent disease recurrence of invasive aspergillosis or mucormycosis and provider attests liver function tests are being monitored, and the member is NOT experiencing clinical signs and symptoms of liver disease or hepatic failure.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	Yes

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

### **CRYSVITA**

#### **Products Affected**

• CRYSVITA

PA Criteria	Criteria Details
Exclusion Criteria	Chronic Kidney Disease (CKD), Severe Renal Impairment or End Stage Renal Disease
Required Medical Information	Diagnosis, lab values
Age Restrictions	TIO-2 years and older (initial therapy)
Prescriber Restrictions	Prescribed by or in consultation with an endocrinologist or nephrologist (initial therapy)
Coverage Duration	XLH-1 year (initial/cont), TIO-initial-6 months, cont-1 year
Other Criteria	XLH-Initial therapy-Approve if the patient has had a baseline (prior to any XLH treatment) serum phosphorus level that was below the normal range for age and patient meets ONE of the following (a or b): a) The patient has had a baseline (i.e., prior to any XLH treatment tubular reabsorption of phosphate corrected for glomerular filtration rate (TmP/GFR) that was below the normal range for age and gender OR b) The patient has had a genetic test confirming the diagnosis of X-linked hypophosphatemia via identification of a PHEX mutation AND if the patient is greater than or equal to 18 years of age, the patient is currently exhibiting one or more signs or symptoms of XLH. Continuation-approve if the patient is continuing to derive benefit as determined by the prescribing physician. TIO-approve if the patient has a mesenchymal tumor that cannot be curatively resected or identified/localized AND the patient is currently exhibiting one or more signs or symptoms of TIO AND patient has had a baseline (prior to any TIO treatment) serum phosphorus level that was below the normal range for age AND patient has had a baseline (prior to any TIO treatment) tubular reabsorption of phosphate corrected for glomerular filtration rate (TmP/GFR) that was below the normal range for age and gender. Cont-approve if the patient is continuing to derive benefit as determined by the prescribing physician.
Indications	All FDA-approved Indications.

PA Criteria	Criteria Details
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

# **CYSTEAMINE (OPHTHALMIC)**

#### **Products Affected**

• CYSTARAN

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an ophthalmologist or a metabolic disease specialist or specialist who focuses in the treatment of metabolic diseases
Coverage Duration	12 months
Other Criteria	Approve if the member has corneal cysteine crystal deposits confirmed by slit-lamp examination.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

# **CYSTEAMINE (ORAL)**

#### **Products Affected**

• CYSTAGON

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with Procysbi
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a nephrologist or a metabolic disease specialist (or specialist who focuses in the treatment of metabolic diseases)
Coverage Duration	12 months
Other Criteria	Nephropathic Cystinosis-Initial: Approve if the member has a diagnosis confirmed by any of the following: 1) White blood cell cystine concentration is greater than 1 nmol per half-cystine per mg of protein using the normal reference range for the reporting laboratory, 2) Genetic testing confirmed a mutation of the CTNS gene, or 3) Elevated baseline granulocyte cystein levels greater than 1 nmol per half-cysting per mg of protein using the normal reference range for the reporting laboratory. Reauthorization: Must have documentation from prescriber indicating improvement in condition and a reduction in WBC cystine levels since beginning treatment.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

# **DALFAMPRIDINE**

#### **Products Affected**

• dalfampridine

PA Criteria	Criteria Details
Exclusion Criteria	Moderate to severe renal impairment (CrCl less than or equal to 50 mL/min), history of seizure, concomitant use with other forms of 4-aminopyridine
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consulatation with a neurologist or multiple sclerosis specialist
Coverage Duration	12 months
Other Criteria	Initial-Approve if the member is ambulatory, the requested medication is being used to improve or maintain mobility in a patient with multiple sclerois, and the member has impaired ambulation as evaluated by an objective measure (e.g., timed 25 foot walk and multiple sclerosis walking scale-12). Reauthorization-Approve if the member continues to meet all the initial criteria and has responded to or is benefiting from therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

# **DANZITEN**

#### **Products Affected**

• DANZITEN

PA Criteria	Criteria Details
Exclusion Criteria	Members with hypokalemia, hypomagnesemia, or long QT syndrome. Concomitant use of medications known to prolong the QT interval.
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Chronic Myeloid Leukemia (CML)-Initial: Approve if the member has Philadelphia chromosome positive (Ph+) disease as detected by an FDA-approved test and meets one of the following A, B, or C: A) Member has newly diagnosed disease in the chronic phase OR B) Member has chronic phase and accelerated phase Ph+ CML that is resistant to or intolerant to prior therapy that included imatinib. Provider must attest that prior to administration member will be monitored for hypokalemia or hypomagnesemia and deficiencies will be corrected. ECGs to monitor the QTc at baseline, seven days after initiation, and periodically thereafter, and following any dose adjustments. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

### **DASATINIB**

#### **Products Affected**

• dasatinib oral tablet 100 mg, 140 mg, 20 mg, 50 mg, 70 mg, 80 mg

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

### **DAURISMO**

#### **Products Affected**

• DAURISMO ORAL TABLET 100 MG, 25 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Acute Myeloid Leukemia (AML)-Initial: Approve if the member meets all the criteria A, B, C: A) Medication will be used in combination with cytarabine, B) the member is 75 years of age or older OR has comorbidities that preclude intensive chemotherapy, and C) medication will be used as a treatment for induction therapy, post-induction/consolidation therapy, or relapsed or refractory disease.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

### **DEFERASIROX**

#### **Products Affected**

• deferasirox oral tablet

• deferasirox oral tablet, dispersible

DA COM	
PA Criteria	Criteria Details
Exclusion Criteria	Concomitant advanced malignancy or high-risk myelodyspastic syndrome. Serum creatinine greater than 2 times the age-appropriate upper limit of normal or creatinine clearance less than 40 mL/min
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a hematologist
Coverage Duration	12 months
Other Criteria	Transfusion-related Iron Overload-Initial: Approve if the member member has a diagnosis of chronic iron overload from receiving blood transfusions at regular intervals for various conditions (eg, thalassemia syndromes, myelodysplastic syndrome, chronic anemia, sickle cell disease) and prior to starting therapy has a serum ferritin level greater than 1,000 mcg/L. Nontransfusion-dependent thalassemia (NTDT) syndromes chronic iron overload-Initial: Approve if member has chronic iron overload NTDT and prior to starting therapy the member has a serum ferritin level is greater than 300 mcg/L. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

### **DIABETIC SUPPLIES**

#### **Products Affected**

- alcohol pads
- GAUZE PADS 2 X 2
- INSULIN PEN NEEDLE

• INSULIN SYRINGE (DISP) U-100 0.3 ML 29 GAUGE, 1 ML 29 GAUGE X 1/2", 1/2 ML 28 GAUGE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Approve if the prescriber confirms that the medical supply is being requested for a use that is directly associated with delivering insulin to the body.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

### **DIACOMIT**

- DIACOMIT ORAL CAPSULE 250 MG, DIACOMIT ORAL POWDER IN 500 MG
  - PACKET 250 MG, 500 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an neurologist
Coverage Duration	12 months
Other Criteria	Dravet Syndrome-Initial: Approve if the member weighs 7 kg (15.4 lbs) or more and is concomitantly receiving clobazam. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

# **DICLOFENAC SODIUM (DROPS)**

#### **Products Affected**

• diclofenac sodium topical drops

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	2 months
Other Criteria	Initial: Approve if the member has a diagnosis of osteoarthritis of the knee(s). Member must have a trial and failure or contraindication to at least two of the following: diclofenac sodium, meloxicam tablets, naproxen. Provider must attest the lowest effective dose and shortest duration of treatment will be utilized. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

# **DICLOFENAC SODIUM (TOPICAL)**

#### **Products Affected**

• diclofenac sodium topical gel 3 %

PA Criteria	Criteria Details
Exclusion Criteria	Coronary Artery Bypass Graft (CABG) surgery
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	2 months
Other Criteria	Initial: Approve if the member has a diagnosis of actinic keratosis. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician and the member requires further treatment up to a maximum of 90 consecutive days.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

### **DIFICID**

- DIFICID ORAL SUSPENSION FOR DIFICID ORAL TABLET RECONSTITUTION

RECONSTITUTION	
PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

### **DIMETHYL FUMARATE**

#### **Products Affected**

• dimethyl fumarate oral capsule,delayed release(dr/ec) 120 mg, 120 mg (14)- 240 mg (46), 240 mg

PA Criteria	Criteria Details
1 A CHICHA	Ci itti ia Details
Exclusion Criteria	Concurrent use with other disease-modifying agents used for multiple sclerosis (MS).
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist or MS specialist.
Coverage Duration	12 months
Other Criteria	Initial: Approve if member has relapsing form of MS, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

### **DRIZALMA**

#### **Products Affected**

• DRIZALMA SPRINKLE ORAL CAPSULE, DELAYED REL SPRINKLE 20 MG, 30 MG, 40 MG, 60 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis. Must have documentation showing that administration via nasogastric tube is required OR documentation of inability to swallow an intact capsule.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Fibromyalgia-Initial: Member must have a trial of gabapentin solution with inadequate response or significant side effects/toxicity or have a contraindication to this therapy. GAD-Initial: Member must have a trial of sertraline concentrate with inadequate response or significant side effects/toxicity or have a contraindication to this therapy. MDD-Initial: Member must have a trial of fluoxetine solution with inadequate response or significant side effects/toxicity or have a contraindication to this therapy. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

# **DROXIDOPA**

#### **Products Affected**

droxidopa

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

### **DUPIXENT**

- DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 200 MG/1.14 ML, 300 MG/2 ML
- DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 200 MG/1.14 ML, 300 MG/2 ML

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

### **EMGALITY**

#### **Products Affected**

• EMGALITY PEN

• EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 120 MG/ML

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

### **EMSAM**

#### **Products Affected**

• EMSAM

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with serotonergic drugs (i.e. selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), clomipramine and imipramine, meperidine, tramadol, methadone, pentazocine, and propoxyphene), dextromethorphan, or carbamazepine. Members with pheochromocytoma or nursing mothers.
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Approve if member has a diagnosis of Major Depressive Disorder based on the following: A) Member has five or more of the following symptoms that have been present during the same two-week period and represent a change from previous functioning (Note: one of the symptoms is either depressed mood or loss of interest or pleasure): 1) depressed mood most of the day, nearly every day, 2) markedly diminished interest or pleasure in all, or almost all, activities most of the day, nearly every day, 3) significant weight loss when not dieting or weight gain (e.g. a change of more than 5% in a month), or change in appetite nearly every day, 4) insomnia or hypersomnia nearly every day, 5) psychomotor agitation or retardation nearly every day that are observable by others, 6) fatigue or loss of energy nearly every day, 7) feelings of worthlessness or excessive or inappropriate guilt, 8) diminished ability to think or concentrate, or indecisiveness, nearly every day, 9) recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attemmpt or a specific plan for committing suicide, B) The episode is not attributable to the psysiologoical effects of a substance or to another medical condition (i.e. serious medical illness or disability, financial hardships), AND C) The occurrence of the major depressive episode is not better explained by schizoaffective

PA Criteria	Criteria Details
	disorder, schizophrenia, schizophreniform disorder, delusional disorder, or other specified and unspecified schizophrenia spectrum and other psychotic disorders. The member must have a trial and failure of two generic antidepressants used to treat the same indication prior to approval (i.e. sertraline concentrate, fluoxetine solution, citalopram solution, escitalopram solution). Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **ENBREL**

- ENBREL MINI
- ENBREL SUBCUTANEOUS SOLUTION
- ENBREL SUBCUTANEOUS SYRINGE
- ENBREL SURECLICK

SOLUTION	
PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

# **ENVARSUS XR**

#### **Products Affected**

• ENVARSUS XR

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a transplant specialist or nephrologist
Coverage Duration	12 months
Other Criteria	Initial: Approve if the member will be using the requested medication for kidney transplant rejection prophylaxis AND member has tried and failed or has an intolerance to immediate-release tacrolimus (i.e. unable to achieve clinically appropriate concentration levels) or provider has submitted documentation with rationale why tacrolimus immediate-release is not expected to provide the same result. Requested medication must be used in combination with other immunosuppressants. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Requested medication will continue to be used in combination with other immunosuppressants. Note: B versus D determination will me made prior to application of clinical criteria
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

# **EPIDIOLEX**

#### **Products Affected**

• EPIDIOLEX

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	12 months
Other Criteria	Dravet Syndrome-Initial: Approve if the member is at least 1 year of age has tried or is concomitantly receiving at least two other antiepileptic drugs or if the patient has tried or is concomitantly receiving one of Diacomit or clobazam or Fintepla. Lennox Gastaut Syndrome-Approve if the member is at least 1 year of age and has tried or is concomitantly receiving at least two other antiepileptics drugs. Tuberous Sclerosis Complex-Initial: Approve if the member has tried or is concomitantly receiving at least two other antiepileptic drugs. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

# **EPOETIN ALFA**

#### **Products Affected**

• PROCRIT

#### • RETACRIT

PA Criteria	Criteria Details
Exclusion Criteria	Uncontrolled hypertension
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a surgeon, nephrologist, hematologist, an oncologist, gastroenterologist, hepatologist, transplant physicisan, or infectious disease physician
Coverage Duration	6 months
Other Criteria	Anemia in patients with chronic renal failure on dialysis - deny under Medicare Part D (claim should be submitted under the ESRD bundled payment benefit). If the drug is determined not to be ESRD-related, criteria applies. Anemia in Chronic Kidney Disease (CKD)-Initial: Member must not be on dialysis. Hemoglobin (Hgb) must be less than 10 g/dL in adults or less than or equal to 11 g/dL for children. Reauthorization: Approve if member is currently on erythropoiesis-stimulating agent (ESA) and Hgb is less than or equal to 12 g/dL. Chemotherapy-induced Anemia-Initial: Approve if member is currently receiving myelosuppressive chemotherapy for non-myeloid malignancy and has documentation of a minimum of 2 more months of therapy planned. Hgb is less than 10 g/dL or if currently on ESA, Hgb is less than or equal to 12 g/dL. Reauthorization: Approve if member is benefitting from therapy and has documentation of a minimum of 2 more months of therapy planned. RBC transfusion Reduction in Surgery: Approve if Hgb is 10-13 g/dL and member is at high risk for perioperateive transfusion due to significant anticipated blood loss. Surgery must be elective, non-cardiac, and non-vascular in nature and member is unwilling or unable to donate autologous blood prior to surgery. All indications must have a requested dose that falls within the recommended dosing guidelines from the manufacturer.
Indications	All FDA-approved Indications.

PA Criteria	Criteria Details
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

# **EPRONTIA**

#### **Products Affected**

• topiramate oral solution

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

### **ERGOT ALKALOIDS**

- dihydroergotamine injection
- dihydroergotamine nasal

PA Criteria	Criteria Details
Exclusion Criteria	Uncontrolled hypertension. Ischemic heart disease (e.g. angina pectoris, history of myocardial infarction, or documented silent ischemia), or clinical symptoms or findings consistent with coronary artery vasospams including Prinzmetal's variant angina. Concomitant use with potent CYP3A4 inhibitors, such as protease inhibitors and macrolide antibiotics (e.g. ritonavir, nelfinavir, erythromycin, clarithyromycin, ketoconazole, itraconazole, etc). Use within 24 hours of ergotamine-containing or ergot-type medications or methysergide. Treatment of hemiplegic or basilar migraines. Known peripheral arterial disease, sepsis, following vascular surgery, and severely impaired hepatic or renal function. Pregnancy or nursing mothers. Concomitant use with peripheral and central vasoconstrictors
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Initial: Approve if member has diagnosis of acute migraine with or without aura. Must not be used for the prophylactic therapy of migraines. Must have trials of two different formulary triptans with inadequate responses or significant side effects/toxicity unless contraindicated. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

# **ERIVEDGE**

#### **Products Affected**

• ERIVEDGE

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

# **ERLEADA**

#### **Products Affected**

• ERLEADA ORAL TABLET 240 MG, 60 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Initial: Approve if member has a diagnosis of prostate cancer and member will be taking requested medication in combination with a gonadotropin-releasing hormone (GnRH) analog or member has had a bilateral orchiectomy. Member must meet either A or B: A) Member's disease is castration sensitive AND metastatic, or B) Member's disease is castration resistant AND non-metastatic. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

# **ERLOTINIB**

#### **Products Affected**

• erlotinib oral tablet 100 mg, 150 mg, 25 mg

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

# **EUCRISA**

#### **Products Affected**

• EUCRISA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Must be prescribed by or in consultation with an allergist, immunologist, or dermatologist.
Coverage Duration	12 months
Other Criteria	Atopic Dermatitis-Initial: 3-23 months: Approve if member has tried and failed one prescription strength topical corticosteroid except where face, eyes, or genitalia are impacted. 2 years and older: Approve if member has tried and failed one prescription strength topical corticosteroid (except where face, eyes, or genitalia are impacted) AND one topical calcineurin inhibitor (i.e. pimecrolimus cream or tacrolimus ointment) unless the member has a documented intolerance or contraindication to aforementioned therapies. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **EULEXIN**

#### **Products Affected**

• EULEXIN

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Initial: Approve if the member has a diagnosis of prostate cancer and the member will be using the medication concurrently with a gonadotropin-releasing hormone (GnRH) analog or if the member has had a bilateral orchiectomy. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

# **EVEROLIMUS**

- everolimus (antineoplastic) oral tablet
- everolimus (antineoplastic) oral tablet for suspension 2 mg, 3 mg, 5 mg

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Breast Cancer-Initial: Approve if member is a postmenopausal woman with advanced hormone receptor-positive (HR+), HER2-negative breast cancer AND medication will be used in combination with exemestane after failure of treatment with letrozole or anastrozole. PNET and NET-Initial: Approve if member has a diagnosis of progressive neuroendocrine tumors of pancreatic origin (PNET) OR diagnosis of progressive, well-differentiated, non-functional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic. RCC-Initial: Approve if member has a diagnosis of advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib (Sutent) or sorafenib (Nexavar). TSC-Initial: Approve if member has diagnosis of renal angiomyolipoma and tuberous sclerosis complex (TSC) not requiring immediate surgery. TSC Associated SEGA-Initial: Approve if member requires therapeutic intervention but cannot be curatively resected. TSC-associated partial-onset seizures-Initial: Approve. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

## **FASENRA**

#### **Products Affected**

• FASENRA PEN

• FASENRA SUBCUTANEOUS SYRINGE 10 MG/0.5 ML, 30 MG/ML

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with another monoclonal antibody (i.e Dupixent, Cinqair, Nucala, Tezspire, or Xolair)
Required Medical Information	Diagnosis
Age Restrictions	EGPA-18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an allergist, immunologist, pulmonologist or rheumatologist
Coverage Duration	Initial: 6 months Reauthorization: 12 months
Other Criteria	Asthma-Initial: Member must have a diagnosis of eosinophilic phenotype severe asthma with a peripheral blood eosinophil count of greater than or equal to 150 cells/uL within the previous 6 weeks and prior to treatment with any monoclonal therapy. Member meet both of the following criteria: 1) Member has received combination therapy with an inhaled corticosteroid AND one additional controller/maintenance medication (e.g. inhaled LABA, inhaled LAMA), AND 2) Member's asthma is uncontrolled prior to any monoclonal antibody therapy definied by one of the following A, B, C, D, or E: A) member experienced one or more asthma exacerbations requiring treatment with systemic corticosteroids in the previous year, B) patient experienced one or more asthma exacerbation requiring hospitalization or an Emergency Department (ED) visit in the previous year, C) Member has a FEV1 less than 80 percent predicted (90 percent for adolescents), D) Member has an FEV1/FVC less than 0.80 (0.90 for adolescents), OR E) Member's asthma worsens upon tapering of oral corticosteroid therapy. Reauthorization: The member has responded to requested therapy as determined by the prescribing physician (e.g., decreased asthma exacerbations, decreased asthma symptoms, decreased hospitalizations, emergency department (ED)/urgent care, or physician visits due to asthma, decreased requirement for oral corticosteroid therapy) AND member continues to receive therapy with an inhaled corticosteroid.

PA Criteria	Criteria Details
	EGPA-Initial: Approve if member meets all of the following A, B, C, D, and E (documenation required): A) Has relapsed or refractory disease, B) Trial and failure or contraindication to treatment with prednisone or prednisolone at a maximally tolerated dose, C) Positive history of asthma, D) Blood eosinophil level of 10 percent or absolute eosinophil count greater than 1000 cells/uL, E) 2 or more criteria that are typical of EGPA (i.e. neuropathy, glomerulonephritis, palpable purpura, etc) OR histopathological evidence of eosinophilic vasculitis, perivascular eosinophilic infiltration, or eosinophil-rich granulomatous inflammation. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

# FELBAMATE (SUSPENSION)

#### **Products Affected**

• felbamate oral suspension

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis and must have documentation showing that administration via nasogastric tube is required OR documentation of inability to swallow an intact tablet.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	12 months
Other Criteria	Initial: Approve if the member has had a trial and failure or contraindication to two generic antiepileptic drugs (e.g. lamotrigine, topiramate) and meets either A or B: A) Member is an adult with partial seziures, with or without generalization, and medication will be used as monotherapy or adjunctive therapy OR B) Member is a child partial and generalized seizures that are associated with Lennox-Gastaut syndrome. Medication will be used as adjunctive therapy. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

# FENTANYL (TRANSDERMAL)

#### **Products Affected**

• fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

## **FINGOLIMOD**

#### **Products Affected**

• fingolimod

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with other disease-modifying agents used for multiple sclerosis (MS). Recent myocardial infarction, unstable angina, stroke, transient ischemic attack (TIA), decompensated heart failure with hospitalization, or Class III/IV heart failure. History of Mobitz Type II 2nd degree or 3rd degree AV block or sick sinus syndrome, unless member has a pacemaker. Baseline QTc interval greater than or equal to 500 msec. Cardiac arrhythmias requiring anti-arrhythmic treatment with Class Ia or Class III anti-arrhythmic drugs.
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist or an MS specialist
Coverage Duration	12 months
Other Criteria	Initial: Approve if the member is at least 10 years of age and has a diagnosis of relapsing multiple sclerosis including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

## **FINTEPLA**

#### **Products Affected**

• FINTEPLA

PA Criteria	Criteria Details
Exclusion Criteria	Use of monoamine oxidase inhibitors within 14 days
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an neurologist
Coverage Duration	12 months
Other Criteria	Must have a baseline echocardiogram to evaluate for valvular heart disease and pulmonary arterial hypersion. For members with established valvular heart disease and/or pulmonary arterial hypertension, attestation from the provider assessing the risks and benefits of therapy must be documented. Dravet Syndrome-Initial: Approve if the member is at least 2 years of age has a trial and failure of or contraindication to cannabidiol (Epidiolex) and one other generic antiepileptic medication. Lennox Gastaut Syndrome-Approve if the member is at least 2 years of age and has tried or is concomitantly receiving at least two other antiepileptics drugs. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

## **FLUCYTOSINE**

#### **Products Affected**

• flucytosine

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

## **FOTIVDA**

#### **Products Affected**

• FOTIVDA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Renal Cell Carcinoma (RCC)-Initial: Approve if member has advanced disease that has relapsed or is refractory following two or more prior systemic therapies for the same indication (i.e. sunitinib, pazopanib). Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

# FRUZAQLA

#### **Products Affected**

• FRUZAQLA ORAL CAPSULE 1 MG, 5 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years of age or older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Colorectal Cancer-Initial: Approve if the member has a diagnosis of metastatic colorectal cancer (mCRC) and meets all of the following A, B, and C: A) Member has been previously treated with fluoropyrimidine-(e.g., 5-fluorouracil, capecitabine), oxaliplatin-, and irinotecan-based chemotherapy, B) an anti-VEGF therapy (e.g. bevacizumab), AND C) if member has RAS wild-type (i.e. KRAS and NRAS mutation negative) and medically appropriate, an anti-EGFR therapy (e.g. cetuximab (Erbitux), panitumumab (Vectibix). Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

## **FYCOMPA**

- FYCOMPA ORAL SUSPENSION
- perampanel oral tablet 10 mg, 12 mg, 2 mg, 4 mg, 6 mg, 8 mg

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, For suspension, must have documentation showing that administration via nasogastric tube is required OR documentation of inability to swallow an intact tablet.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	12 months
Other Criteria	Initial: Approve if the member has had a trial and failure or contraindication to two generic antiepileptic drugs (e.g. lamotrigine, topiramate) and meets either A or B: A) Member has partial seziures, with or without generalization, and medication will be used as monotherapy or adjunctive therapy OR B) Member has primary generalized tonic-clonic seizures and medication will be used as adjunctive therapy. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

## **GATTEX**

#### **Products Affected**

• GATTEX 30-VIAL

#### GATTEX ONE-VIAL

PA Criteria	Criteria Details
Exclusion Criteria	Active intestinal obstruction or active gastrointestinal malignancy
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a gastroenterologist
Coverage Duration	12 months
Other Criteria	Initial: Approve if the member has a diagnosis of short bowel syndrome (SBS). Must provide date of bowel resection, baseline parenteral or intravenous nutrition (PN/IV) support scheduled including frequency and volume, colonoscopy if an adult or pediatric member with unexplained blood in the stool within 6 months before starting requested medication and at baseline (within 6 months) lab monitoring of bilirubin, alkaline phosphatase, lipase, and amylase. Must be receiving PN or IV nutrition support at least 3 times weekly. Reauthorization: Documentation from provider indicating improvement in condition, that member has weaned off or decreased PN/IV requirements, the member had a colonoscopy (if appropriate) after 1 year of treatment and at least every 5 years after the first year, and the member is undergoing laboratory testing of bilirubin, alkaline phosphatase, lipase, and amylase every 6 months.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

## **GAVRETO**

#### **Products Affected**

• GAVRETO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	NSCLC-18 years and older, Thyroid cancer-12 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Non-Small Cell Lung Cancer (NSCLC)-Initial: Approve if the member has metastatic disease and rearranged during transfection (RET) fusion-positive disease detected by an FDA-approved test. Thyroid cancer-Initial: Approve if the member has advanced or metastatic RET fusion-positive disease and meets both the following criteria A and B: A) the disease is radioactive iodine-refractory (if radioactive iodine is appropriate) and B) the disease requires treatment with systemic therapy. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

## **GILOTRIF**

#### **Products Affected**

• GILOTRIF

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

## **GLATIRAMER**

- glatiramer subcutaneous syringe 20 mg/ml, 40 mg/ml
- glatopa subcutaneous syringe 20 mg/ml, 40 mg/ml

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with other disease-modifying agent used for multiple sclerosis
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or after consultation with a neurologist or an MS specialist.
Coverage Duration	12 months
Other Criteria	Initial: Approve if member has a diagnosis of relapsing forms of multiple sclerosis (RRMS). Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

## **GLUCAGON-LIKE PEPTIDE-1 AGONISTS**

- liraglutide
- MOUNJARO
- OZEMPIC SUBCUTANEOUS PEN INJECTOR 0.25 MG OR 0.5 MG (2
- MG/3 ML), 1 MG/DOSE (4 MG/3 ML), 2 MG/DOSE (8 MG/3 ML)
- RYBELSUS
- TRULICITY

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

## **GLUTAMINE**

#### **Products Affected**

• glutamine (sickle cell)

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with Adakveo
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	12 months
Other Criteria	Initial: Member must have a diagnosis of sickle cell disease. Must have documentation the member has experienced at least 2 sickle cell-related vaso-occlusive crises within the last 12 months requiring a medical facility visit (e.g., emergency department, infusion center, or hospital). Chart documentation of medical facility visit is required. Must have an adequate trial of at least 90 days on oral hydroxyurea (e.g., hydroxyurea tablet) with an inadequate response or significant side effects/toxicity or have a contraindication to this therapy. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

## **GOMEKLI**

- GOMEKLI ORAL CAPSULE 1 MG, 2 GOMEKLI ORAL TABLET FOR MG
  - SUSPENSION

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Neurofibromatosis Type 1 (NF1)-Initial: Member must plexiform neurofibromas (PNs) that are both of the following: inoperable and causing significant morbidity (e.g. disfigurement, motor dysfunction, pain, airway dysfunction, visual impairment, bladder/bowel dysfunction). Member must use the requested medication as monotherapy. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

# GONADOTROPIN-RELEASING HORMONE AGONISTS - INJECTABLE LONG ACTING

- leuprolide subcutaneous kit
- LUPRON DEPOT
- LUPRON DEPOT (3 MONTH)
- LUPRON DEPOT (4 MONTH)
- LUPRON DEPOT (6 MONTH)

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

## **GROWTH HORMONES**

#### **Products Affected**

• OMNITROPE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	GHD in Children/Adolescents. Pt meets one of the following-1-had 2 GH stim tests with the following-levodopa, insulin-induced hypoglycemia, arginine, clonidine, or glucagon and both are inadequate as defined by a peak GH response which is below the normal reference range of the testing laboratory OR had at least 1 GH test and results show inadequate response and has at least one risk factor for GHD (e.g., ht for age curve deviated down across 2 major height percentiles [e.g., from above the 25 percentile to below the 10 percentile], growth rate is less than the expected normal growth rate based on age and gender, low IGF-1 and/or IGFBP-3 levels). 2.brain radiation or tumor resection and pt has 1 GH stim test and results is inadequate response or has def in at least 1 other pituitary hormone (that is, ACTH, TSH, gonadotropin deficiency [LH and/or FSH] are counted as 1 def], or prolactin).3. congenital hypopituitarism and has one GH stim test with inadequate response OR def in at least one other pituitary hormone and/or the patient has the imaging triad of ectopic posterior pituitary and pituitary hypoplasia with abnormal pituitary stalk 4.pt has panhypopituitarism and has pituitary stalk agenesis, empty sella, sellar or supra-sellar mass lesion, or ectopic posterior pituitary bright spot on MRI or CT or pt has 3 or more pituitary hormone deficiencies or pt has had one GH test and results were inadequate 5.pt had a hypophysectomy. Cont-pt responding to therapy
Age Restrictions	N/A
Prescriber Restrictions	GHD (Initial tx children or adolescents w/o hypophysectomy), GHD adults or transitional adolescents, Prader Willi (initial for child/adult and cont tx in adults), SGA (initial) - prescribed by or in consultation with an endocrinologist.
Coverage Duration	ISS - 6 mos initial, 12 months cont tx, others 12 mos
Other Criteria	GHD initial in adults and adolescents 1. endocrine must certify not being prescribed for anti-aging or to enhance athletic performance, 2. has either

PA Criteria	Criteria Details
	childhood onset or adult onset resulting from GHD alone, multiple hormone deficiency from pituitary dx, hypothalamic dz, pituitary surgery, cranial radiation tx, tumor treatment, TBI or subarachnoid hemorrhage, AND 3. meets one of the following - A. has known mutations, embryonic lesions, congenital or genetic defects or structural hypothalamic pituitary defects, B. 3 or more pituitary hormone def (ACTH, TSH, LH/FSH, or prolactin, IGF1 less than 84 mcg/L (Esoterix RIA), AND other causes of low serum IGF-1 have been excluded, C. Neg response to ONE preferred GH stim test (insulin peak response less than or equal to 5 mcg/L, Glucagon peak less than or equal to 3 mcg/L (BMI is less than or equal to 25), less than or equal to 3 mth a high pretest probability of GH deficiency, less than or equal to 1 and BMI is greater than or equal to 25 and less than or equal to 30 with a low pretest probability of GH deficiency or less than or equal to 1 mcg/L (BMI is greater than 30), if insulin and glucagon contraindicated then Arginine alone test with peak of less than or equal to 0.4 mcg/L, or Macrilen peak less than 2.8 ng/ml AND BMI is less than or equal to 40 AND if a transitional adolescent must be off tx for at least one month before retesting. Cont tx - endocrine must certify not being prescribed for anti-aging or to enhance athletic performance. ISS initial - baseline ht less than the 1.2 percentile or a standard deviation score (SDS) less than -2.25 for age and gender, open epiphyses, does not have CDGP and height velocity is either growth rate (GR) is a. less than 4 cm/yr for pts greater than or equal to 5 or b. growth velocity is less than 10th percentile for age/gender. Cont tx - prescriber confirms response to therapy. PW cont tx in adults or adolescents who don't meet child requir - physician certifies not being used for anti-aging or to enhance athletic performance. SGA initial -baseline ht less than 5th percentile for age/gender and born SGA (birth weight/length that is more than 2 SD below mean for gestational
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

## **HERNEXEOS**

#### **Products Affected**

• HERNEXEOS

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

## **IBRANCE**

#### **Products Affected**

• IBRANCE

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

## **IBTROZI**

#### **Products Affected**

• IBTROZI

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

## **ICLUSIG**

#### **Products Affected**

• ICLUSIG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Philadelphia Chromosome-positive (Ph+) Acute Lymphoblastic Leukemia (ALL)-Initial: Approve if member meets one of the following A, B, or C: A) Approve if member has newly diagnosed Ph+ ALL AND medication will be used in combination with chemotherapy, B) Member has T315I-positive ALL, OR C) Requested medication will be used as monotherapy in members for whom no other TKIs are indicated. Chronic Myeloid Leukemia (CML)-Approve if member meets one of the following A, B, or C: A) Member has chronic phase (CP) CML with resistance or intolerance to at least two prior kinase inhibitors B) Member has Accelerated phase (AP) or blast phase (BP) CML for whom no other kinase inhibitors are indicated or C) Member has T315I-positive CML (chronic, accelerated, or blast phase). Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

## **IDHIFA**

#### **Products Affected**

• IDHIFA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Initial: Member must have a confirmed diagnosis of acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. Member must have relapsed or refractory disease from prior treaments for the same indication. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

## **IMATINIB**

#### **Products Affected**

• imatinib oral tablet 100 mg, 400 mg

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Initial: Newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase-Approve. Ph+ CML in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy-Approve. Relapsed or refractory Ph+ acute lymphoblastic leukemia (ALL)-Approve. Newly diagnosed Ph+ ALL-Approve if member is a pediatric patient AND medication will be used in combination with chemotherapy. Myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements-Approve for adult members. Aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown-Approve for adult members. Hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL)-Approve for adult members who have the FIP1L1-PDGFRa fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) OR members with HES and/or CEL who are FIP1L1-PDGFRa fusion kinase negative or unknown. Unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP)-approve for adult members. Gastrointestinal Stromal Tumors (GIST)-Approve if member has Kit (CD117) positive unresectable and/or metastatic, malignant tumors OR if requested medication will be used as adjuvant treatment for adult members following resection of Kit (CD117) positive GIST. Reauthorization:

PA Criteria	Criteria Details
	Member has responded positively to therapy as determined by the prescriber.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

## **IMBRUVICA**

- IMBRUVICA ORAL CAPSULE 140 MG, 70 MG
- IMBRUVICA ORAL SUSPENSION
- IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG

IIVIDRU VICA URAL SUSPENSION	
PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

## **IMKELDI**

#### **Products Affected**

• IMKELDI

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, Must have documentation showing that administration via nasogastric tube is required OR documentation of inability to swallow an intact tablet.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Initial: Newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase-approve. Ph+ CML in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy-approve. Relapsed or refractory Ph+ acute lymphoblastic leukemia (ALL)-approve. Newly diagnosed Ph+ ALL-Approve if member is a pediatric patient AND medication will be used in combination with chemotherapy. Myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements-Approve for adult members. Aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown-Approve for adult members. Hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL)-Approve for adult members who have the FIP1L1-PDGFRa fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) OR members with HES and/or CEL who are FIP1L1-PDGFRa fusion kinase negative or unknown. Unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP)-approve for adult members. Gastrointestinal Stromal Tumors (GIST)-Approve if member has Kit (CD117) positive unresectable and/or metastatic, malignant tumors OR if requested medication will be used as adjuvant treatment for adult members following resection of Kit (CD117) positive GIST. Reauthorization:

PA Criteria	Criteria Details
	Member has responded positively to therapy as determined by the prescriber.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

## **IMPAVIDO**

#### **Products Affected**

• IMPAVIDO

PA Criteria	Criteria Details
Exclusion Criteria	Pregnancy, Sjogren-Larsson-Syndrome
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an infectious disease specialist
Coverage Duration	30 Days
Other Criteria	Initial: Member must weigh greater than or equal to 30 kg (66 lbs) and have a diagnosis of one of the following confirmed using methods such as histopathology, parasite isolation by in vitro culture, polymerase chain reaction, molecular detection of parasite DNA, serologic testing (visceral leishmaniasis): (1) Visceral leishmaniasis due to Leishmania donovani, (2) Cutaneous leishmaniasis due to Leishmania braziliensis, Leishmania guyanensis, and Leishmania panamensis, or (3) Mucosal leishmaniasis due to Leishmania braziliensis. Must have a trial and failure, contraindication or intolerance to Liposomal Amphotericin B prior to approval.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	Yes
Prerequisite Therapy Required	No

## **INCRELEX**

#### **Products Affected**

• INCRELEX

PA Criteria	Criteria Details
Exclusion Criteria	Closed epiphyses, malignant neoplasia or history of malignancy. Concomitant use with growth hormone treatments. Secondary forms of IGF-1 deficiency, such as malnutrition, hypopituitarism, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids. Premature babies or neonates.
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an endocrinologist
Coverage Duration	12 months
Other Criteria	Insulin-like Growth Factor-1 (IGF-1) deficiency (initial): Diagnosis of severe primary IGF-1 deficiency (SPIGFD) defined by all the following: 1) Height standard deviation score of -3.0 or less, 2) basal IGF-1 levels below the 2.5th percentile for age and gender, and 3) Growth hormone (GH) sufficiency (i.e. normal or elevated GH). GH gene deletion (initial): Diagnosis of GH gene deletion in patients who have developed neutralizing antibodies to GH. SPIGFD includes members with mutations in the GH receptor (GHR) gene/Laron's syndrome, post-GHR signaling pathway, and IGF-1 gene defects. Reauthorization: Confirmation that epiphyses have not closed and chart note documentation from the provider indicating the member's condition has improved while on the requested medication.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

## **INLYTA**

#### **Products Affected**

• INLYTA ORAL TABLET 1 MG, 5 MG

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

# **INQOVI**

#### **Products Affected**

• INQOVI

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Myelodysplastic Syndromes (MDS)-Initial: Approve if the member has a diagnosis of MDS, including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed myelomonocytic leukemia (CMML), and intermediate-1, intermediate-2, adn high-risk internationanal prognostic scoring system groups.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

### **INREBIC**

#### **Products Affected**

• INREBIC

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Myelofibrosis (MF), including Primary MF, Post-Polycythemia Vera MF, and Post-Essential Thrombocythemia MF-Initial: Approve if the member has a diagnosis of intermediate-2 or high-risk disease. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

### **IRESSA**

#### **Products Affected**

• gefitinib

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Non-Small Cell Lung Cancer (NSCLC)-Initial: Approve if the member has a diagnosis of metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

## **ITOVEBI**

#### **Products Affected**

• ITOVEBI ORAL TABLET 3 MG, 9 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Initial: Member must have a diagnosis of endocrine-resistant, PIK3CA-mutated, hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or within 12 months of completing adjuvant endocrine therapy (i.e. tamoxifen, anastrozole, exemestane). Member must use requested medication in combination with palbociclib (Verzenio) and fulvestrant. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

# **IVERMECTIN (ORAL)**

#### **Products Affected**

• ivermectin oral tablet 3 mg

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	30 days
Other Criteria	Provider must attest medication will not be used for the treatment of COVID-19. Requested medication has not been approved for this use given no evidence of improving health outcomes for those infected with COVID-19 has been established in clinical trials.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

## **IVIG**

#### **Products Affected**

• GAMASTAN

• GAMUNEX-C INJECTION SOLUTION 1 GRAM/10 ML (10 %)

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Part B versus D determination per CMS guidance to establish if drug used for PID in pt's home.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

### **IWILFIN**

#### **Products Affected**

• IWILFIN

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

### **JAKAFI**

#### **Products Affected**

• JAKAFI

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	MF/PV-18 and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist, hematologist, or transplant specialist
Coverage Duration	12 months
Other Criteria	Myelofibrosis-Initial: Approve if the member is an adult with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemica vera myelofibrosis and post-essential thrombocythemia myelofibrosis. Polycythemia Vera (PV)-Initial: Approve if the member has a diagnosis of PV and the member has tried and failed or has a contraindication to hydroxyurea (documentation required). Acute Graft versus Host Disease (aGVHD)-Initial: Approve if the member has tried and failed one systemic corticosteroid. Chronic Graft versus Host Disease (cGVHD)-Initial: Approve if the member has tried and failed one or two lines of systemic therapy prior to approval. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

## **JAYPIRCA**

#### **Products Affected**

• JAYPIRCA ORAL TABLET 100 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Mantle Cell Lymphoma-Initial: Approve if the member has relapsed or refractory disease after a trial and failure of two prior lines of systemic therapy including one Bruton Tyrosine Kinase (BTK) inhibitor (i.e. Brukinsa, Imbruvica, Calquence). Chronic Lymphocytic Leukemia (CLL)/Small lymphocyctic lymphoma (SLL)-Initial: Approve if member has received at least two prior lines of therapy including one BTK inhibitor (i.e. Brukinsa, Imbruvica, Calquence) AND one B-Cell Lymphoma inhibitor (BCL-2 inhibitor) (i.e. Venclexta). Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **KALYDECO**

#### **Products Affected**

- KALYDECO ORAL GRANULES IN KALYDECO ORAL TABLET **PACKET**

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with other medications containing ivacaftor
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist or a cystic fibrosis specialist
Coverage Duration	12 months
Other Criteria	Initial: Must have a diagnosis of cystic fibrosis and documentation of one of the following: 1) One mutation in the CFTR gene that is responsive to ivacaftor based on clinical and/or in vitro assay data OR 2) If the member's genotype is unknown, an FDA-cleared cystic fibrosis mutation test used to detect the presence of a CFTR mutation followed by verification with bidirectional sequencing when recommended by the mutation test instructions for use. Provider attestation liver function tests will be assessed prior to initiation of treatement, during the first 6 months of treatment, every 3 months for the next 12 months, then at least annually thereafter. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician, absent of toxicities, and provider attestation to monitor liver function tests at least annually.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

### **KERENDIA**

#### **Products Affected**

• KERENDIA ORAL TABLET 10 MG, 20 MG

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

## **KESIMPTA**

#### **Products Affected**

• KESIMPTA PEN

PA Criteria	Criteria Details
Exclusion Criteria	Active hepatitis B infection, concomitant use with other disease-modifying agents used for multiple sclerois
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	12 months
Other Criteria	Initial: Approve if the member has diagnosis of a relapsing form of multiple sclerosis (MS) to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Must have had inadequate response or intolerance to ONE of the following: dimethyl fumarate, fingolimod, teriflunomide, or glatiramer. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

# KISQALI

#### **Products Affected**

 KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1), 400 MG/DAY (200 MG X 2), 600 MG/DAY (200 MG X 3)

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Breast cancer-Initial: Approve if member has hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative disease and meets either A or B: A) Member has early disease (i.e. stage II and III) at high risk of recurrence AND medication will be used as adjuvant treatment in combination with an aromatase inhibitor (i.e. anastrozole, exemestane, letrozole) OR B) Member has advanced or metastatic disease AND medication will be used in combination with either i or ii: i) an aromatase inhibitor as initial endocrine-based therapy (i.e. anastrozole, exemestane, letrozole) OR ii) fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

### **KOSELUGO**

#### **Products Affected**

• KOSELUGO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Neurofibromatosis Type 1 (NF1)-Initial: Member must plexiform neurofibromas (PNs) that are both of the following: inoperable and causing significant morbidity (e.g. disfigurement, motor dysfunction, pain, airway dysfunction, visual impairment, bladder/bowel dysfunction). Member must use the requested medication as monotherapy. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

### **KRAZATI**

#### **Products Affected**

• KRAZATI

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Non-Small Cell Lung Cancer (NSCLC)-Initial: Approve if the member has a diagnosis of locally advanced or metastatic NSCLC and meets both of the following A and B: A) Disease has a KRAS G12C-mutation as determined by an FDA-approved test AND B) Member has been previously treated with at least one systemic regimen (i.e. bevacizumab, cisplatin, carboplatin, docetaxel). Colorectal Cancer (CRC)-Initial: Approve if member has a diagnosis of locally advanced or metastatic CRC and meets all criteria A, B, and C: A) Disease has a KRAS G12C-mutation as determined by an FDA-approved test, B) Member has received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, AND C) Medication will be used in combination with cetuximab.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

## **LAPATINIB**

#### **Products Affected**

• lapatinib

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

## **LAZCLUZE**

#### **Products Affected**

• LAZCLUZE ORAL TABLET 240 MG, 80 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 Months
Other Criteria	Initial: Approve if member has a diagnosis of locally advanced or metastatic non-small cell lung cancer (NSCLC) and meets all the following A, B, and C: A) Disease is positive for epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test, B) Requested medication will be used as a first-line treatment in combination with amivantamab, AND C) Provider attests anticoagulant prophylaxis will be administered for the first four months of treatment. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

## **LENALIDOMIDE**

#### **Products Affected**

• lenalidomide

PA Criteria	Criteria Details
Exclusion Criteria	Pregnancy
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Mantle Cell Lymphoma (MCL)-Initial: Approve if the member has relapsed or progressed after bortezomib (Velcade) and one other therapy. Follicular lymphoma (FL) and Marginal Zone Lymphoma (MZL)-Initial: Approve if the member has been previously treated and will be using the requested medication in combination with rituximab. Multiple myeloma (MM)-Initial: Approve if the member has a diagnosis of MM and will be using the requested medication in combination with dexamethasone OR as maintenance following an autologous hematopoietic stem cell transplantation (auto-HSCT). Myelodysplastic Syndromes (MDS)-Initial: Approve if the member has transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q abnormality with or without addition cytogenetic abnormalties as detected by an FDA-approved test. For all diagnoses: Member must have baseline negative pregnancy test prior to initiation of therapy if a natal female of reproductive potential. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician and member must have baseline negative pregnancy test prior to initiation of therapy if a natal female of reproductive potential.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **LENVIMA**

#### **Products Affected**

LENVIMA ORAL CAPSULE 10
 MG/DAY (10 MG X 1), 12 MG/DAY (4
 MG X 3), 14 MG/DAY(10 MG X 1-4 MG
 X 1), 18 MG/DAY (10 MG X 1-4 MG

X2), 20 MG/DAY (10 MG X 2), 24 MG/DAY(10 MG X 2-4 MG X 1), 4 MG, 8 MG/DAY (4 MG X 2)

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Differentiated Thyroid Cancer (DTC)-Initial: Member must have locally recurrent or metastatic, progressive, radioactive iodine-refractory disease AND medication will be used as monotherapy. Renal Cell Carcinoma (RCC)-Initial: Approve if the member has advanced disease and meets either A or B: A) Medication will be used as a first line treatment AND will be used in combination with pembrolizumab OR B) Medication will be used as second line treatment following one prior anti-angiogenic therapry AND will be used in combination with everolimus. Endometrial Carcinoma (EC)-Initial: Approve if the patient meets all the following criteria (A, B, C, and D): A) Member has advanced disease that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H) as determinded by an FDA-approved test, B) Member had disease progression following prior systemic therapy in any setting, C) Medication will be used in combination with pembrolizumab (Keytruda), AND D) Member is not a candidate for curative surgery or radiation. Hepatocellular Carcinoma (HCC)-Initial: Approve. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.

PA Criteria	Criteria Details
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **LEUKERAN**

#### **Products Affected**

• LEUKERAN

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Initial: Approve if member has a diagnosis of chronic lymphatic leukemia (CLL) or malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkins disease. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

### LIDOCAINE PATCH

#### **Products Affected**

- dermacinrx lidocan
- lidocaine topical adhesive patch,medicated 5 %
  • lidocan iii

- lidocan iv
- lidocan v
- tridacaine ii

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Approve if member has diagnosis of pain associated with post-herpetic neuralgia.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

## **LIVTENCITY**

#### **Products Affected**

• LIVTENCITY

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Hematologist, oncologist, infectious disease physician, or transplant physician
Coverage Duration	2 months
Other Criteria	Initial: Member must have a diagnosis of cytomegalovirus (CMV) infection/disease and meet all the following A, B, C: A) Member weighs greater than or equal to 35kg, B) Member is post-transplant, including members who have received a solid organ transplant or hematopoietic stem cell transplant, and C) Disease is refractory to treatment (with or without genotype resistance) with ganciclovir, valganciclovir, cidofovir, or foscarnet. Must have chart documentation of at least ONE of the following: cytomegalovirus (CMV) DNA level in whole blood or plasma that has not decreased by greater than or equal to 1 log10 (e.g., a 10 fold decrease, reduction by 90%) after 14 days of antiviral therapy at the treatment dose OR dose limiting toxicity preventing the continuation of current antiviral therapy (e.g. bone marrow suppression, renal toxicity). Must not be used concomitantly with ganciclovir or valganciclovir. Must not have CMV disease involving the central nervous system, including the retina. Reauthorization: Must have chart documentation from the provider that the member's condition has improved based upon the prescriber's assessment while on therapy or the member continues to benefit from therapy. For requests for doses that exceed 400mg twice daily: must be administered with carbamazepine, phenytoin, or phenobarbital AND must follow recommended dosing in the prescribing information.
Indications	All FDA-approved Indications.

PA Criteria	Criteria Details
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

### LONG ACTING OPIOIDS

#### **Products Affected**

- buprenorphine
- methadone intensol
- methadone oral concentrate
- methadone oral solution 10 mg/5 ml, 5 mg/5 ml
- methadone oral tablet 10 mg, 5 mg
- methadose oral concentrate
- morphine oral tablet extended release 100 mg, 15 mg, 200 mg, 30 mg, 60 mg

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	For pain severe enough to require daily, around-the-clock, long-term opioid treatment, approve if member meets all of the following A, B, C, D, and E: A) patient is not opioid naive, B) non-opioid therapies have been tried and are being used in conjunction with opioid therapy according to the prescribing physician, C) the prescribing physician has checked the patient's history of controlled substance prescriptions using state prescription drug monitoring program (PDMP), D) the prescribing physician has discussed risks (eg, addiction, overdose) and realistic benefits of opioid therapy with the patient, AND E) according to the prescriber physician there is a treatment plan (including goals for pain and function) in place and reassessments are scheduled at regular intervals. Patients with cancer, in hospice, sickle cell disease or who reside in a long term care facility are not required to meet above criteria. Clinical criteria incorporated into the quantity limit edits for all oral long-acting opioids require confirmation that the indication is intractable pain (ie, FDA labeled use) prior to reviewing for quantity exception.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **LONSURF**

#### **Products Affected**

• LONSURF

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Initial: Approve if the member meets either A or B: A) Member has a diagnosis of gastric or gastroesophageal junction adenocarcinoma AND has been previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy OR B) Member has a diagnosis of metastatic colorectal cancer and meets either i or ii: i) medication will be used as a single agent OR ii) medication will be used in combination with bevacizumab when member has been previously treated with a fluropyrimidine-, oxaliplatin-, AND irinotecan-based chemotherapy, an anti-VEGF biological therapy, AND if the tumors are wild-type RAS (KRAS wild type and NRAS wild type) as determined by an FDA-approved test, an anti-EGFR therapy.Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

### **LORBRENA**

#### **Products Affected**

• LORBRENA ORAL TABLET 100 MG, 25 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Non-Small Cell Lung Cancer (NSCLC)-Initial: Approve if the member has metastatic disease that is anaplastic lymphona kinase (ALK) positive as detected by an FDA approved test. Member must have a trial and failure of alectinib (Alecensa) prior to approval or a medical reason as to why it cannot be started or continued. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **LUMAKRAS**

#### **Products Affected**

• LUMAKRAS ORAL TABLET 120 MG, 240 MG, 320 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Non-Small Cell Lung Cancer (NSCLC)-Initial: Approve if the member has KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test AND has been previously treated with at least one systemic regimen. Metastatic Colorectal Cancer (mCRC)-Approve if member meets all the following A, B, and C: A) Member has diagnosis of KRAS G12C-mutated mCRC as determined by an FDA-approved test, B) Member will be receiving requested medication in combination with panitumamab (Vectibix), and C) Member has received prior treatement with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **LYNPARZA**

#### **Products Affected**

• LYNPARZA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Breast Cancer-Initial: Approve if the member has a deleterious or suspected deleterious gBRCAm (germline BRCA-mutated), HER-2 negative disease as confirmed by an FDA-approved test and meets either A or B: A) Member has high-risk, early disease. Member has been treated with neoadjuvant or adjuvant chemotherapy. Medication will be used as adjuvant treatment. OR B) Member has metastatic disease and has been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. If member is hormone receptor (HR-) positive, member should have also been treated with a prior endocrine therapy, if appropriate. Pancreatic Cancer-Initial: Approve if the member has a deleterious or suspected deleterious gBRCAm, metastatic disease that has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Member will be using medication as maintenance. therapy. Prostate Cancer: Initial: Approve if the member will be taking in combination with a gonadotropin-releasing hormone (GnRH) analog unless member had a bilateral orchiectomy and has a diagnosis of metastatic castration-resistant prostate cancer (mCRPC) and meets either A or B: A) Member has a deleterious or suspected deleterious germline or soatic homologous recombination repair (HRR) gene-mutation as determined by an FDA-approved test. Disease has progressed following prior treatment with enzalutamide (Nubeqa) or abiraterone OR B) Member has a deleterious or suspected deleterious BRCA-mutated germline AND medication will be

PA Criteria	Criteria Details
	used in combination with abiraterone and either prednisone or prednisolone. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **LYSODREN**

#### **Products Affected**

• LYSODREN

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

### **LYTGOBI**

#### **Products Affected**

• LYTGOBI ORAL TABLET 12 MG/DAY (4 MG X 3), 16 MG/DAY (4 MG X 4), 20 MG/DAY (4 MG X 5)

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Cholangiocarcinoma-Initial: Approve if the member has intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements as detected by an FDA-approved test. Member has unresectable locally advanced or metastatic disease. Member has received prior treatment with at least one systemic regimen (i.e. gemcitabine + cisplatin). Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **MARPLAN**

#### **Products Affected**

• MARPLAN

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	2 months
Other Criteria	Initial: Approve if the member has a diagnosis of depression using the DSM-V criteria with the presence of five or more of the following symptoms in the same two-week period with at least one of the symptoms being depressed mood or loss of interest or pleasure: depressed mood most of the day, nearly every day, anhedonia, significant weight loss, insomnia or hypersomnia nearly every day, psychomotor agitation or retardation, fatigue or loss of energy nearly every day, feelings of worthlessness or excessive guilt, diminished ability to think or concentrate, or indecisiveness, recurrent thoughts of death, suicidal ideation, or a suicide attempt. Member must have tried and failed two other antidepressants prior to approval. Provider must attest the member will be continuously evaluated for clinical worsening, suicidality, or unusual changes in behaviors. Reauthorization: Additional authorizations for treatment are made on a case-by-case basis, are subject to the above criteria, and require chart documentation describing the previous response and clinical rationale for re-treatment.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

# **MATULANE**

#### **Products Affected**

• MATULANE

PA Criteria	Criteria Details
Exclusion Criteria	Members with inadequate marrow reserve as demonstrated by bone marrow aspiration.
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Initial: Approve if member has a diagnosis of Stage III or IV Hodgkin's disease and medication will be used in combination with other anticancer medications (i.e. MOPP regimen including mechlorethamine, vincristine, procarbazine, and prednisone). Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

### **MAVYRET**

- MAVYRET ORAL PELLETS IN MAVYRET ORAL TABLET **PACKET**

TACKET	
PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

# **MEGESTROL**

- megestrol oral suspension 400 mg/10 ml (40 mg/ml), 625 mg/5 ml (125 mg/ml)
- megestrol oral tablet

(10 1118/1111), 022	mg/5 mi (125 mg/mi)
PA Criteria	Criteria Details
Exclusion Criteria	Coverage is not provided for weight gain for cosmetic reasons.
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

### **MEKINIST**

- MEKINIST ORAL RECON SOLN
- MEKINIST ORAL TABLET 0.5 MG, 2 MG

PA Criteria	Criteria Details
TA CITICITA	Criteria Details
Exclusion Criteria	Members with colorectal cancer
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Melanoma-Initial: Approve if member has a diagnosis of unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test and member meets either A, B, or C: A) Member is treatment-naive and medication will be used as monotherapy, B) Member will be using the medication in combination with dabrafenib (Tafinlar), OR C) Member has lymph node involvement following complete resection and medication will be used as adjuvant treatment in combination with dabrafenib (Tafinlar). Non-Small Cell Lung Cancer (NSCLC)-Initial: Approve if member has a diagnosis of metastatic NSCLC with BRAF V600E mutations as detected by an FDA-approved test and medication will be used in combination with dabrafenib (Tafinlar). Anaplastic Thyroid Cancer (ATC)-Initial: Approve if member has a diagnosis of locally advanced or metastatic ATC with BRAF V600E mutations as detected by an FDA-approved test and there are no satisfactory locoregional treatment options available for the member. Medication must be used in combination with dabrafenib (Tafinlar). Solid Tumors-Initial: Approve if member has unresectable or metastatic solid tumors with BRAF V600E mutations as detected by an FDA-approved test. Member's disease has progressed following prior treatment and now have no satisfactory alternative treatment options. Medication must be used in combination with dabrafenib (Tafinlar). Low-Grade Glioma (LGG)-Initial:

PA Criteria	Criteria Details
	Approve if member has LGG with BRAF V600E mutations as detected by an FDA-approved test and disease requires systemic therapy. Medication must be used in combination with dabrafenib (Tafinlar). Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

# **MEKTOVI**

#### **Products Affected**

• MEKTOVI

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Melanoma-Initial: Approve if the member has unresectable or metastatic disease with a BRAF V600E or V600K mutation as detected by an FDA-approved test AND requested medication will be used in combination with encorfenib (Braftovi). Non-Small Cell Lung Cancer (NSCLC)-Initial: Approve if member has metastatic disease with a BRAF V600E mutation as detected by an FDA-approved test AND requested medication will be used in combination with encorfenib (Braftovi). Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

### **MEMANTINE**

#### **Products Affected**

- memantine oral capsule, sprinkle, er 24hr memantine oral tablet

• memantine oral solution

• memanine oral solution	
PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

# MERCAPTOPURINE SUSPENSION

#### **Products Affected**

• mercaptopurine oral suspension

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis and must have documentation showing that administration via nasogastric tube is required OR documentation of inability to swallow an intact tablet.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Approve if member has a diagnosis of Acute Lymphoblastic Leukemia (ALL) and will be using the requested medication as a part of a combination chemotherapy maintenance regimen. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

# **METHYLERGONOVINE**

#### **Products Affected**

• methylergonovine oral

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	7 days
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

# **METYROSINE**

#### **Products Affected**

• metyrosine

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an endocrinologist or a physician who specializes in the management of pheochromocytoma
Coverage Duration	12 months
Other Criteria	Initial: Approve if the member has a diagnosis of pheochromocytoma and member has tried a selective alpha blocker (e.g., doxazosin, terazosin or prazosin). Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

# **MIFEPRISTONE**

#### **Products Affected**

• mifepristone oral tablet 300 mg

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an endocrinologist or a physician who specializes in the treatment of Cushing's syndrome
Coverage Duration	12 months
Other Criteria	Endogenous Cushing's Syndrome-Initial: Approve if the requested medication is being used to control hyperglycemia secondary to hypercortisolism in members who have type 2 diabetes mellitus or glucose intolerance and member meets either A, B, or C: A) Member is not a candidate for surgery or surgery has not been curative, B) member is awaiting surgery for endogenous Cushing's Syndrome, OR C) Member is awaiting therapeutic response after radiotherapy for endogenous Cushing's Syndrome. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

### **MODAFINIL**

#### **Products Affected**

• modafinil oral tablet 100 mg, 200 mg

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

### **MODEYSO**

#### **Products Affected**

• MODEYSO

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

# **MULTAQ**

#### **Products Affected**

• MULTAQ

PA Criteria	Criteria Details
Exclusion Criteria	Permanent atrial fibrillation (sinus rhythm will never be restored), recently decompensated heart failure requiring hospitalization or Class IV heart failure, second or third-degree atrioventricular (AV) block or sick sinus syndrome (except when used in conjuction with a functioning pacemaker), bradycardia less than 50 bpm, concomitant use of a strong CYP3A inhibitor or drugs and herbal products that prolong the QT interval and may induce torsade de pointes, severe hepatic impairment, QTc Bazett interval greater than or equal to 500ms, pregnancy or nursing mothers
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Initial: Approve if the member is in sinus rhythm and has a history of paroxymal or persistent atrial fibrillation (AF). Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

# **NAYZILAM**

#### **Products Affected**

• NAYZILAM

PA Criteria	Criteria Details
Exclusion Criteria	Acute, narrow-angle glaucoma
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	12 months
Other Criteria	Intermittent Episodes of Frequent Seizure Activity (i.e., seizure clusters, acute repetitive seizures)-Initial: Approve if the member is currently receiving maintenance antiepileptic medication(s). Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician and member is still receiving maintenance antiepileptic medication(s).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

# **NERLYNX**

#### **Products Affected**

• NERLYNX

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Breast Cancer-Initial: Approve if member has HER-2-positive disease as detected by an FDA-approved test and meets either A or B: A) Member has early-stage disease and medication will be used as a single agent, for the extended adjuvant treatment to follow adjuvant trastuzumab-based therapy, OR B) Member has advanced or metastatic disease after receiving two or more prior anti-HER-2 based regimens in the metastatic setting and medication will be used in combination with capecitabine. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician and member has not exceeded total treatment of 1 year when being ised for extended adjuvant treatment of early-stage breast cancer.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **NEXLIZET**

#### **Products Affected**

• NEXLIZET

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Applicable definitions for all diagnoses include the following: High-Intensity Statin-Defined as atorvastatin 40 mg or higher OR rosuvastatin 20 mg or higher. Statin Intolerance-Defined as experiencing statin related rhabdomyolysis or skeletal-related muscle symptoms while reciving separate trieals of atorvastatin and rosuvastatin and during both trials the skeletal-related symptoms resolved upon discontinuation of the statin. Heterozygous Familial Hypercholesterolemia (HeFH)-Initial: Approve if member has a diagnosis of HeFH and meets both A and B: A) Member has one of the following (documentation required) i, ii, iii, or iv: i) untreated LDL-C at least 190 mg/dL, ii) phenotypic confirmation (i.e. mutations at the LDLR, apo B, PCSK-9, or LDLRAP1 genes), iii) Dutch Lipid Netowrk criteria score greater than 5, OR iv) Simon Broome criteria meets threshold for definite or possible/probable AND B) Member meets 1 or 2: 1) Member has tried one high-intensity statin and LDL-C remains 70 mg/dL or higher OR b) Member is statin intolerant. Primary Hyperlipidemia-Initial: Approve if the member has a diagnosis of primary hyperlipidemia that is not associated with established CVD or HeFH and meets either A or B: A) Member tried one high-intensity statin for 8 weeks or longer and the LDL-C remains at least 70 mg/dL OR B) Member is statin intolerant. High-Risk CVD and Established CVD-Initial: Approve if the member meets either 1 or 2: 1) Member tried one high-intensity statin and the LDL-C remains at least 55 mg/dL OR B) Member is statin intolerant (including

PA Criteria	Criteria Details
	those not taking a statin) AND Member meets either A or B: A) Member is a high risk for a CVD event, but without established CVD (i.e. i.e family history of premature ASCVD, primary hypercholesterolemia (LDL-C 160-189), metabolic syndrome, CKD, chronic inflammatory conditions, history of premature menopause and and pregnancy-associated conditions that increase later ASCVD risk, high-risk races/ethnicities, lipid/biomarkers associated with increased ASCVD risk, and diabetes-specific high-risk features but without established CVD) OR B) Member has established CVD with chart documentation of one of the following events: Prior MI, ACS, angina, CVA or TIA, CAD, PAD, coronary or other arterial revascularization procedure. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

# **NILUTAMIDE**

#### **Products Affected**

• nilutamide

PA Criteria	Criteria Details
Exclusion Criteria	Severe hepatic impairment or severe respiratory insufficiency
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Prostate cancer-Initial: Approve if the member had surgical castration for the treatment of metastatic prostate cancer (Stage D2). Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

# **NINLARO**

#### **Products Affected**

• NINLARO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Multiple Myeloma (MM)-Initial: Approve if the member has received at least one prior therapy for multiple myeloma and the requested medication will used in combination with lenalidomide and dexamethasone. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

# **NITISINONE**

#### **Products Affected**

• nitisinone

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a gastroenterologist, a hematologist, a nephrologist, or a physician who specializes in the treatment of inherited metabolic disorders
Coverage Duration	12 months
Other Criteria	Hereditary Tyrosinemia, Type 1 (HT-1)-Initial: Approve if the member has a diagnosis of HT-1 confirmed by chart note documentation showing one of the following A, B, or C: A) newborn screening for HT-1 with a positive succinylacetone test (test result and reference range required), B) genetic test result showing fumarylacetoacetate hydrolase (FAH) gene mutation (test result and reference range required), OR C) elevated blood or urine succinylacetone or succinylacetoacetate (SA) level (test result and reference range required). Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

# **NIVESTYM**

#### **Products Affected**

• NIVESTYM

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with filgrastim or pegfilgrastim products within seven days of dose
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist, hematologist, or transplant specialist
Coverage Duration	6 months
Other Criteria	Members with cancer receiving chemotherapy: Approve if the member meets either A, B, or C: A) Member is receiving myelosuppressive anticancer medications that are associated with a high risk of febrile neutropenia (the risk is at least 20 percent based on the chemotherapy regimen), B) Member is receiving myelosuppressive anti-cancer medications that are associated with a risk of febrile neutropenia but the risk is less than 20 percent based on the chemotherapy regimen and the member has one or more risk factors for febrile neutropenia (eg, aged greater than or equal to 65 years, prior chemotherapy or radiation therapy, persistent neutropenia, bone marrow involvement by tumor, recent surgery and/or open wounds, liver and/or renal dysfunction, poor performance status or HIV infection, OR C) Member has had a neutropenic complication from prior chemotherapy and did not receive prophylaxis with a colony stimulating factor and a reduced dose or frequency of chemotherapy may compromise treatment.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

# **NOVOFINE DIABETIC SUPPLIES**

#### **Products Affected**

• NEEDLES, INSULIN DISP., SAFETY

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Clinical rationale why the member is unable to use the preferred product (i.e. BD Autoshield Duo Needle 5mm x 30G, BD Autoshield Duo Pen Needle 5mm x 30G) must be submitted.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Approve if the prescriber confirms that the medical supply is being requested for a use that is directly associated with delivering insulin to the body.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

# **NUBEQA**

#### **Products Affected**

NUBEQA

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

### **NUCALA**

- NUCALA SUBCUTANEOUS AUTO-INJECTOR
- NUCALA SUBCUTANEOUS RECON SOLN
- NUCALA SUBCUTANEOUS SYRINGE 100 MG/ML, 40 MG/0.4 ML

SOLN	
PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

# **NUEDEXTA**

#### **Products Affected**

• NUEDEXTA

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with quinidine, quinine, or mefloquine. Members with a history of quinidine, guinine, or mefloquine-induced thrombocytopenia, hepatitis, or other hypersensitivity reactions. Use with MAOI or within 14 days of stopping an MAOI. Prolonged QT interval, congenital long QT syndrome, history suggestive of torsades de pointes, or heart failure. Complete atrioventricular (AV) block without implanted pacemaker, or patients at high risk of complete AV block. Concomitant use with drugs that both prolong QT interval and are metabolized by CYP2D6 (e.g. thiordazine or pimozide).
Required Medical Information	Diagnosis
Age Restrictions	Diagnosis
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	Initial: 3 months Reauthorization: 12 months
Other Criteria	Pseudobulbar Affect (PBA)-Initial: Member must have a diagnosis of PBA supported by chart documentation of the following: involuntary outbursts of laughing and/or crying that are incongruous or disproportionate to the member's emotional state and documentation of a clinical work-up, including clinical rationale for the PBA diagnosis and exclusion of other possible conditions that could result in emotional lability (e.g. depression, bipolar disorder, schizophrenia, epilepsy). Must have underlying neurological disorder such amyotrophic lateral scelerosis, multiple scloerosis, Alzheimer's and related diseases, stroke, traumatic brain injury, or Parkinsonian Syndrome. Reauthorization: Must have documentation from provider indicating decrease in number of laughing and/or crying episodes as a result of therapy.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	No

# **NUPLAZID**

#### **Products Affected**

• NUPLAZID

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	12 months
Other Criteria	Initial: Member must be using medication for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. Must provide clinical rationale for diagnosis and exclusion of other diagnoses (e.g., dementia with Lewy bodies, visual processing deficits/loss of visual acuity, infectious causes, a general medical condition including delirium, or psychiatric disorders such as schizophrenia, schizoaffective disorder, delusional disorder, or mood disorder with psychotic features). Must have tried to discontinue or reduce dose of any medication(s) that may cause or contribute to hallucinations and delusions (e.g., dopamine agonist, amantadine, monoamine oxidase B inhibitors, anticholinergics) or provide clinical rationale indicating why dose reduction or discontinuation of applicable medications would not be appropriate. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

# **NURTEC**

#### **Products Affected**

• NURTEC ODT

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

# **OCTREOTIDE (INJECTABLE)**

#### **Products Affected**

• octreotide acetate

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Acromegaly: Prescribed by or in consultation with an endocrinologist. Carcinoid tumor, VIP-secreting tumor: Prescribed by or in consultation with an oncologist.
Coverage Duration	12 months
Other Criteria	Acromegaly-Initial: Approve if the member has a confirmed diagnosis of acromegaly with elevated serum IGF-1 for age/gender (test results with reference range required) or elevated growth hormone level greater than or equal to 1 ng/mL during an oral glucose intolerance test (test result with reference range required). Member must have inadequate response to surgery or documentation that this therapy is inappropriate. Severe Diarrhea and Flushing-Initial: Approve if the member has severe diarrhea and flushing associated with a metatstatic carcinoid tumor. Profuse Watery Diarrhea-Initial: Approve if the member has profuse watery diarrhea associated with Vasoactive Intestinal Peptide Tumors (VIPomas). Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

# **ODOMZO**

#### **Products Affected**

• ODOMZO

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

# **OFEV**

### **Products Affected**

• OFEV

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	IPF: Prescribed by or in consultation with a pulmonologist. Interstitial lung disease associated with systemic sclerosis: Prescribed by or in consultation with a pulmonologist or rheumatologist.
Coverage Duration	12 months
Other Criteria	Idiopathic Pulmonary Fibrosis (IPF)-Initial: Member must have FVC greater than or equal to 40% of the predicted value. Must have diffusing capacity for carbon monoxide (DLCO) 30% to 90% of predicted. IPF must be diagnosed with either findings on high-resolution computed tomography (HRCT) indicating usual interstitial pneumonia (UIP) or surgical lung biopsy demonstrating UIP with all other diagnoses ruled out (e.g. domestic and occupational enviornmental exposures, connective tissue disease, and drug toxicity). Interstitial lung disease associated with systemic sclerosis-Initial: Approve if the FVC is greater than or equal to 40% of the predicted value. Must have DLCO 30% to 89% of predicted. Diagnosis is confirmed by high-resolution computed tomography (CT) with evidence of fibrosis. Member must meet the 2013 ACR/EULAR criteria for definite systemic sclerosis (total score of 9 or more). Chronic fibrosing interstitial lung disease (ILDs)-Initial: Approve if the member has progressive phenotype disease (defined as meeting one of the following criteria for disease progression in the previous 24 months despite treatement for ILD: FVC decline greater than or equal to 10%. FVC decline 5% to less than 10% and worsening of respiratory symptoms, FVC decline 5% to less than 10% and increased extent of fibrosis on imaging, FVC greater than or equal to 45% of predicted, and DLCO 30% to less than 80% of predicted. Diagnosis is confirmed by CT with evidence of fibrosis (documenation required).

PA Criteria	Criteria Details
	Reauthorization: Must have documentation from prescriber indicating improvement or stabilization in condition and must provide current FVC and DLCO values.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

# **OGSIVEO**

### **Products Affected**

• OGSIVEO ORAL TABLET 100 MG, 150 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with a hematologist or oncologist
Coverage Duration	12 months
Other Criteria	Initial: Approve if member has been diagnosed with progressing desmoid tumor (progressing desmoid tumors are defined as greater than or equal to 20% progression based on Response Evaluation Criteria in Solid Tumors (RECIST) within 12 months. Tumor is not amenable to surgery or radiotherapy and if the member requires systemic treatment. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

### **OJEMDA**

#### **Products Affected**

• OJEMDA ORAL SUSPENSION FOR RECONSTITUTION

MG/WEEK (100 MG X 5), 600 MG/WEEK (100 MG X 6)

• OJEMDA ORAL TABLET 400 MG/WEEK (100 MG X 4), 500

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, For suspension: must have chart note documentation of the clinical rationale for why tablets cannot be used.
Age Restrictions	Pediatrics 6 months - 21 years of age
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Low-grade glioma (LGG)-Initial: Approve if the member has relapsed or refractory LGG harboring a BRAF fusion or rearrangment or BRAF V600 mutation as detected by an FDA-approved test. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

# **OJJAARA**

### **Products Affected**

OJJAARA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Myelofibrosis (MF), including Primary MF, Post-Polycythemia Vera MF, and Post-Essential Thrombocythemia MF-Initial: Approve if the member has anemia and a diagnosis of intermediate-2 or high-risk disease. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

# **ONUREG**

### **Products Affected**

• ONUREG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Acute Myeloid Leukemia (AML)-Initial: Approve if the member meets both A and B: A) Member achieved first complete remission (CR) or complete remission with incomplete blood count recover (CRi) following intensive induction chemotherapy AND B) Member is not able to complete intensive curative therapy.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

# **OPIPZA**

### **Products Affected**

• OPIPZA ORAL FILM 10 MG, 2 MG, 5 MG

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

# **ORGOVYX**

### **Products Affected**

• ORGOVYX

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Prostate Cancer-Initial: Approve if the member has advanced disease. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

## **ORKAMBI**

### **Products Affected**

- ORKAMBI ORAL GRANULES IN ORKAMBI ORAL TABLET **PACKET**

PA Criteria	Criteria Details	
Exclusion Criteria	Concomitant use with other medications containing ivacaftor	
Required Medical Information	Diagnosis	
Age Restrictions	N/A	
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist or a cystic fibrosis specialist	
Coverage Duration	12 months	
Other Criteria	Initial: Must have a diagnosis of cystic fibrosis and documentation of one of the following: 1) Member is homozygous (two copies) for the F508del mutation in the CFTR gene OR 2) If the member's genotype is unknown, an FDA-cleared cystic fibrosis mutation test used to detect the presence of the F508del mutation on both alleles of the CFTR gene. Provider attestation liver function tests will be assessed prior to initiation of treatement, during the first 6 months of treatment, every 3 months for the next 12 months, then at least annually thereafter. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician, absent of toxicities, and provider attestation to monitor liver function tests at least annually.	
Indications	All FDA-approved Indications.	
Off-Label Uses	N/A	
Part B Prerequisite	No	
Prerequisite Therapy Required	No	

# **ORSERDU**

### **Products Affected**

• ORSERDU ORAL TABLET 345 MG, 86 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Initial: Approve if the member has a diagnosis of breast cancer that meets meets the following criteria (A, B, and C): A) Member has advanced or metastatic disease with progression after trying at least one line of endocrine therapy (e.g. fulvestrant, anastrozole, exemestane, letrozole), B) Disease is estrogen receptor positive (ER+) disease, human epidermal growth factor receptor 2 (HER2)-negative disease, estrogen receptor 1 gene (ESR1)-mutated as determined by an FDA-approved test, AND C) Member is a postmenopausal woman or adult male. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **OTEZLA**

### **Products Affected**

• OTEZLA

MG (51), 10 MG (4)-20 MG (4)-30 MG (47)

• OTEZLA STARTER ORAL TABLETS,DOSE PACK 10 MG (4)- 20

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

# **PANRETIN**

### **Products Affected**

• PANRETIN

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with a dermatologist, oncologist, or infectious disease specialist
Coverage Duration	12 months
Other Criteria	Kaposi Sarcoma (KS)-Initial: Approve if the member will be using the medication for the topical treatment of cutaneous lesions in AIDS-related KS and the provider has confirmed the member does not require systemic treatment. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

## **PAZOPANIB**

### **Products Affected**

• pazopanib

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Renal Cell Carcinoma (RCC)-Initial: Approve if the member has advanced, relapsed, or unresectable disease with predominant clear cell histology and meets either A or B: A) Medication will be used as first-line therapy as a single agent OR B) Medication will be used as subsequent therapy and as a single agent after disease progression on prior first-line therapy. Soft Tissue Sarcomas (STS)-Initial: Member has a diagnosis of STS other than GIST (e.g. angiosarcoma, Pleomorphic rhabdomyosarcoma, retroperitoneal/intra-abdominal soft tissue sarcoma that is unresectable or progressive, soft tissue sarcoma of the extremity/superficial trunk or head/neck, including synovial sarcoma, or solitary fibrous tumor/hemangiopericytoma or alveolar soft part sarcoma) and the member has progressed after prior chemotherapy. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

# **PEMAZYRE**

### **Products Affected**

• PEMAZYRE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Cholangiocarcinoma-Initial: Approve if the member has unresectable, locally advanced or metastatic disease and the tumor has a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement, as detected by an approved test. Member must has been previously treated with at least one systemic therapy regimen prior to approval. Myeloid/Lymphoid Neoplasm (MLN)-Initial: Approve if the member has relapsed or refractory disease. MLN must be documented as fibroblast growth factor receptor 1 (FGFR1) rearrangement as detected by an FDA-approved test. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

# **PENICILLAMINE**

### **Products Affected**

• penicillamine oral tablet

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

# **PHENYLBUTYRATE**

### **Products Affected**

• sodium phenylbutyrate

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

# **PIMECROLIMUS (TOPICAL)**

### **Products Affected**

• pimecrolimus

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Initial: Approve if the member has a diagnosis of atopic dermatitis. Member must have a trial and failure or contraindication to a moderate to high potency topical corticosteroid (Note: Potency exceptions may be made for members with dermatitis affecting the face or intertriginous areas) and topical tacrolimus ointment. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

# **PIQRAY**

### **Products Affected**

• PIQRAY ORAL TABLET 200 MG/DAY (200 MG X 1), 250 MG/DAY (200 MG

X1-50 MG X1), 300 MG/DAY (150 MG X 2)

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Breast Cancer-Initial: Approve if the member has advanced or metastatic disease meets the following criteria (A, B, and C): A) Disease is hormone receptor (HR)-positive, has human epidermal growth factor receptor 2 (HER2)-negative, and PIK3CA-mutated breast cancer as detected by an FDA-approved test, B) Disease has progressed on or after an endocrine-based regimen (e.g., anastrozole, letrozole, exemestane, tamoxifen, toremifene) AND C) Medication will be used in combination with fulvestrant injection.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

# **PIRFENIDONE**

### **Products Affected**

• pirfenidone oral capsule

• pirfenidone oral tablet 801 mg

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist
Coverage Duration	12 months
Other Criteria	Idiopathic Pulmonary Fibrosis (IPF)-Initial: Member must have FVC greater than or equal to 40% of the predicted value. Must have diffusing capacity for carbon monoxide (DLCO) 30% to 90% of predicted. IPF must be diagnosed with either findings on high-resolution computed tomography (HRCT) indicating usual interstitial pneumonia (UIP) or surgical lung biopsy demonstrating UIP with all other diagnoses ruled out (e.g. domestic and occupational enviornmental exposures, connective tissue disease, and drug toxicity). Reauthorization: Must have documentation from prescriber indicating improvement or stabilization in condition and must provide current FVC and DLCO values.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

### **PLEGRIDY**

#### **Products Affected**

- PLEGRIDY INTRAMUSCULAR
- PLEGRIDY SUBCUTANEOUS PEN INJECTOR 125 MCG/0.5 ML, 63 MCG/0.5 ML- 94 MCG/0.5 ML
- PLEGRIDY SUBCUTANEOUS SYRINGE 125 MCG/0.5 ML, 63 MCG/0.5 ML- 94 MCG/0.5 ML

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use of with other disease-modifying agents used for multiple sclerosis (MS).
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or after consultation with a neurologist or an MS specialist.
Coverage Duration	12 months
Other Criteria	Initial: Approve if member has a diagnosis of relapsing forms of multiple sclerosis (RRMS). Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

# **POMALYST**

### **Products Affected**

• POMALYST

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

# POSACONAZOLE (ORAL)

### **Products Affected**

• posaconazole oral tablet,delayed release (dr/ec)

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with CYP3A4 substrates that prolong the QT interval (e.g., pimozide, quinidine), sirolimus, HMG-CoA reductase inhibitors that are primarily metabolized through CYP3A4 (e.g., atorvastatin, lovastatin, simvastatin), ergot alkaloids, venetoclax at initiation and during the rampup phase in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	6 months
Other Criteria	Prophylaxis-Initial: Member must be using medication as prophylaxis against invasive aspergillus and candida infections. Member must be severely immunocompromised (i.e. hematopoietic stem cell transplant [HSCT], recipient with graft vs host disease [GvHD], or members with prolonged neutropenic from chemotherapy for hematologic malignancies such as acute myelogenous leukemia [AML] or myelodysplastic syndromes [MDS]). Reauthorization: Members requiring further treatment will be reassessed using the initial criteria.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

# **PREVYMIS**

### **Products Affected**

- PREVYMIS ORAL PELLETS IN PREVYMIS ORAL TABLET **PACKET**

PACKET	
PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with pimozide and/or ergot alkaloids or with pitavastatin and simvastatin when co-administered with cyclosporine
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by a hematologist, infectious disease physician, oncologist, or transplant physician
Coverage Duration	210 days
Other Criteria	Prophylaxis of Cytomegalovirus (CMV)-Initial: Approve if the member is using the requested medication as prophylaxis of CMV infection and disease and the member meets either A or B: A) Member weighs at least 6 kg and is a CMV-seropositive recipient [R+] of an allogenic hematopoietic stem cell transplant (HSCT). Member must have received an allogeneic hematopoietic stem cell transplant. Medication will be initiated within 28 days post-transplant OR B) Member weighs at least 40 kg and is a kidney transplant recipient at high risk where the donor is CMV seropositive and the recipient is CMV seronegative (D+/R-). Member must have a medical reason as to why valganciclovir therapy cannot be started or continued (e.g., breakthrough CMV infection, adverse effects leading to discontinuation of valganciclovir). For all diagnoses, treatment duration must not exceed 200 days post-transplant. Reauthorization: Members requiring further treatment will be reassessed using the initial criteria.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

# **PROLIA**

### **Products Affected**

• PROLIA

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

## **PROMACTA**

#### **Products Affected**

- eltrombopag olamine oral powder in packet 12.5 mg, 25 mg
- eltrombopag olamine oral tablet 12.5 mg, 25 mg, 50 mg, 75 mg

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

# **PULMOZYME**

### **Products Affected**

• PULMOZYME

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

# **PYRIMETHAMINE**

### **Products Affected**

• pyrimethamine

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an infectious diseases specialist
Coverage Duration	3 months
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

# QINLOCK

### **Products Affected**

QINLOCK

PA Criteria	Criteria Details
ra Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Gastrointestinal Stromal Tumor (GIST)-Initial: Approve if the member has a diagnosis of advanced GIST and has received prior treatment with imatinib AND two or more other kinase inhibitors (e.g. sunitinib, dasatinib). Medication will be used as monotherapy. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

# **QULIPTA**

### **Products Affected**

• QULIPTA

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

# **RALDESY**

### **Products Affected**

• RALDESY

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, must have documentation showing that administration via nasogastric tube is required OR documentation of inability to swallow an intact tablet.
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Approve if member has a diagnosis of Major Depressive Disorder based on the following: A) Member has five or more of the following symptoms that have been present during the same two-week period and represent a change from previous functioning (Note: one of the symptoms is either depressed mood or loss of interest or pleasure): 1) depressed mood most of the day, nearly every day, 2) markedly diminished interest or pleasure in all, or almost all, activities most of the day, nearly every day, 3) significant weight loss when not dieting or weight gain (e.g. a change of more than 5% in a month), or change in appetite nearly every day, 4) insomnia or hypersomnia nearly every day, 5) psychomotor agitation or retardation nearly every day that are observable by others, 6) fatigue or loss of energy nearly every day, 7) feelings of worthlessness or excessive or inappropriate guilt, 8) diminished ability to think or concentrate, or indecisiveness, nearly every day, 9) recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attemmpt or a specific plan for committing suicide, B) The episode is not attributable to the psysiologoical effects of a substance or to another medical condition (i.e. serious medical illness or disability, financial hardships), AND C) The occurrence of the major depressive episode is not better explained by schizoaffective disorder, schizophrenia, schizophreniform disorder, delusional disorder, or other specified and unspecified schizophrenia spectrum and other psychotic disorders. The member must have a trial and failure of two generic

PA Criteria	Criteria Details
	antidepressants used to treat the same indication prior to approval (i.e. sertraline concentrate, fluoxetine solution, citalopram solution, escitalopram solution). Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **REPATHA**

### **Products Affected**

• REPATHA

- REPATHA SURECLICK
- REPATHA PUSHTRONEX

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use of with other injectable lipid lowering medications
Required Medical Information	Diagnosis
Age Restrictions	ASCVD/Primary Hyperlipidemia - 18 yo and older, HoFH/HeFH - 10 yo and older.
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist, endocrinologist, or a physician who focuses in the treatment of CV risk management and/or lipid disorders
Coverage Duration	12 months
Other Criteria	Hyperlipidemia with HeFH-Initial: Approve if the member meets both A and B: A) Member has a diagnosis of HeFH AND 2) tried ONE high intensity statin (i.e. atorvastatin greater than or equal to 40 mg daily or rosuvastatin greater than or equal to 20 mg daily) and LDL remains 70 mg/dL or higher unless member is statin intolerant defined by experiencing statin related rhabdomyolysis or skeletal-related muscle symptoms while receiving separate trials of atorvastatin and rosuvastatin and during both trials the symptoms resolved upon discontinuation. Hyperlipidemia with ASCVD-Initial: Approve if the member meets both A and B: A) Member has one of the following conditions: history of coronary artery disease, prior MI, history of ACS, diagnosis of angina, history of CVA or TIA, PAD, undergone a coronary or other arterial revascularization procedure, AND B) tried ONE high intensity statin (defined above) and LDL remains 70 mg/dL (55 mg/dL for members with T2DM) or higher unless pt is statin intolerant (defined above). HoFH-Initial: Approve if the member meets both A and B: A) Member must have one of the following: a) genetic confirmation of two mutant alleles at the LDLR, APOB, PCSK9, or LDLRAP1 gene locus, OR b) untreated LDL greater than 500 mg/dL (prior to treatment), OR c) treated LDL greater than or equal to 300 mg/dL (after treatment but prior to agents such as PCSK9 inhibitors), OR d) has clinical

PA Criteria	Criteria Details
	manifestations of HoFH (e.g., cutaneous xanthomas, tendon xanthomas, arcus cornea, tuberous xanthomas or xanthelasma), AND 2) tried ONE high intensity statin (defined above) for 8 weeks or longer and LDL remains 70 mg/dL or higher unless statin intolerant (defined above). Primary hyperlipidemia (not associated with ASCVD, HeFH, or HoFH)-Initial: Approve if the member meets either A or B: A) tried one high-intensity statin therapy (defined above) and ezetimibe for 8 weeks or longer and LDL remains 100 mg/dL or higher unless statin intolerant (defined above) OR B) has baseline LDL-C 190 or greater prior to treatment with antihyperlipidemic therapy. Reauthorization: Approve if the provider has submitted documentation demonstrating an improvement in the members condition while on therapy, showing recent assessment of LDL-C level that has decreased from baseline.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **RETEVMO**

#### **Products Affected**

• RETEVMO ORAL TABLET 120 MG, 160 MG, 40 MG, 80 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	Medullary Thyroid Cancer/Thyroid Cancer/Solid tumors with RET gene fusion: 2 years and older, NSCLC: 18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Non-Small Cell Lung Cancer (NSCLC)-Initial: Approve if the member has locally advanced or metastatic disease AND the tumor is RET fusion-positive as detected by an FDA-approved test. Medullary Thyroid Cancer-Initial: Approve if the member has advanced or metastatic RET-mutant disease as detected by an FDA-approved test AND the disease requires treatment with systemic therapy. RET Fusion-Thyroid Cancer-Initial: Approve if the member has advanced or metastatic thyroid cancer with a RET gene fusion as detected by an FDA-approved test. Member requires systemic therapy and is radioactive iodine-refractory (if radioactive iodine is appropriate). RET Fusion-Positive Solid Tumors-Initial: Approve if member has locally advanced or metastatic solid tumors with a RET gene fusion as detected by an FDA-approved test that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	No

# **REVCOVI**

### **Products Affected**

• REVCOVI

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

# **REVUFORJ**

#### **Products Affected**

• REVUFORJ ORAL TABLET 110 MG, 160 MG, 25 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Initial: Approve if member has a diagnosis of relapsed or refractory acute leukemia AND has a lysine methyltransferase 2A gene (KMT2A) translocation as detected by an FDA-approved test. Reauthorization: Member has responded positively to therapy as determined by the prescriber.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

### **REZDIFFRA**

### **Products Affected**

• REZDIFFRA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a hepatologist or gastroenterologist
Coverage Duration	12 months
Other Criteria	Initial: Approve if member has a diagnosis of non-alcoholic steatohepatitis or metabolic dysfunction associated steatohepatitis (NASH/MASH). Member must have at least one of the following cardeometabolic risk factors: BMI at least 25 kg/m2, hypertension, dyslipidemia, prediabeties, or type 2 diabetes. Member must have steatosis on imagining (e.g., ultrasound, Fibroscan CAP, MRI-PDFF) or liver biopsy (documentation required). Member must have moderate to advanced liver fibrosis confirmed by one of the following performed in the last 6 months: 1) Liver biopsy shows fibrosis stage F2 or F3 AND a non-alcoholic fatty liver disease activity score (NAS) of at least 4 with a score of greater than 1 in all the following: steatosis, ballooning, and lobular inflammation OR 2) Test results from the previous 6 months documenting liver fibrosis stage F2 to F3 OR FIB-4 greater than or equal to 1.3 AND one of the following non-invasive tests consistent with F2 to F3 fibrosis (documentation required): transient elastography (FibroScan), magnetic resonance elastography (MRE), or shear wave elastography. Must not have evidence of cirrhosis (stage 4 fibrosis) by imaging or liver biopsy or one or more liver-related complications associated with cirrhosis (i.e. variceal bleeding, ascites, hepatic encephalopathy). Provider must attest member does not have significant alcohol use (defined as alcohol consumption of more than 1 drink per day for natal females or more than 2 drinks per day for natal males). Requested medication will be used in combination with appropriate

PA Criteria	Criteria Details
	diet and exercise therapy (prescriber confirms the patient has received counseling on diet and exercise). Reauthorization: Approve if the member has chart note documentation of all the following: improvement or stabilization in condition, no evidence of cirrhosis (stage F4 fibrosis) by imaging or liver biopsy or one or more liver-related complications associated with cirrhosis (e.g., variceal bleeding, ascites, hepatic encephalopathy, etc.). Must have attestation from prescriber that the member does not have significant alcohol use (defined as alcohol consumption of more than 1 drink/day for natal females or more than 2 drinks/day for natal males), and must continue to be used in conjunction with diet and exercise.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

### **REZLIDHIA**

### **Products Affected**

• REZLIDHIA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Acute Myeloid Leukemia (AML)-Initial: Approve if the member has relapsed or refractory disease with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

### **REZUROCK**

### **Products Affected**

• REZUROCK

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

# **RILUZOLE**

### **Products Affected**

• riluzole

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist, a neuromuscular disease specialist, or a physician specializing in the treatment of ALS
Coverage Duration	12 months
Other Criteria	Initial: Approve if according to the prescribing physician, the member has a definite or probably diagnosis of amyotrophic lateral sclerois (ALS), based on the application of the El Escorial or the revised Airlie house diagnostic criteria. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

# **RINVOQ**

#### **Products Affected**

• RINVOQ ORAL TABLET EXTENDED RELEASE 24 HR 15 MG, 30 MG, 45 MG

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

# **ROFLUMILAST**

### **Products Affected**

• roflumilast

PA Criteria	Criteria Details
Exclusion Criteria	Moderate to severe liver impairment (Child-Pugh B or C)
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Chronic Obstructive Pulmonary Disease (COPD)-Initial: Approve if member has a diagnosis of severe COPD and meets the following: A) Patient has a history of exacerbations, B) Member has tried a medication from two of the three following drug categories: long-acting beta2-agonist (LABA) [eg, salmeterol, indacaterol], long-acting muscarinic antagonist (LAMA) [eg, tiotropium], inhaled corticosteroid (eg, fluticasone), C) Member will be titrated to maintenance dose of 500 mcg after 4 weeks of therapy, and D) Member will continue maintenance medication with LABA or LAMA for duration of therapy. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician and member will continue maintenance medication with LABA or LAMA for duration of therapy
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **ROMVINZA**

### **Products Affected**

• ROMVIMZA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Approve if member has a diagnosis of symptomatic tenosynovial giant cell tumor (TGCT) where surgical resection will potentially cause worsening functional limitation or severe morbidity. Provider must attest liver function tests will be evaluation prior to initiation of treatment. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician and provider attests liver function tests will continue to be monitored during treatment.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

### **ROZLYTREK**

#### **Products Affected**

- ROZLYTREK ORAL CAPSULE 100 MG, 200 MG
- ROZLYTREK ORAL PELLETS IN PACKET

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Solid Tumors-Initial: Approve if the member meets the following (A, B, and C): A) The member has metastatic tumors or surgical resection is likely to result in severe morbidity, B) Tumors have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion as detected by an FDA-approved test without a known acquired resistance mutation, AND C) Disease has progressed on prior therapies or there are no acceptable alternative therapies. Non-Small Cell Lung Cancer-Initial: Approve if member has ROS1-positive metastatic disease as detected by an FDA-approved test. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **RUBRACA**

### **Products Affected**

• RUBRACA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Ovarian, Fallopian Tube, or Primary Peritoneal Cancer-Initial: Approve if the member will be using the requested medication for maintenance therapy. The member's disease is recurrent, metastatic, and positive for a deleterious BRCA mutation (germline and/or somatic) as detected by an FDA-approved test. Member had complete or partial response to platinum-based chemotherapy. Medication will be used as monotherapy. Prostate Cancer-Initial: Approve if the member's disease is metastic and castration-resistant prostate cancer (mCRPC) and member meets the following (A, B, and C): A) Disease is positive for a deleterious BRCA mutation (germline or somatic) as detected by an FDA-approved test, B) Member has been treated with androgen receptor-directed therapy (e.g. abiraterone, apalutamide [Erleada]) and a taxane-based chemotherapy (e.g. docetaxel), AND C) Medication will be used concurrently with a gonadotropin-releasing hormone (GnRH) analog OR member has had a bilateral orchiectomy. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **RUFINAMIDE**

#### **Products Affected**

- rufinamide oral suspension
- rufinamide oral tablet 200 mg, 400 mg

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, For suspension, must have documentation showing that administration via nasogastric tube is required OR documentation of inability to swallow an intact tablet.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	12 months
Other Criteria	Initial: Approve if the member has a diagnosis of Lennox-Gastaut Syndrome (LGS) and meets the following (A and B): A) Requested medication will be used as adjunctive treatment to other antiepileptic drugs, AND B) Member had a trial and failure or contraindication to two generic antiepileptic drugs (e.g. lamotrigine, topiramate). Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **RYDAPT**

### **Products Affected**

• RYDAPT

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Acute Myeloid Leukemia (AML)-Initial: Approve if the member has a diagnosis of AML that is newly diagnosed and meets the following (A and B): A) Disease is FLT3 mutation-positive as detected by an FDA-approved test AND, B) Medication will be used in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. Aggressive Systemic Mastocytosis (ASM), Systemic Mastocytosis with Associated Hematological Neoplasm (SM-AHN), or Mast Cell Leukemia-Initial: Approve. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

# SANDOSTATIN LAR

#### **Products Affected**

• octreotide, microspheres

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, previous treatments/therapies
Age Restrictions	N/A
Prescriber Restrictions	Acromegaly-prescr/consult w/endocrinologist. All neuroendocrine tumors-prescr/consult w/oncologist, endocrinologist, or gastroenterologist. Pheochromocytoma/paraganglioma-prescr/consult w/endo/onc/neuro.Meningioma-prescr/consult w/oncologist, radiologist or neurosurgeon. Merkel cell/Thymoma/Thymic carcinoma-prescr/consult w/oncologist. Diarrhea assoc w chemo-presc/consult oncologist/gastro.
Coverage Duration	Enterocutaneous fistula/diarrhea assoc w chemo - 3 months, all others - 1 year
Other Criteria	Acromegaly-approve if the patient has (or had) a pre-treatment (baseline) insulin-like growth factor-1 (IGF-1) level above the upper limit of normal based on age and gender for the reporting laboratory AND the patient meets i., ii., or iii: i. has had an inadequate response to surgery and/or radiotherapy or iii. is not an appropriate candidate for surgery and/or radiotherapy or iii. the patient is experiencing negative effects due to tumor size (e.g., optic nerve compression). Diarrhea assoc w chemo (A and B): A) grade 3 or 4 diarrhea and B) patient has tried at least one antimotility medication. Merkel cell carcinoma (A and B): A) patient has regional or distant metastatic disease and B) has contraindications to or has progressed on checkpoint immunotherapy. Neuroendocrine Tumor(s) [NETs] of the Gastrointestinal Tract, Lung, Thymus (Carcinoid Tumors), and Pancreas (including glucagonomas, gastrinomas, vasoactive intestinal peptides-secreting tumors [VIPomas], insulinomas)-approve.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.

PA Criteria	Criteria Details
Off-Label Uses	Pheochromocytoma/paraganglioma, Meningioma, Thymoma and thymic carcinoma, enterocutaneous fistulas, diarrhea associated with chemotherapy, Merkel cell carcinoma
Part B Prerequisite	No
Prerequisite Therapy Required	No

# **SAPROPTERIN**

### **Products Affected**

• sapropterin

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with Pegvaliase-pqpz (Palynziq)
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a specialist who focuses in the treatment of metabolic diseases
Coverage Duration	Initial: 3 months Reauthorization: 12 months
Other Criteria	Initial: Approve if member has hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive phenylketonuria (PKU. Provider must send chart note documentation of baseline blood phenylalanine showing a level greater than 360 micromol/L. Must provide current weight and requested dose must fall within recommended dosing guidelines from the manufacturer. Member will be using requested medication in conjunction with a Phe-restricted diet, including dietary protein and Phe restriction. Reauthorization: Approve if the member has responded positively to therapy as evidenced by a decrease in blood phenylalanine level from baseline. If member has not had a decrease in blood phenylalanine level, must have documentation of dose increase to 20 mg/kg/day. Authorizations for these members are extended for an additional one month trial at the higher dose. Authorizations for members who have not had a decrease in blood phenylalanine level at the 20 mg/kg/day dose may not be extended. Member will continue using requested medication in conjunction with a Phe-restricted diet, including dietary protein and Phe restriction
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	No

### **SCEMBLIX**

#### **Products Affected**

• SCEMBLIX ORAL TABLET 100 MG, 20 MG, 40 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Chronic Myeloid Leukemia (CML)-Initial: Approve if the member meets either of the following (A, B, or C): A) Member has newly diagnosed Philadelphia chromosome-positive (Ph+) CML as detected by an FDA-approved test and member is in chronic phase, B) Member has Ph+ CML as detected by an FDA-approved test that has been previously treated and is in chronic phase, OR C) Member has Ph+ CML that is T315I-positive as detected by an FDA-approved test. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **SIGNIFOR**

### **Products Affected**

• SIGNIFOR

PA Criteria	Criteria Details
Exclusion Criteria	Severe Hepatic impairment (Child-Pugh C)
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an endocrinologist or a physician who specializes in the treatment of Cushing's Disease
Coverage Duration	12 months
Other Criteria	Cushing's Disease-Initial: Member must have diagnosis of Cushing's Disease and meet the following (A, B, C, and D): A) Previously had pituitary surgery (e.g., transsphenoidal surgery) that was not curative or must not be a candidate for surgery, B) Must provide a baseline 24-hour urinary free cortisol level, C) Must have recent (within 6 months) baseline assessment of hemoglobin A1C and provide documentation of anti-diabetic therapy if baseline hemoglobin is greater than 8%, AND D) Documention showing confirmation that the source of Cushing's Disease is pituitary. Reauthorization: Documentation of positive clinical response to therapy (e.g., a clinically meaningful reduction in 24-hour urinary free cortisol levels, improvement in signs or symptoms of the disease).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

# **SILDENAFIL (PAH)**

### **Products Affected**

• sildenafil (pulmonary arterial hypertension) oral tablet

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use of nitrate products or guanylate cyclase (GC) stimulators
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist or pulmonologist
Coverage Duration	12 months
Other Criteria	Initial: Member must have a diagnosis of pulmonary arterial hypertension (PAH) WHO Group 1. Must have chart note documentation of a right-heart catheterization that indicates the following hemodynamic values: mean pulmonary arterial pressure greater than 20 mmHg, pulmonary capillary wedge pressure or left atrial pressure or left ventricular end-diastolic pressure less than or equal to 15 mmHg, pulmonary vascular resistance greater than or equal to 3 wood units. Member must have WHO Functional Class II-IV symptoms. Clinical criteria incorporated into the quantity limit edits for sildenafil 20 mg tablets require confirmation that the indication is PAH (ie, FDA labeled use) prior to reviewing for quantity exception. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Clinical criteria incorporated into the quantity limit edits for sildenafil 20 mg tablets require confirmation that the indication is PAH (ie, FDA labeled use) prior to reviewing for quantity exception.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

### **SIRTURO**

### **Products Affected**

• SIRTURO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an infectious disease physician or a pulmonologist
Coverage Duration	6 months
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **SKYRIZI**

#### **Products Affected**

- SKYRIZI SUBCUTANEOUS PEN INJECTOR
- SKYRIZI SUBCUTANEOUS SYRINGE
- SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 180 MG/1.2 ML (150 MG/ML), 360 MG/2.4 ML (150 MG/ML)

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

### **SODIUM OXYBATE**

### **Products Affected**

• SODIUM OXYBATE

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with sedative hypnotics or alcohol. Succinic semialdehyde dehydrogenase deficiency.
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by a board certified sleep specialist or neurologist
Coverage Duration	12 months
Other Criteria	Excessive daytime sleepiness (EDS)-Initial: Approve for members with a diagnosis of EDS in members with narcolepsy where the member has tried and failed at least one central nervous system (CNS) stimulant (e.g., methylphenidate, dextroamphetamine), modafinil, or armodafinil (for members 18 years of age and older only). Member must have chart note documentation of a history of excessive daytime sleepiness. Narcolepsy must been confirmed with polysomnography and a multiple sleep latency test (MSLT) with documentation submitted. Cataplexy-Initial: Approve for members using the requested medication for cataplexy treatment in members with narcolepsy when the diagnosis has been confirmed with polysomnography and a multiple sleep latency test (MSLT). Documentation of both is required prior to approval. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

# **SOLTAMOX**

### **Products Affected**

• SOLTAMOX

PA Criteria	Criteria Details
Exclusion Criteria	Members who require concomitant warfarin therapy or have a history of deep vein thrombosis or pulmonary embolus, if the indication for treatment is either reduction of breast cancer incidence in high-risk patients or risk reduction of invasive breast cancer after treatment of DCIS.
Required Medical Information	Diagnosis and must have documentation showing that administration via nasogastric tube is required OR documentation of inability to swallow an intact tablet.
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

### **SOMAVERT**

### **Products Affected**

• SOMAVERT

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an endocrinologist
Coverage Duration	12 months
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **SORAFENIB**

### **Products Affected**

• sorafenib

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with carboplatin and paclitaxil in members with squamous cell lung cancer
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Hepatocellular Carcinoma-Initial: Approve if disease is unresectable. Renal Cell Carcinoma-Initial: Approve if disease is advanced after member has tried at least one systemic therapy. Differentiated Thyroid Carcinoma (DTC): Approve if disease is locally recurrent, metastatic, or progressive and refractory to iodine treatment. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **SPRITAM**

#### **Products Affected**

• SPRITAM ORAL TABLET FOR SUSPENSION 1,000 MG, 250 MG, 500 MG, 750 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, Must have chart documentation of the clinical rationale for why levetiracetam oral tablet and oral solution cannot be used.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	12 months
Other Criteria	Initial: Approve if the member has a diagnosis of seizures. Member had a trial and failure or contraindication of two generic antiepileptic drugs and meets either A, B, or C: A) Member has partial-onset seizures and weighs more than 20 kg, B) Member has myoclonic seizures and will be using medication as adjunctive therapy, OR C) Member has primary generalized tonic-clonic seizures and will be using the requested medication as adjunctive therapy. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician and will continue to use the medication as adjunctive therapy if treating myoclonic or generalized tonic-clonic seizures.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **STIVARGA**

### **Products Affected**

• STIVARGA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Gastrointestinal Stromal Tumor (GIST)-Initial: Approve if the member has a diagnosis of locally advanced, unresectable or metastatic GIST after treatment with imatinib mesylate AND sunitinib malate (Sutent). Hepatocellular Carcinoma (HCC)-Initial: Approve if the member has a diagnosis of HCC and has been previously treated with sorafenib (Nexavar). Metastatic Colorectal Cancer (mCRC)-Initial: Approve if the member has a diagnosis of mCRC and has been previously treated with all the following: A )fluoropyrimidine- (e.g., 5-fluorouracil, capecitabine), oxaliplatin-, and irinotecan-based chemotherapy, B) an anti-VEGF therapy (e.g. bevacizumab), AND C) if member has RAS wild-type (i.e. KRAS and NRAS mutation negative) and medically appropriate, an anti-EGFR therapy (e.g. cetuximab (Erbitux), panitumumab (Vectibix). Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

# **STRENSIQ**

### **Products Affected**

• STRENSIQ

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, genetic and lab test results
Age Restrictions	Disease onset-less than or equal to 18
Prescriber Restrictions	Prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of hypophosphatasia or related disorders.
Coverage Duration	1 year
Other Criteria	Hypophosphatasia - Perinatal/Infantile- and Juvenile-Onset-Patient must meet both A and B for approval. A) Diagnosis is supported by one of the following (i, ii, or iii): i. Molecular genetic testing documenting tissue nonspecific alkaline phosphatase (ALPL) gene mutation OR ii. Low baseline serum alkaline phosphatase activity OR iii. An elevated level of a tissue non-specific alkaline phosphatase substrate (i.e., serum pyridoxal 5'-phosphate, serum or urinary inorganic pyrophosphate, urinary phosphoethanolamine) AND B) Patient meets one of the following (i or ii): i. Patient currently has, or has a history of clinical manifestations consistent with hypophosphatasia (e.g., skeletal abnormalities, premature tooth loss, muscle weakness, poor feeding, failure to thrive, respiratory problems, Vitamin B6-dependent seizures) OR ii. Patient has a family history (parent or sibling) of hypophosphatasia without current clinical manifestations of hypophosphatasia
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

# **SUCRAID**

### **Products Affected**

• SUCRAID

PA Criteria	Criteria Details
Exclusion Criteria	Hypersensitivity to yeast, yeast products, glycerin (glycerol) or papain
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a geneticist, gastroenterologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of congenital diarrheal disorders
Coverage Duration	12 months
Other Criteria	Initial: Approve if the member has a sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID) and meets both A and B: A) Diagnosis of CSID is established by one of the following (i or ii): i) Member has endoscopic biopsy of the small bowel with disaccharidase levels consistent with congenital sucrose-isomaltase deficiency as evidenced by all the following (a, b, c, and d) (test result with reference ranges must be provided): a) Decreased (usually absent) sucrase levels, b) Decreased or normal isomaltase (palatinase), c) Decreased maltase, and d) Decreased or normal lactase OR ii) Member has a molecular genetric test demonstrating homozygous or compound heterozygous pathogenic or likely patogenic sucrase-isomaltase gene variant, AND B) Member has symptomatic congenital sucrose-isomaltase deficiency (e.g. diarrhea, bloating, abdominal cramping). Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

# **SUNITINIB**

### **Products Affected**

• sunitinib malate

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Gastrointestinal Stromal Tumors (GIST)-Initial: Approve if the member has a diagnosis of GIST and had disease progression on or intolerance to imatinib mesylate. Renal Cell Carcinoma (RCC)-Initial: Approve if the member meets A or B: A) Member has advanced disease OR B) Member is at high risk of recurrent RCC following nephrectomy and will be using the requested medication as adjuvant therapy. Pancreatic Neuroendocrine Tumors (pNET)-Initial: Approve if the member has unresectable locally advanced or metastatic disease. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

# **SYMLIN**

#### **Products Affected**

• SYMLINPEN 120

#### • SYMLINPEN 60

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

# **SYNAREL**

### **Products Affected**

• SYNAREL

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	Endometriosis: 18 years and older
Prescriber Restrictions	N/A
Coverage Duration	Central Precocious Puberty: 12 months, Endometriosis: 6 months
Other Criteria	Central Precocious Puberty (CPP)-Initial: Approve. Endometriosis-Initial: Approve if the member has tried one of the following, unless contraindicated, a contraceptive, an oral progesterone or a depomedroxyprogesterone injection. Note: An exception to the requirement for a trial of the above therapies can be made if the member has previously used a gonadotropin-releasing hormone (GnRH) agonist or antagonist for endometriosis. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

# **TABLOID**

### **Products Affected**

• TABLOID

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	2 months
Other Criteria	Approve if requested medication will be used for the remission induction and remission consolidation treatment of acute nonlymphocytic leukemias. Provider must attest medication will not be used during maintenance therapy or similar long term continuous treatments due to the high risk of liver toxicity.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

# **TABRECTA**

### **Products Affected**

• TABRECTA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Non-Small Cell Lung Cancer (NSCLC)-Initial: Approve if the member has metastatic disease with tumors positive for a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

# TACROLIMUS (TOPICAL)

### **Products Affected**

• tacrolimus topical

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Initial: Approve if the member has a diagnosis of atopic dermatitis.  Member must have a trial and failure or contraindication to a topical corticosteroid. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

# TADALAFIL (BPH)

### **Products Affected**

• tadalafil oral tablet 5 mg

PA Criteria	Criteria Details
Exclusion Criteria	Use for erectile dysfunction (ED) without the signs and symptoms of benign prostatic hyperplasia (BPH). Concomitant use of nitrate products or guanylate cyclase (GC) stimulators.
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Initial: Approve if the member has a diagnosis of benign prostatic hyperlasia (BPH) and had a trial and failure or documented contraindication to an alpha blocker (e.g. tamsulosin, alfuzosin) and a 5-alpha reductase inhibitor (e.g. finasteride, dutasteride). Medication will be dosed once daily. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

# TADALAFIL (PAH)

#### **Products Affected**

• tadalafil (pulmonary arterial hypertension) oral tablet 20 mg

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use of nitrate products or guanylate cyclase (GC) stimulators
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist or pulmonologist
Coverage Duration	12 months
Other Criteria	Initial: Member must have a diagnosis of pulmonary arterial hypertension (PAH) WHO Group 1. Must have chart note documentation of a right-heart catheterization that indicates the following hemodynamic values: mean pulmonary arterial pressure greater than 20 mmHg, pulmonary capillary wedge pressure or left atrial pressure or left ventricular end-diastolic pressure less than or equal to 15 mmHg, pulmonary vascular resistance greater than or equal to 3 wood units. Member must have WHO Functional Class II-IV symptoms. Must have a trial and failure or contraindication to sildenafil 20 mg tablets (Revatio) prior to approval. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **TAFINLAR**

#### **Products Affected**

- TAFINLAR ORAL CAPSULE
- TAFINLAR ORAL TABLET FOR SUSPENSION

PA Criteria	Criteria Details
Exclusion Criteria	Members with colorectal cancer or wild-type BRAF solid tumors
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Melanoma-Initial: Approve if the member has melanoma with BRAF V600 mutations as detected by an FDA-approved test and meets either of the following (A, B, or C): A) Member has unresectable or metastatic disease with BRAF V600E mutations and medication will be used as a single agent, B) Member has unresectable or metastatic disease with BRAF V600E or V600K mutations and medication will be used in combination with trametinib (Mekinist), OR C) Member has BRAF V600E or V600K mutations with involvement of lymph node(s) following complete resection and medication will be used as adjuvant treatment in combination with trametinib (Mekinist). Non-Small Cell Lung Cancer (NSCLC)-Initial: Approve if member has NSCLC with the BRAF V600E mutation as detected by an FDA-approved test and requested medication will be used in combination with trametinib (Mekinist). Anaplastic Thyroid Cancer (ATC)-Initial: Approve if member has a diagnosis of locally advanced or metastatic ATC with BRAF V600E mutations as detected by an FDA-approved test and there are no satisfactory locoregional treatment options available for the member. Medication must be used in combination with trametinib (Mekinist). Solid Tumors-Initial: Approve if member has unresectable or metastatic solid tumors with BRAF V600E mutations as detected by an FDA-approved test. Member's disease has progressed following prior treatment and now have no satisfactory alternative

PA Criteria	Criteria Details
	treatment options. Medication must be used in combination with trametinib (Mekinist). Low-Grade Glioma (LGG)-Initial: Approve if member has LGG with BRAF V600E mutations as detected by an FDA-approved test and disease requires systemic therapy. Medication must be used in combination with trametinib (Mekinist). Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

# **TAGRISSO**

### **Products Affected**

• TAGRISSO

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

### **TALZENNA**

#### **Products Affected**

 TALZENNA ORAL CAPSULE 0.1 MG, 0.25 MG, 0.35 MG, 0.5 MG, 0.75 MG, 1 MG

DA COM	
PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Breast Cancer-Initial: Approve if the member has a diagnosis of locally advanced or metastatic disease that has a deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) and is human epidermal growth factor receptor 2 (HER2) negative as determined by an FDA-approved test. Prostate Cancer-Initial: Approve if the member has metastatic castration resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene mutations (e.g. ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, or RAD51C). Requested medication will be used in combination with enzalutamide (Xtandi) and a gonadotropin-releasing hormone (GnRH) analog unless the member has had a bilateral orchiectomy. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

# **TASIGNA**

#### **Products Affected**

• TASIGNA ORAL CAPSULE 150 MG, 200 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

# **TASIMELTEON**

### **Products Affected**

• tasimelteon

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	Non-24-Hour Sleep-Wake Disorder: 18 years and older, Smith-Magenis Syndrome (SMS): 16 years and older
Prescriber Restrictions	Prescribed by or in consultation with a physician specializing in sleep medicine
Coverage Duration	12 months
Other Criteria	Non-24-Hour Sleep-Wake Disorder (Non-24)-Initial: Approve if member is totally blind with no perception of light and has diagnosis of Non-24 is confirmed by either assessment of one physiologic circadian phase marker (e.g., measurement of urinary melatonin levels, dim light melatonin onset, assessment of core body temperature), or if assessment of physiologic circadian phase marker cannot be done, the diagnosis must be confirmed by actigraphy plus evaluation of sleep logs. Smith-Magenis Syndrome (SMS): Approve if member has a confirmed diagnosis of SMS using genetic testing (documentation required). Chart note documentation describing the sleep disturbances (e.g. early sleep onset, early awakening, etc)) and the associated symptoms (e.g. nighttime roaming, excessive daytime sleepiness, etc) must be submitted. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

# **TAZAROTENE**

#### **Products Affected**

- tazarotene topical cream 0.1 %
- tazarotene topical gel

PA Criteria	Criteria Details
Exclusion Criteria	Cosmetic diagnoses are not covered (i.e. solar elastosis, sun damage, wrinkles, actinic damage, melasma, lentigines or freckles, hyperpigmented macules, liver spots, heliodermatosis, dermatoheliosis)
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Plaque Psoriasis-Initial: Approve if the member has less than or equal to 20% of affected body surface area (BSA) and had a trial and failure or contraindication to the use of topical corticosteroids. Acne Vulgaris-Initial: Approve if the member has tried and failed A and B: A) topical antibiotic used to treat acne vulgaris (i.e. clindamycin topical, erythromycin topical) AND B) tretinoin topical. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

# **TAZVERIK**

### **Products Affected**

• TAZVERIK

PA Criteria	Criteria Details
1 A CITICITA	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Epitheliod Sarcoma-Initial: Approve if the member has metastatic or locally advanced disease that is not eligible for complete resection. Follicular Lymphoma-Initial: Approve if the member is an adult with relapsed or refractory disease and meets either A or B: A) According to the prescriber, there are no appropriate alternative therapies, OR B) Member's tumor is positive for an EZH2 mutation as detected by an FDA-approved test and the member has tried at least two prior systemic therapies. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

# **TEPMETKO**

### **Products Affected**

• TEPMETKO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Non-Small Cell Lung Cancer (NSCLC)-Initial: Approve if the member has metastatic disease and the tumor is positive for mesenchymal-epithelial transition (MET) exon 14 skipping mutations as detected by an approved test. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

# **TERIFLUNOMIDE**

### **Products Affected**

• teriflunomide

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with leflunomide (Arava) or other disease-modifying agents used for multiple sclerosis (MS), severe hepatic impairment, and pregnancy
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist or MS specialist.
Coverage Duration	12 months
Other Criteria	Initial: Approve if the member has a diagnosis of relapsing multiple sclerosis (i.e. relapsing-remitting or active secondary progressive disease and clinically-isolatted syndrome). Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

### **TERIPARATIDE**

#### **Products Affected**

• teriparatide subcutaneous pen injector 20 mcg/dose (560mcg/2.24ml)

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

# **TESTOSTERONE (INJECTABLE)**

#### **Products Affected**

• testosterone cypionate

• testosterone enanthate

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	Delayed puberty or induction of puberty in males-12 years and older
Prescriber Restrictions	N/A
Coverage Duration	Delayed puberty or induction of puberty in males-6 months, All others-12 months
Other Criteria	Hypogonadism (primary or secondary) in males-Initial: Approve if the member meets all of the following criteria: 1) Member has persistent signs and symptoms of androgen deficiency prior to start of androgen therapy (i.e. depressed mood, decreased energy, progressive decrease in muscle mass, osteoporosis, loss of libido), 2) Member has had two pre-treatment serum testosterone (total or available) measurements, each taken in the morning on two separate days, AND 3) the two serum testosterone levels are both low, as defined by the normal laboratory reference values. Delayed puberty or induction of puberty in males-Initial: Approve testosterone cypionate or enanthate. Breast cancer in females - Approve testosterone enanthate. Male is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression. Female is defined as an individual with the biological traits of a woman, regardless of the individual's gender identity or gender expression. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician and it is deemed necessary to continue treatment.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	No

# **TESTOSTERONE (NON-INJECTABLE)**

#### **Products Affected**

- testosterone transdermal gel
- testosterone transdermal gel in metereddose pump 20.25 mg/1.25 gram (1.62 %)
- testosterone transdermal gel in packet 1 % (25 mg/2.5gram), 1 % (50 mg/5 gram),

1.62 % (20.25 mg/1.25 gram), 1.62 % (40.5 mg/2.5 gram)

 testosterone transdermal solution in metered pump w/app

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Hypogonadism (primary or secondary) in males-Initial: Approve if the member meets all of the following criteria: 1) Member has persistent signs and symptoms of androgen deficiency prior to start of androgen therapy (i.e. depressed mood, decreased energy, progressive decrease in muscle mass, osteoporosis, loss of libido), 2) Member has had two pre-treatment serum testosterone (total or available) measurements, each taken in the morning on two separate days, AND 3) the two serum testosterone levels are both low, as defined by the normal laboratory reference values. Male is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician and it is deemed necessary to continue treatment.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

### **TETRABENAZINE**

#### **Products Affected**

• tetrabenazine oral tablet 12.5 mg, 25 mg

PA Criteria	Criteria Details
Exclusion Criteria	Actively suicidal. Uncontrolled depression. Currently using a monoamine oxidase inhibitor or reserpine. Hepatic impairment.
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	12 months
Other Criteria	Chorea associated with Huntington's Disease-Initial: Approve if member has a confirmed diagnosis of Huntington's Disease either by Huntington Disease Mutation analysis (with laboratory result indicating expanded CAG repeat of greater than or equal to 36 in the huntington gene) or a positive family history of Huntington's Disease with autosomal dominant inheritance pattern. Member must have clinical signs of Huntington's Disease to include chart documentation of a clinical work-up showing one or more of the following signs: motor (e.g. finger tapping, rigidity), oculomotor, bulbar (e.g. dysarthria, dysphagia), affective (e.g. depression), cognitive. For doses greater than 50mg/day: Member must have chart documentation of a trial of 50mg/day dose with inadequate response OR must be CYP2D6 intermediate or extensive metabolizer (as documented through CYP2D6 genotyping results), must provide documentation of slow dose titration with close monitoring of side effects. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician and showing monitoring for depression and suicidal ideation. For doses greater than 50mg/day: must have chart documentation from prescriber showing inadequate efficacy of lower doses and slow titration of dose with close monitoring of side effects.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	No

# **THALOMID**

#### **Products Affected**

• THALOMID ORAL CAPSULE 100 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	Pregnancy
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist, hematologist, dermatologist, or infectious disease specialist.
Coverage Duration	12 months
Other Criteria	Multiple Myeloma (MM)-Initial: Approve if the member has been newly diagnosed and the requested medication will used in combination with dexamethasone. Erythema Nodosum Leprosum (ENL)-Initial: Approve if the member has a diagnosis of ENL and meets either A, B, or C: A) Medication will be used as acute treatment of the cutaneous manifestations of moderate to severe disease, B) Member has moderate to severe neuritis and requested medication will not be used as monotherapy, OR C) Member will be using the requested medication as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

# **TIBSOVO**

### **Products Affected**

• TIBSOVO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Acute Myeloid Leukemia (AML)-Initial: Approve if the member has a diagnosis of AML with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test and meets either of the following: A) Member will be using the medication in combination with azacitadine or as monotherapy in adults 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy, OR B) Member has relapsed or refractory disease. Myelodysplastic Syndrome (MDS)-Initial: Approve if member has diagnosis of relapsed or refractory MDS. Cholangiocarcinoma-Initial: Approve if the member has locally advanced or metastatic disease that has been previously treated. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

# **TOBRAMYCIN (NEBULIZATION)**

### **Products Affected**

• tobramycin in 0.225 % nacl

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Cystic fibrosis-Initial: Approve if the member has pseudomonas aeruginosa in the culture of the airway (documentation required).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

# **TOLVAPTAN**

### **Products Affected**

• tolvaptan

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with other medications containing tolvaptan, strong CYP3A inhibitors, or hypertonic saline. Members requiring intervention to raise serum sodium urgently to prevent or to treat serious neurological symptoms. Use in members with autosomal dominant polycystic kidney disease (ADPKD) outside of FDA-approved REMS. Members who are unable to respond appropriately to thirst. Hypovolemic hyponatremia and anuria.
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	30 days
Other Criteria	Approve if the member has clinically significant hypervolemic and euvolemic hyponatremia defined as serum sodium less than 125 mEq/L at baseline or less marked hyponatremia that is symptomatic (eg, nausea, vomiting, headache, lethargy, confusion) and has resisted correction with fluid restriction. Provider must have consideration of discontinuation of agents known to cause Syndrome of Inappropriate Antidiuretic Hormone (SIADH) when clinically feasible (e.g. chlorpropamide, selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, clofibrate, carbamazepine, vincristine, nicotine, narcotics, phenothiazines, butyrophenones, ifosfamide, cyclophosphamide, NSAIDs, MDMA, desmopressin, oxytocin, vasopressin, carbamazepine, oxcarbazepine). Must have CrCl greater than 10mL/min. Must be initiated and titrated in hospital setting with close serum sodium monitoring. Must be able to sense and appropriately respond to thirst. If SIADH is underlying cause of hyponatremia, the member must demonstrate all of the following: decreased plasma osmolality of less than 275 mosm/kg, increased urinary osmolality of greater than 100mosm/kg during hypotonicity, urinary

PA Criteria	Criteria Details
	sodium greater than 20mmol/L with normal dietary salt intake, clinical euvolemia, normal thyroid and adrenal function, and no recent use of diuretics within 24 hours of laboratory testing.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

## **TOLVAPTAN (JYNARQUE)**

#### **Products Affected**

- tolvaptan (polycys kidney dis) oral tablet 15 mg, 30 mg
- tolvaptan (polycys kidney dis) oral tablets, sequential

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with strong CYP3A inhibitors or other V2-receptor antagonists. Members who are unable to respond appropriately to thirst. Members with uncorrected abnormal blood serum concentrations, a history of signs or symptoms of significant liver impairment or injury (Note: this does not include uncomplicated polycystic liver disease). Members with hyponatremia, uncorrected urinary outflow obstruction, and anuria.
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with a nephrologist
Coverage Duration	12 months
Other Criteria	Approve if the member has a diagnosis of Autosomal Dominant Polycystic Kidney Disease (ADPKD) confirmed via imagining or genetic testing (documentation required). Member must be at risk of rapid disease progression as indicated by either A or B (documentation required): A) Mayo Imaging Class of 1C, 1D, or 1E OR B) Historical rate of eGFR decline greater than or equal to 3 mL/min per 1.73 m2 per year. Provider attests there are no alternative explanations for loss of eGFR (e.g., vascular disease, uncontrolled hypertension, diabetic nephropathy, proteinuria at least 1 g/d) and/or acute kidney injury. If member does have alternative explanations for rapid eGFR decline, additional information (including magnetic resonance imaging or computed tomography imaging will be undertaken, if not previously performed, PROPKD score greater than 6, a family history with onset of KRT at less than 60 years of age in at least 2 first-line family members) should be acquired to ensure ADPKD as the primary reason for eGFR loss. Documentation showing the member has a current eGFR at least 25 mL/min per 1.73 m2 must be submitted. Provider attests baseline liver function tests (AST, ALT, total bilirubin) prior to

PA Criteria	Criteria Details
	initiation of therapy and will continue to monitor LFTs monthly for the first 18 months, then every 3 months thereafter. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Provider attests to continual monitoring of liver function.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

### TRANSMUCOSAL FENTANYL DRUGS

#### **Products Affected**

• fentanyl citrate buccal lozenge on a handle 200 mcg

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 12 months.
Other Criteria	For breakthrough pain in patients with cancer if patient is unable to swallow, has dysphagia, esophagitis, mucositis, or uncontrollable nausea/vomiting OR patient is unable to take 2 other short-acting narcotics (eg, oxycodone, morphine sulfate, hydromorphone, etc) secondary to allergy or severe adverse events AND patient is on or will be on a long-acting narcotic (eg, Duragesic), or the patient is on intravenous, subcutaneous, or spinal (intrathecal, epidural) narcotics (eg, morphine sulfate, hydromorphone, fentanyl citrate). Clinical criteria incorporated into the quantity limit edits for all transmucosal fentanyl drugs require confirmation that the indication is breakthrough cancer pain (ie, FDA labeled use) prior to reviewing for quantity exception.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

## TRETINOIN (TOPICAL)

### **Products Affected**

• tretinoin topical

PA Criteria	Criteria Details
Exclusion Criteria	Cosmetic diagnoses are not covered (i.e. solar elastosis, sun damage, wrinkles, actinic damage, melasma, lentigines or freckles, hyperpigmented macules, liver spots, heliodermatosis, dermatoheliosis)
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Initial: Approve if member has a diagnosis of acne vulgaris. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

### **TRIENTINE**

#### **Products Affected**

• trientine oral capsule 250 mg

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a gastroenterologist, hepatologist, or liver transplant physician
Coverage Duration	12 months
Other Criteria	Wilson's Disease-Initial: Approve if member has chart note documentation of how the diagnosis was confirmed including at least one of the following: A) genetic testing indicating biallelic pathogenetic mutation in ATP7B gene OR B) Two of the following clinical features (a, b, c, or d): a) liver biopsy findings consistent with Wilson's desease, b) presence of Kayser-Fleisher Ring in cornea, c) serum ceruloplasmin level less than 20 mg/dL, or 24-hour urinary excretion of copper greater than 40 micrograms (1.6 micromoles) per 24 hours. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

## **TRIKAFTA**

#### **Products Affected**

• TRIKAFTA ORAL TABLETS, SEQUENTIAL

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with other medications containing ivacaftor or severe hepatic impairment (Child-Pugh Class C)
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist or a physician who specializes in cystic fibrosis
Coverage Duration	12 months
Other Criteria	Initial: Member must have a diagnosis of cystic fibrosis and at least one F508del mutation in the CFTR gene. If the member's genotype is unknown, an FDA-approved cystic fibrosis mutation test must be used to confirm a mutation in the CFTR gene that is responsive to the requested medication. Provider attestation liver function tests will be assessed prior to initiation of treatment, every 3 months during the first 12 months of treatment, then at least annually thereafter. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician, absent of toxicities, and provider attestation to monitor liver function tests at least annually.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

## TRUQAP

### **Products Affected**

• TRUQAP

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Breast Cancer-Approve if the member has a diagnosis of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has PIK2CA/AKT1/PTEN-alterations as detected by an FDA-approved test and member both A and B: A) Member has locally advanced or metastatic disease AND B) Member had progression with at least one endocrine-based regimen in the metastatic setting (i.e. anastrozole, exemestane, letrozole.) OR member had recurrence on or within 12 months of completing adjuvant endocrine therapy. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **TUKYSA**

#### **Products Affected**

• TUKYSA ORAL TABLET 150 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Breast Cancer-Initial: Approve if the member has human epidermal growth factor receptor 2 (HER2)-positive disease as determined by an FDA-approved test and meets the following A, B, and C: A) Disease is advanced, unresectable or metastatic, B) Member has received one or more prior anti-HER2-based regimens in the metastatic setting, AND C) The requested medication will be used in combination with trastuzumab and capecitabine. Colorectal Cancer-Initial: Approve if the member has wild-type RAS (KRAS wild-type and NRAS wild-type) tumors as determined by an FDA-approved test and member meets the following A, B, and C: A) Member has been previously treated with a fluoropyrimidine, oxaliplatin, and irinotecan-based chemotherapy, B) Member has unresectable or metastatic disease, AND C) Member will be using the requested medication in combination with trastuzumab. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **TURALIO**

#### **Products Affected**

• TURALIO ORAL CAPSULE 125 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Tenosynovial Giant Cell Tumor (TGCT)-Initial: Approve if the member has TGCT associated with severe morbidity or functional limitations. Member must be symptomatic with tumors not amenable to improvement with surgery. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

### **TYENNE**

#### **Products Affected**

• TYENNE AUTOINJECTOR

#### TYENNE SUBCUTANEOUS

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

### **UNBRANDED USTEKINUMAB SC**

#### **Products Affected**

- USTEKINUMAB SUBCUTANEOUS SOLUTION
- USTEKINUMAB SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

## **UPTRAVI**

### **Products Affected**

• UPTRAVI ORAL

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist or cardiologist
Coverage Duration	12 months
Other Criteria	Initial: Approve if the member has a diagnosis of pulmonary arterial hypertension (PAH) with chart notes documenting all the following are required: A) mean arterial pressure (mPAP) measured greater than or equal to 20 mmHg at rest, B) pulmonary artery wedge pressure (PAWP) measured less than or equal to 15 mmHg, AND C) pulmonary vascular resistance (PVR) greater than or equal to 2 woods units. Member must meet either A or B: A) Member has PAH WHO Group 1 confirmed by hemodynamic definitions obtained from a right heart catheterization (RHC) (documentation required) and is currently established on therapy for the diagnosis of PAH
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

### **USTEKINUMAB SC**

#### **Products Affected**

- SELARSDI SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML
- STELARA SUBCUTANEOUS SOLUTION
- STELARA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML
- YESINTEK SUBCUTANEOUS SOLUTION
- YESINTEK SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML

STRICE IS IN	AG/0.5 ML, 90 MG/ML
PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

## **VALCHLOR**

### **Products Affected**

• VALCHLOR

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	Cutaneous lymphoma-18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Cutaneous Lymphomas (Note-includes mycosis fungoides/Sezary syndrome, primary cutaneous B-cell lymphoma, primary cutaneous CD30+ T-cell lymphoproliferative disorders)-approve.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

## **VALTOCO**

### **Products Affected**

• VALTOCO

PA Criteria	Criteria Details
Exclusion Criteria	Acute narrow-angle glaucoma
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	12 months
Other Criteria	Approve if the member is using the requested medication for the acute treatment of intermittent, sterotypic episodes of frequent seizure activity (i.e. seizure clusters, acute repetitive seizures) that are distinct from the member's usual seizure pattern. Member must be currently receiving maintenance antiepileptic medication(s) and will continue to receive the current maintenance therapy. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

## **VANFLYTA**

### **Products Affected**

• VANFLYTA

PA Criteria	Criteria Details
Exclusion Criteria	Members with severe hypokalemia, hypomagnesemia, long QT syndrome, or in members with a history of ventricular arrhythmias or torsades de pointes
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Acute Myeloid Leukemia (AML)-Initial: Approve if the member has AML that is newly diagnosed and is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test. Member must be using the requested medication in combination with standard cytarabine and anthracycline induction and cytarabine consolidation or as maintenance monotherapy following consolidation chemotherapy. Provider attests member will not be using the medication as maintenance monotherapy following an allogenic hematopoietic stem cell transplantation (HSCT). Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

### **VEMLIDY**

### **Products Affected**

• VEMLIDY

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a gastroenterologist, hepatologist, transplant physician, or infectious disease physician
Coverage Duration	12 months
Other Criteria	Initial: Approve if the member has diagnosis of chronic hepatitis B confirmed by all the following A, B, and C: A) HBsAg positive or negative for at least 6 months, B) Documented evidence of active viral replication (HBeAg+ and HBV DNA greater than 100,000 copies per mL), AND C) Documented evidence of active liver disease as demonstarated by persistent elevation in serum alanine aminotransferase (ALT) greater than two times the upper limit of normal OR moderate to severe hepatitis on biopsy. Must have a trial and failure or contraindication to entecavir and tenofovir disoproxil fumarate. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **VENCLEXTA**

#### **Products Affected**

100 MG, 50 MG	
PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with strong CYP3A4 inhibitors at initiation and during the ramp-up phase in members with CLL/SLL
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Acute Myeloid Leukemia (AML)-Initial: Approve if the member has diagnosis of AML and will be using the medication in combination with azacitadine, decitabine, or low-dose cytarabine in members meeting either A or B: A) Member is newly diagnosed and 75 years or older OR B) Members who have comorbidities that preclude the use of intensive induction chemotherapy. Small Lymphocytic Lymphoma (SLL) and Chronic Lymphocytic Leukemia (CLL)-Initial: Approve if the member has a diagnosis of CLL or SLL and has tried and failed or has a contraindication to ibrutinib (Imbruvica) prior to approval. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

## **VERQUVO**

### **Products Affected**

• VERQUVO

PA Criteria	Criteria Details
Exclusion	Concomitant use with other soluble guanylate cyclase stimulators or
Criteria	members who are pregnant
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist
Coverage Duration	12 months
Other Criteria	Initial: Approve if member has a diagnosis of heart failure with a reduced ejection fraction. Member must be symptomatic and have a left ventricular ejection fraction (LVEF) less than 45%. Must have had a recent hospitalization for heart failure (e.g., within the past 6 months) or received recent outpatient intravenous diuretics (e.g. furosemide within the past 3 months). Must have an attestation from the prescriber that the member is on at least one other drug used for chronic heart failure at maximally tolerated doses (e.g., beta-blockers, ACE inhibitors, or sacubitril/valsartan). Must have a systolic blood pressure greater than or equal to 100 mmHg. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **VERSACLOZ**

### **Products Affected**

• VERSACLOZ

DA Cuitania	Cuitania Dataila
PA Criteria	Criteria Details
Exclusion Criteria	Elderly members with dementia-related psychosis
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Initial: Approve if member has a diagnosis of treatment-resistant schizophrenia or will be used to reduce suicidal behavior in members with schizophrenia or schizoaffective disorder. Must provide clinical rationale why clozapine orally disentigrating tablet (ODT) is not expected to produce the same clinical results as would be expected with the requested medication. Member must have a trial and failure or contraindication to a generic formulary antipsychotic: aripiprazole, asenapine, lurasidone, olanzapine, quetiapine, risperidone, or ziprasidone AND one of the following brand medications: Caplyta, Rexulti, Secuado, or Vraylar. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **VERZENIO**

### **Products Affected**

VERZENIO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Initial: Approve if the member has a diagnosis of breast cancer that is hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative as detected by an FDA-approved test and meets either A, B, C, or D: A) Member has early breast cancer that is node-positive at high risk of recurrence (e.g. members with greater than or equal to 4 positive lymph nodes or 1-3 positive lymph nodes with one or more of the following: Grade 3 disease or tumor size greater than or equal to 5 cm) and will be using the requested medication in combination with endocrine therapy (i.e. anastrozole, exemestane), B) Member has advanced or metastatic disease and will be using the requested medication in combination with an aromatase inhibitor (i.e. letrozole, anastrozole) as initial endocrine therapy, C) Member has advanced or metastatic disease progression following endocrine therapy and will be using the requested medication in combination with fulvestrant, OR D) Member has advanced or metastatic disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. Requested medication will be used as monotherapy. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	No

### **VIGABATRIN**

### **Products Affected**

vigabatrin

• vigadrone

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Complex Partial Seizures-Initial: Approve if the member as a diagnosis of refractory complex partial seizures (i.e. focal impaired awareness seizures) and meets the following (A, B, and C): A) Member has a trial and failure to two combination anticonvulsant regimens where at least one of the medications contains phenytoin or carbamazepine, B) Member will be using the requested medication in combination with at least one other anticonvulsant (i.e. lamotrigine, topiramate), AND C) Member will undergo vision testing prior to beginning treatment. Infantile Spasms: Initial: Approve if the member has diagnosis of infantile spasms and medication will be used as monotherapy for members aged 1 month to 2 years of age for whom the potential benefit outweighs the potential risk of vision loss. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician and memberwill continue to undergo vision testing at least every 3 months during treatment.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

### **VITRAKVI**

#### **Products Affected**

• VITRAKVI ORAL CAPSULE 100 MG, • VITRAKVI ORAL SOLUTION 25 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Initial: Approve if the member has a diagnosis of solid tumors that meets all the following A, B, and C: A) Member has a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation as determined by an FDA-approved test, B) tumors are metastatic or surgical resection is likely to result in severe morbidity, AND C) there are no satisfactory alternative treatments or the patient has disease progression following treatment. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

### **VIZIMPRO**

### **Products Affected**

• VIZIMPRO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Non-Small Cell Lung Cancer (NSCLC)-Initial: Approve if the member has metastatic disease with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an approved test and member will be using the requested medication as first-line treatment. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

## **VONJO**

### **Products Affected**

• VONJO

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with strong CYP3A4 inhibitors or inducers
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Myelofibrosis (MF), including Primary MF, Post-Polycythemia Vera MF, and Post-Essential Thrombocythemia MF-Initial: Approve if the member has a platelet count of less than 50 X 10 9/L (less than 50,000 cells/mcL) and a diagnosis of intermediate-2 or high-risk disease. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

### **VORANIGO**

#### **Products Affected**

• VORANIGO ORAL TABLET 10 MG, 40 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Initial: Approve if member has a Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation as detected by an approved test. Member will be using the requested medication as monotherapy following surgery including biopsy, sub-total resection, or gross total resection. Provider attests liver laboratory tests (AST, ALT, GGT, total bilirubin and ALP) have been monitored prior to the start of the requested medication and monitoring will continue every 2 weeks during the first two months of treatment, then monthly for the first 2 years of treatment. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

# VORICONAZOLE (ORAL)

#### **Products Affected**

- voriconazole oral suspension for reconstitution
- voriconazole oral tablet

PA Criteria	Criteria Details
Exclusion Criteria	Coadministration with rifampin, carbamazepine, long-acting barbiturates, efavirenz, ritonavir, rifabutin, ergot alkaloids, and St. Johns Wort due to risk of loss of efficacy. Coadministration with naloxegol, tolvaptan, finerenone and lurasidone due to risk of adverse reactions.  Coadministration with venetoclax at initiation and during the ramp-up phase in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) due to increased risk of adverse reactions.  Coadministration with pimozide, quinidine, sirolimus or ivabradine due to risk of serious adverse reactions.
Required Medical Information	Diagnosis, For suspension: must have chart note documentation of the clinical rationale for why tablets cannot be used.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	3 months
Other Criteria	Approve if the member has a diagnosis of either A, B, C, or D (Lab results and documentation required): A) invasive aspergillosis, B) candidemia in non-neutropenics and other deep tissue Candida infections, C) esophageal candidiasis, OR D) serious fungal infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani, in members intolerant of, or refractory to, other therapy.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

## **VOWST**

### **Products Affected**

• VOWST

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with a gastroenterologist or infectious disease specialist
Coverage Duration	30 days
Other Criteria	Initial: Approve if the member has a diagnosis of recurrent Clostridioides difficile infection (CDI). Provider must submit documentation of a stool test positive for toxigenic Clostridioides difficile. Must have a trial and failure or contraindication to fecal microbiota, live-jslm and standard of care treatment (defined as 10-21 days of treatment with vancomycin 125mg orally four times daily or fidaxomycin (Dificid) 200mg orally twice daily) within 2-4 days before initiating requested medication. Member must drink 296 mL of magnesium citrate on the day before and at least 8 hours prior to taking the first dose of medication. Members unable to take magnesium citrate due to impaired kidney function should receive polyethylene glycol electrolyte solution instead. Reauthorization: Additional authorizations for treatment are made on a case-by-case basis, are subject to the above criteria, and require chart documentation describing the previous response and clinical rationale for re-treatment.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	Yes

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

### **VUMERITY**

### **Products Affected**

• VUMERITY

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with other disease-modifying agents used for multiple sclerosis (MS)
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of MS.
Coverage Duration	12 months
Other Criteria	Initial: Approve if member has a diagnosis of relapsing forms of multiple sclerosis (RRMS). Member must have tried and failed one generic MS disease modifying agent prior to approval. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

# WELIREG

### **Products Affected**

• WELIREG

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

### **WINREVAIR**

### **Products Affected**

• WINREVAIR

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

### **XALKORI**

#### **Products Affected**

- XALKORI ORAL CAPSULE
- XALKORI ORAL PELLET 150 MG, 20 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Dignosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Non-Small Cell Lung Cancer (NSCLC)-Initial: Approve if the member has metastatic disease that meets either A or B: A) Disease is anaplastic lymphona kinase (ALK) positive as detected by an FDA approved test. Member must have a trial and failure of alectinib (Alecensa) prior to approval or a medical reason as to why it cannot be started or continued OR B) Disease is ROS1-positive as detected by an FDA approved test. Anaplastic Large Cell Lymphoma (ALCL)-Initial: Approve if the member has systemic disease that is ALK-positive as detected by an FDA-approved test that is relapsed or refractory. Inflammatory Myofibroblastic Tumor (IMT)-Initial: Approve if member has unresectable, recurrent, or refractory disease that is ALK-positive as detected by an FDA-approved test. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

# **XDEMVY**

### **Products Affected**

• XDEMVY

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

### **XELJANZ**

#### **Products Affected**

- XELJANZ ORAL SOLUTION
- XELJANZ ORAL TABLET

XELJANZ XR

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

# **XERMELO**

### **Products Affected**

• XERMELO

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

# **XGEVA**

### **Products Affected**

• XGEVA

PA Criteria	Criteria Details
Exclusion Criteria	Members with hypocalcemia. Concomitant use with other bisphosphonate therapies
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Bone Metastases of Solid Tumors-Initial: Approve if the member has a diagnosis of solid tumor cancer with documented bone metastases. The member must have experienced disease progression or an intolerance or contraindication following treatment with zoledronic acid or pamidronate. Hypercalcemia of Malignancy-Initial: Approve if the member has a definite diagnosis defined as albumin-corrected calcium of greater than 12.5 mg/dL and the member has tried and failed or has a documented contraindication to intravenous bisphonate therapy (e.g. pamidronate or zoledronic acid). Multiple Myeloma (MM)-Initial: Approve if member has diagnosis of MM and has experienced disease progression or an intolerance or contraindication following treatment with zoledronic acid or pamidronate. Giant Cell Tumor of Bone-Initial: Approve if member has unresectable disease or if surgical resection is likely to result in severe morbidity. Note: For all indications a B versus D determination will me made prior to application of clinical criteria. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

PA Criteria	Criteria Details
Part B Prerequisite	Yes
Prerequisite Therapy Required	Yes

### **XIFAXAN**

#### **Products Affected**

• XIFAXAN ORAL TABLET 200 MG, 550 MG

PA Criteria	Criteria Details
Exclusion Criteria	Travelers Diarrhea complicated by fever or blood in stool or diarrhea due to pathogens other than Escherichia coli
Required Medical Information	Diagnosis
Age Restrictions	Travelers Diarrhea: 12 years or older, HE and IBS-D: 18 years or older
Prescriber Restrictions	For hepatic encephalopathy: No prescriber restriction. For IBS-D: Must be prescribed by or in consultation with a gastroenterologist, hepatologist, or infectious disease physician.
Coverage Duration	Traveler's Diarrhea and IBS-D: 14 days. Hepatic Encephalopathy: 12 months
Other Criteria	Travelers Diarrhea (TD): Approve if provider attest member's diagnosis has not been complicated by fever nor bloody stools AND TD is caused by non-invasive strains of E. coli. Member must have previous treatment, intolerance or contraindication to ciprofloxacin, levofloxacin, or azithromycin. Irritable bowel syndrome with Diarrhea (IBS-D)-Approve if member has diagnosis of diarrhea-predominant irritable bowel syndrome (IBS-D). Must have previous treatment, intolerance or contraindication of loperamide AND antispasmodic (e.g. dicyclomine) with inadequate response to these therapies. Must have chart note documentation on how the diagnosis was confirmed. Reauthorization-IBS-D: Must have chart note documentation indicating recurrence. Recurrence must not have been treated more than twice with the the same regimen. Hepatic Encephalopathy (HE)-Initial: Approve if member has diagnosis of HE. Must have previous treatment, intolerance or contraindication of lactulose. Reauthorization-HE: Approve if the member has responded positively to therapy as determined by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **XOLAIR**

#### **Products Affected**

- XOLAIR SUBCUTANEOUS AUTO-INJECTOR 150 MG/ML, 300 MG/2 ML, 75 MG/0.5 ML
- XOLAIR SUBCUTANEOUS RECON SOLN
- XOLAIR SUBCUTANEOUS SYRINGE 150 MG/ML, 300 MG/2 ML, 75 MG/0.5 ML

SOLN	
PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

# **XOSPATA**

### **Products Affected**

• XOSPATA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Acute Myeloid Leukemia (AML)-Initial: Approve if the member has a diagnosis of relapsed or refractory AML with an FLT3 mutation as detected by an FDA-approved test. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

### **XPOVIO**

#### **Products Affected**

XPOVIO ORAL TABLET 100
 MG/WEEK (50 MG X 2), 40 MG/WEEK
 (10 MG X 4), 40 MG/WEEK (40 MG X
 1), 40MG TWICE WEEK (40 MG X 2),

60 MG/WEEK (60 MG X 1), 60MG TWICE WEEK (120 MG/WEEK), 80 MG/WEEK (40 MG X 2), 80MG TWICE WEEK (160 MG/WEEK)

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Multiple Myeloma (MM)-Initial: Approve if the member has a diagnosis of multiple myeloma and meets either of the following (A or B): A) Member has received at least one prior therapy for MM and the requested medication will be taken in combination with dexamethasone OR B) Member has received at least four prior regimens for MM and disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. Member must take the requested medication in combination with dexamethasone. Diffuse Large B-cell Lymphoma (DLBCL)-Initial: Approve if the member has a diagnosis of relapsed or refractory disease, not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two prior lines of systemic therapy. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **XTANDI**

#### **Products Affected**

- XTANDI ORAL CAPSULE
- XTANDI ORAL TABLET 40 MG, 80 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Initial: Approve if the member has a diagnosis of prostate cancer and meets either: A) Disease is castration-resistant and the member will be using the medication concurrently with a gonadotropin-releasing hormone (GnRH) analog or if the member has had a bilateral orchiectomy, B) Disease is non-metastatic, castration-sensitive with biochemical recurrence at high risk for metastasis (i.e. prostate-specific antigen (PSA) doubling time less than or equal to 9 months), C) Disease is metastatic, castration-sensitive and the member will be using the medication concurrently with a gonadotropin-releasing hormone (GnRH) analog or if the member has had a bilateral orchiectomy. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

# **ZARXIO**

### **Products Affected**

• ZARXIO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Cancer/AML, oncologist or a hematologist. Cancer patients receiving BMT and PBPC, prescribed by or in consultation with an oncologist, hematologist, or a physician who specializes in transplantation. Radiation-expertise in acute radiation. SCN - hematologist.
Coverage Duration	chemo/SCN/AML-6mo.MDS-3mo.PBPC,BMT- 3mo. Other-12mo.
Other Criteria	Cancer patients receiving chemotherapy, approve if the patient meets one of the following conditions: patient is receiving myelosuppressive anticancer medications that are associated with a high risk of febrile neutropenia (the risk is at least 20 percent based on the chemotherapy regimen), patient is receiving myelosuppressive anti-cancer medications that are associated with a risk of febrile neutropenia but the risk is less than 20 percent based on the chemotherapy regimen and the patient has one or more risk factors for febrile neutropenia (eg, aged greater than or equal to 65 years, prior chemotherapy or radiation therapy, persistent neutropenia, bone marrow involvement by tumor, recent surgery and/or open wounds, liver and/or renal dysfunction, poor performance status or HIV infection, OR the patient has had a neutropenic complication from prior chemotherapy and did not receive prophylaxis with a colony stimulating factor and a reduced dose or frequency of chemotherapy may compromise treatment.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	No

# ZEJULA

### **Products Affected**

• ZEJULA ORAL TABLET 100 MG, 200 MG, 300 MG

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

# **ZELBORAF**

### **Products Affected**

• ZELBORAF

PA Criteria	Criteria Details
Exclusion Criteria	Members with wild-type BRAF melanoma
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Initial: Approve if the member has a BRAF V600 mutation as detected by an FDA-approved test and meets either A or B: A) Member has unresectable or metastatic melanoma with a BRAF V600E mutation OR B) Member has Erdheim-Chester disease. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

### **ZEPOSIA**

#### **Products Affected**

• ZEPOSIA

- ZEPOSIA STARTER PACK (7-DAY)
- ZEPOSIA STARTER KIT (28-DAY)

PA Criteria	Criteria Details
Exclusion Criteria	MS-Concurrent use with other disease-modifying agents used for multiple sclerosis.UC- Concurrent Use with a Biologic or with a Targeted Synthetic Disease-modifying Antirheumatic Drug (DMARD) for Ulcerative Colitis
Required Medical Information	Diagnosis
Age Restrictions	UC-18 years and older
Prescriber Restrictions	MS-Prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of multiple sclerosis. UC-Prescribed by or in consultation with a gastroenterologist
Coverage Duration	12 months
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

# **ZOLINZA**

### **Products Affected**

• ZOLINZA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Cutaneous T-Cell Lymphoma (CTCL)-Initial: Approve if the member has a diagnosis of CTCL that is progressive, persistent, or recurrent following two prior systemic therapies. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

# **ZONISADE**

### **Products Affected**

• ZONISADE

PA Criteria	Criteria Details
Exclusion Criteria	Members with a hypersensitivity to sulfonamides.
Required Medical Information	Diagnosis and must have documentation showing that administration via nasogastric tube is required OR documentation of inability to swallow an intact tablet.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	12 months
Other Criteria	Initial: Approve if member has a diagnosis of partial-onset seizures (i.e. focal seizures). Member must have tried and failed or have a contraindication to two or more generic formulary antiepileptic medications used to treat the same indication: levetiracetam, lamotrigine, carbamazepine, zonisamide, divalproex, gabapentin, or topiramate. Member must be using the medication as adjunctive treatment.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **ZTALMY**

### **Products Affected**

• ZTALMY

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

# **ZURZUVAE**

#### **Products Affected**

• ZURZUVAE ORAL CAPSULE 20 MG, 25 MG, 30 MG

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off-Label Uses	Pending CMS Review
Part B Prerequisite	Pending CMS Review
Prerequisite Therapy Required	Pending CMS Review

# **ZYDELIG**

### **Products Affected**

• ZYDELIG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Chronic Lymphocytic leukemia (CLL)-Initial: Member must have a confirmed diagnosis of CLL. Member must have tried and failed ibrutinib (Imbruvica) prior to approval. Requested medication must be for relapsed disease and used in combination with rituximab, in members for whom rituximab alone would be considered appropriate therapy due to other comobidities.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

### **ZYKADIA**

### **Products Affected**

• ZYKADIA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Non-Small Cell Lung Cancer (NSCLC)-Initial: Approve if the member has metastatic disease that is anaplastic lymphona kinase (ALK) positive as detected by an FDA approved test. Member must have a trial and failure of alectinib (Alecensa) prior to approval or a medical reason as to why it cannot be started or continued. Reauthorization: Approve if the member has responded positively to therapy as determined by the prescribing physician. Documentation required that disease progression has not occurred.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

#### PART B VERSUS PART D

#### **Products Affected**

- acetylcysteine solution 100 mg/ml (10 %), 200 mg/ml (20 %)
- acyclovir sodium intravenous solution 50 mg/ml
- albuterol sulfate inhalation solution for nebulization 0.63 mg/3 ml, 1.25 mg/3 ml, 2.5 mg/3 ml (0.083 %), 2.5 mg/0.5 ml, 5 mg/ml
- amphotericin b injection recon soln 50 mg
- amphotericin b liposome intravenous suspension for reconstitution 50 mg
- aprepitant oral capsule 125 mg, 40 mg, 80 mg
- aprepitant oral capsule, dose pack 125 mg
   (1)-80 mg
- arformoterol inhalation solution for nebulization 15 mcg/2 ml
- azathioprine oral tablet 50 mg
- budesonide inhalation suspension for nebulization 0.25 mg/2 ml, 0.5 mg/2 ml, 1 mg/2 ml
- CLINIMIX 5%/D15W SULFITE FREE INTRAVENOUS PARENTERAL SOLUTION 5 %
- CLINIMIX 4.25%/D10W SULF FREE INTRAVENOUS PARENTERAL SOLUTION 4.25 %
- CLINIMIX 4.25%/D5W SULFIT FREE INTRAVENOUS PARENTERAL SOLUTION 4.25 %
- CLINIMIX 5%-D20W(SULFITE-FREE) INTRAVENOUS PARENTERAL SOLUTION 5 %
- cromolyn inhalation solution for nebulization 20 mg/2 ml
- cyclophosphamide oral capsule 25 mg, 50 mg
- CYCLOPHOSPHAMIDE ORAL TABLET 25 MG, 50 MG
- cyclosporine modified oral capsule 100 mg, 25 mg, 50 mg
- cyclosporine modified oral solution 100 mg/ml

- cyclosporine oral capsule 100 mg, 25 mg
- dronabinol oral capsule 10 mg, 2.5 mg, 5 mg
- ENGERIX-B (PF) INTRAMUSCULAR SUSPENSION 20 MCG/ML
- ENGERIX-B (PF) INTRAMUSCULAR SYRINGE 20 MCG/ML
- ENGERIX-B PEDIATRIC (PF)
   INTRAMUSCULAR SYRINGE 10
   MCG/0.5 ML
- everolimus (immunosuppressive) oral tablet 0.25 mg, 0.5 mg, 0.75 mg, 1 mg
- FIRMAGON KIT W DILUENT SYRINGE SUBCUTANEOUS RECON SOLN 120 MG, 80 MG
- formoterol fumarate inhalation solution for nebulization 20 mcg/2 ml
- gengraf oral capsule 100 mg, 25 mg
- granisetron hcl oral tablet 1 mg
- HEPLISAV-B (PF) INTRAMUSCULAR SYRINGE 20 MCG/0.5 ML
- IMOVAX RABIES VACCINE (PF) INTRAMUSCULAR RECON SOLN 2.5 UNIT
- intralipid intravenous emulsion 20 %
- ipratropium bromide inhalation solution 0.02 %
- ipratropium-albuterol inhalation solution for nebulization 0.5 mg-3 mg(2.5 mg base)/3 ml
- JYLAMVO ORAL SOLUTION 2 MG/ML
- JYNNEOS (PF) SUBCUTANEOUS SUSPENSION 0.5X TO 3.95X 10EXP8 UNIT/0.5
- levalbuterol hcl inhalation solution for nebulization 0.31 mg/3 ml, 0.63 mg/3 ml, 1.25 mg/0.5 ml, 1.25 mg/3 ml
- methotrexate sodium (pf) injection solution 25 mg/ml
- methotrexate sodium injection solution 25 mg/ml
- *methotrexate sodium oral tablet 2.5 mg*

- methylprednisolone oral tablet 16 mg, 32 mg, 4 mg, 8 mg
- mycophenolate mofetil oral capsule 250 mg
- mycophenolate mofetil oral suspension for reconstitution 200 mg/ml
- mycophenolate mofetil oral tablet 500 mg
- mycophenolate sodium oral tablet,delayed release (dr/ec) 180 mg, 360 mg
- ondansetron hcl oral solution 4 mg/5 ml
- ondansetron hcl oral tablet 4 mg, 8 mg
- ondansetron oral tablet, disintegrating 4 mg, 8 mg
- pentamidine inhalation recon soln 300 mg
- PLENAMINE INTRAVENOUS PARENTERAL SOLUTION 15 %
- premasol 10 % intravenous parenteral solution 10 %
- PROGRAF ORAL GRANULES IN PACKET 0.2 MG, 1 MG

- RABAVERT (PF) INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 2.5 UNIT
- RECOMBIVAX HB (PF)
   INTRAMUSCULAR SUSPENSION 10
   MCG/ML, 40 MCG/ML, 5 MCG/0.5 ML
- RECOMBIVAX HB (PF)
   INTRAMUSCULAR SYRINGE 10
   MCG/ML, 5 MCG/0.5 ML
- sirolimus oral solution 1 mg/ml
- sirolimus oral tablet 0.5 mg, 1 mg, 2 mg
- tacrolimus oral capsule 0.5 mg, 1 mg, 5 mg
- travasol 10 % intravenous parenteral solution 10 %
- TROPHAMINE 10 % INTRAVENOUS PARENTERAL SOLUTION 10 %
- XATMEP ORAL SOLUTION 2.5 MG/ML
- YUPELRI INHALATION SOLUTION FOR NEBULIZATION 175 MCG/3 ML

#### **Details**

This drug may be covered under Medicare Part B or D depending upon the circumstances. Information may need to be submitted describing the use and setting of the drug to make the determination.

### Index

A	AUSTEDO XR TITRATION KT(WK1-4)
abiraterone oral tablet 250 mg, 500 mg 1	ORAL TABLET, EXT REL 24HR DOSE
abirtega1	PACK 12-18-24-30 MG30
acetylcysteine solution 100 mg/ml (10 %),	AUVELITY19
200 mg/ml (20 %)	AVMAPKI-FAKZYNJA31
acitretin2	AVONEX INTRAMUSCULAR PEN
ACTIMMUNE 3, 4	INJECTOR KIT32
acyclovir sodium intravenous solution 50	AVONEX INTRAMUSCULAR SYRINGE
mg/ml 388	KIT32
ADBRY7	AYVAKIT33, 34
ADEMPAS 8, 9	azathioprine oral tablet 50 mg388
AIMOVIG AUTOINJECTOR	В
AKEEGA	BALVERSA ORAL TABLET 3 MG, 4
albuterol sulfate inhalation solution for	MG, 5 MG35
nebulization 0.63 mg/3 ml, 1.25 mg/3 ml,	BENLYSTA SUBCUTANEOUS 36, 37
2.5 mg/3 ml (0.083 %), 2.5 mg/0.5 ml, 5	BESREMI
mg/ml	BETASERON SUBCUTANEOUS KIT39
alcohol pads	bexarotene oral
ALECENSA	bexarotene topical41
alosetron	bosentan oral tablet
ALUNBRIG ORAL TABLET 180 MG, 30	BOSULIF ORAL CAPSULE 100 MG, 50
MG, 90 MG17	MG44
ALUNBRIG ORAL TABLETS,DOSE	BOSULIF ORAL TABLET 100 MG, 400
PACK	MG, 500 MG44
ambrisentan	BOTOX
amphotericin b injection recon soln 50 mg	BRAFTOVI
	BRIVIACT ORAL SOLUTION49
amphotericin b liposome intravenous	BRIVIACT ORAL TABLET49
suspension for reconstitution 50 mg 388	BRUKINSA ORAL CAPSULE50
aprepitant oral capsule 125 mg, 40 mg, 80	budesonide inhalation suspension for
mg	nebulization 0.25 mg/2 ml, 0.5 mg/2 ml, 1
aprepitant oral capsule,dose pack 125 mg	mg/2 ml
(1)- 80 mg (2)	budesonide oral tablet, delayed and
ARCALYST22, 23	ext.release51
arformoterol inhalation solution for	buprenorphine
nebulization 15 mcg/2 ml	C
ARIKAYCE24, 25	CABOMETYX54, 55
armodafinil	CALQUENCE (ACALABRUTINIB MAL)
AUGTYRO ORAL CAPSULE 160 MG, 40	56
MG28, 29	CAPLYTA27
AUSTEDO ORAL TABLET 12 MG, 6 MG,	CAPELSA ORAL TABLET 100 MG, 300
9 MG30	MG57
AUSTEDO XR	carglumic acid
AUSTEDU AK	
	CAYSTON59

CLINIMIX 5%/D15W SULFITE FREE	D
INTRAVENOUS PARENTERAL	dalfampridine75
SOLUTION 5 % 388	DANZITEN
CLINIMIX 4.25%/D10W SULF FREE	dasatinib oral tablet 100 mg, 140 mg, 20 mg,
INTRAVENOUS PARENTERAL	50 mg, 70 mg, 80 mg78
SOLUTION 4.25 % 388	DAURISMO ORAL TABLET 100 MG, 25
CLINIMIX 4.25%/D5W SULFIT FREE	MG79
INTRAVENOUS PARENTERAL	deferasirox oral tablet80
SOLUTION 4.25 % 388	deferasirox oral tablet, dispersible80
CLINIMIX 5%-D20W(SULFITE-FREE)	dermacinrx lidocan167
INTRAVENOUS PARENTERAL	DIACOMIT ORAL CAPSULE 250 MG,
SOLUTION 5 % 388	500 MG82
clobazam oral suspension	DIACOMIT ORAL POWDER IN PACKET
clobazam oral tablet61	250 MG, 500 MG82
COBENFY 62	diclofenac sodium topical drops83
COBENFY STARTER PACK 62	diclofenac sodium topical gel 3 %84
COMETRIQ ORAL CAPSULE 100	DIFICID ORAL SUSPENSION FOR
MG/DAY(80 MG X1-20 MG X1), 140	RECONSTITUTION85
MG/DAY(80 MG X1-20 MG X3), 60	DIFICID ORAL TABLET85
MG/DAY (20 MG X 3/DAY) 63	dihydroergotamine injection99, 100
COPIKTRA64	dihydroergotamine nasal
CORLANOR ORAL SOLUTION 65	dimethyl fumarate oral capsule,delayed
COSENTYX (2 SYRINGES)66, 67	release(dr/ec) 120 mg, 120 mg (14)- 240
COSENTYX PEN66, 67	mg (46), 240 mg86
COSENTYX PEN (2 PENS)66, 67	DRIZALMA SPRINKLE ORAL
COSENTYX SUBCUTANEOUS	CAPSULE, DELAYED REL SPRINKLE
SYRINGE 150 MG/ML, 75 MG/0.5 ML	20 MG, 30 MG, 40 MG, 60 MG87
66, 67	dronabinol oral capsule 10 mg, 2.5 mg, 5 mg
COSENTYX UNOREADY PEN66, 67	388
COTELLIC	droxidopa88
CRESEMBA ORAL CAPSULE 186 MG,	DUPIXENT PEN SUBCUTANEOUS PEN
74.5 MG69, 70	INJECTOR 200 MG/1.14 ML, 300 MG/2
cromolyn inhalation solution for	ML89
nebulization 20 mg/2 ml 388	DUPIXENT SYRINGE SUBCUTANEOUS
CRYSVITA71, 72	SYRINGE 200 MG/1.14 ML, 300 MG/2
cyclophosphamide oral capsule 25 mg, 50	ML89
mg 388	E
CYCLOPHOSPHAMIDE ORAL TABLET	eltrombopag olamine oral powder in packet
25 MG, 50 MG 388	12.5 mg, 25 mg243
cyclosporine modified oral capsule 100 mg,	eltrombopag olamine oral tablet 12.5 mg, 25
25 mg, 50 mg	mg, 50 mg, 75 mg243
cyclosporine modified oral solution 100	EMGALITY PEN90
mg/ml	EMGALITY SYRINGE
cyclosporine oral capsule 100 mg, 25 mg388	SUBCUTANEOUS SYRINGE 120
CYSTAGON	MG/ML90
CYSTARAN	EMSAM91, 92

ENBREL MINI	FETZIMA ORAL CAPSULE,EXTENDED
ENBREL SUBCUTANEOUS SOLUTION	RELEASE 24 HR19
93	fingolimod112
ENBREL SUBCUTANEOUS SYRINGE 93	FINTEPLA113
ENBREL SURECLICK 93	FIRMAGON KIT W DILUENT SYRINGE
ENGERIX-B (PF) INTRAMUSCULAR	SUBCUTANEOUS RECON SOLN 120
SUSPENSION 20 MCG/ML 388	MG, 80 MG388
ENGERIX-B (PF) INTRAMUSCULAR	fluconazole in nacl (iso-osm) intravenous
SYRINGE 20 MCG/ML 388	piggyback 200 mg/100 ml, 400 mg/200
ENGERIX-B PEDIATRIC (PF)	ml20
INTRAMUSCULAR SYRINGE 10	flucytosine114
MCG/0.5 ML 388	formoterol fumarate inhalation solution for
ENVARSUS XR94	nebulization 20 mcg/2 ml388
EPIDIOLEX	FOTIVDA115
ERIVEDGE101	FRUZAQLA ORAL CAPSULE 1 MG, 5
ERLEADA ORAL TABLET 240 MG, 60	MG116
MG102	FYCOMPA ORAL SUSPENSION117
erlotinib oral tablet 100 mg, 150 mg, 25 mg	G
103	GAMASTAN149
eslicarbazepine oral tablet 200 mg, 400 mg,	GAMUNEX-C INJECTION SOLUTION 1
600 mg, 800 mg21	GRAM/10 ML (10 %)149
EUCRISA	GATTEX 30-VIAL118, 119
EULEXIN 105	GATTEX ONE-VIAL 118, 119
everolimus (antineoplastic) oral tablet 106, 107	GAUZE PAD TOPICAL BANDAGE 2 X 2
everolimus (antineoplastic) oral tablet for	GAVRETO120
suspension 2 mg, 3 mg, 5 mg 106, 107	gefitinib
everolimus (immunosuppressive) oral tablet	gengraf oral capsule 100 mg, 25 mg388
0.25 mg, 0.5 mg, 0.75 mg, 1 mg 388	GILOTRIF121
F	glatiramer subcutaneous syringe 20 mg/ml,
FANAPT27	40 mg/ml
FANAPT TITRATION PACK A	glatopa subcutaneous syringe 20 mg/ml, 40
FANAPT TITRATION PACK B	mg/ml
FANAPT TITRATION PACK C27	glutamine (sickle cell)124
FASENRA PEN	GOMEKLI ORAL CAPSULE 1 MG, 2 MG
FASENRA SUBCUTANEOUS SYRINGE	125
10 MG/0.5 ML, 30 MG/ML 108, 109	GOMEKLI ORAL TABLET FOR
felbamate oral suspension	SUSPENSION125
fentanyl citrate buccal lozenge on a handle	granisetron hel oral tablet 1 mg388
200 mcg	H
fentanyl transdermal patch 72 hour 100	HADLIMA6
mcg/hr, 12 mcg/hr, 25 mcg/hr, 50 mcg/hr,	HADLIMA PUSHTOUCH6
75 mcg/hr111	HADLIMA(CF)6
FETZIMA ORAL CAPSULE,EXT REL	HADLIMA(CF) PUSHTOUCH6
24HR DOSE PACK 20 MG (2)- 40 MG	HAEGARDA
(26)	

HEPLISAV-B (PF) INTRAMUSCULAR	JYNNEOS (PF) SUBCUTANEOUS
SYRINGE 20 MCG/0.5 ML 388	SUSPENSION 0.5X TO 3.95X 10EXP8
HERNEXEOS 129	UNIT/0.5388
I	K
IBRANCE 130	KALYDECO ORAL GRANULES IN
IBTROZI131	PACKET153
icatibant5	KALYDECO ORAL TABLET153
ICLUSIG132, 133	KERENDIA ORAL TABLET 10 MG, 20
IDHIFA	MG154
imatinib oral tablet 100 mg, 400 mg135, 136	KESIMPTA PEN155
IMBRUVICA ORAL CAPSULE 140 MG,	KISQALI ORAL TABLET 200 MG/DAY
70 MG 137	(200 MG X 1), 400 MG/DAY (200 MG X
IMBRUVICA ORAL SUSPENSION 137	2), 600 MG/DAY (200 MG X 3) 156, 157
IMBRUVICA ORAL TABLET 140 MG,	KOSELUGO158
280 MG, 420 MG 137	KRAZATI159
IMKELDI138, 139	L
IMOVAX RABIES VACCINE (PF)	lapatinib160
INTRAMUSCULAR RECON SOLN 2.5	LAZCLUZE ORAL TABLET 240 MG, 80
UNIT388	MG161
IMPAVIDO140	LEDIPASVIR-SOFOSBUVIR11
INCRELEX141, 142	lenalidomide162, 163
INLYTA ORAL TABLET 1 MG, 5 MG 143	LENVIMA ORAL CAPSULE 10 MG/DAY
INQOVI 144	(10 MG X 1), 12 MG/DAY (4 MG X 3),
INREBIC 145	14 MG/DAY(10 MG X 1-4 MG X 1), 18
INSULIN PEN NEEDLE NEEDLE 29	MG/DAY (10 MG X 1-4 MG X2), 20
GAUGE X 1/2 81	MG/DAY (10 MG X 2), 24 MG/DAY(10
INSULIN SYRINGE (DISP) U-100	MG X 2-4 MG X 1), 4 MG, 8 MG/DAY
SYRINGE 0.3 ML 29 GAUGE, 1 ML 29	(4 MG X 2) 164, 165
GAUGE X 1/2 81	LEUKERAN166
intralipid intravenous emulsion 20 % 388	leuprolide subcutaneous kit126
ipratropium bromide inhalation solution	levalbuterol hel inhalation solution for
0.02 %	nebulization 0.31 mg/3 ml, 0.63 mg/3 ml,
ipratropium-albuterol inhalation solution for	1.25 mg/0.5 ml, 1.25 mg/3 ml388
nebulization 0.5 mg-3 mg(2.5 mg base)/3	lidocaine topical adhesive patch, medicated 5
ml	%167
ITOVEBI ORAL TABLET 3 MG, 9 MG	lidocan iii167
	lidocan iv167
ivabradine	lidocan v167
ivermectin oral tablet 3 mg	liraglutide
IWILFIN 150	LIVTENCITY 168, 169
J	LONSURF 172, 173
JAKAFI	LORBRENA ORAL TABLET 100 MG, 25
JAYPIRCA ORAL TABLET 100 MG, 50	MG174
MG	LUMAKRAS ORAL TABLET 120 MG,
JYLAMVO ORAL SOLUTION 2 MG/ML	240 MG, 320 MG
	LUPRON DEPOT126

LUPRON DEPOT (3 MONTH) 126	morphine oral tablet extended release 100
LUPRON DEPOT (4 MONTH) 126	mg, 15 mg, 200 mg, 30 mg, 60 mg 170,
LUPRON DEPOT (6 MONTH) 126	171
LYBALVI 27	MOUNJARO123
LYNPARZA176, 177	MULTAQ195
LYSODREN	mycophenolate mofetil oral capsule 250 mg
LYTGOBI ORAL TABLET 12 MG/DAY	
(4 MG X 3), 16 MG/DAY (4 MG X 4),	mycophenolate mofetil oral suspension for
20 MG/DAY (4 MG X 5)179	reconstitution 200 mg/ml389
M	mycophenolate mofetil oral tablet 500 mg
MARPLAN180, 181	389
MATULANE	mycophenolate sodium oral tablet,delayed
MAVYRET ORAL PELLETS IN PACKET	
	release (dr/ec) 180 mg, 360 mg389 N
	NAYZILAM196
megestrol oral suspension 400 mg/10 ml (40	NEEDLES, INSULIN DISP.,SAFETY
mg/ml), 625 mg/5 ml (125 mg/ml) 184	SYRINGE 1 ML 29 GAUGE X 1/2205
megestrol oral tablet	NERLYNX
MEKINIST ORAL RECON SOLN 185, 186	NEXLIZET 198, 199
MEKINIST ORAL TABLET 0.5 MG, 2	nilutamide200
MG185, 186	NINLARO201
MEKTOVI 187	nitisinone202
memantine oral capsule, sprinkle, er 24hr 188	NIVESTYM203, 204
memantine oral solution 188	NUBEQA206
memantine oral tablet	NUCALA SUBCUTANEOUS AUTO-
mercaptopurine oral suspension 189	INJECTOR207
methadone intensol170, 171	NUCALA SUBCUTANEOUS RECON
methadone oral concentrate170, 171	SOLN207
methadone oral solution 10 mg/5 ml, 5 mg/5	NUCALA SUBCUTANEOUS SYRINGE
ml170, 171	100 MG/ML, 40 MG/0.4 ML207
methadone oral tablet 10 mg, 5 mg. 170, 171	NUEDEXTA208, 209
methadose oral concentrate170, 171	NUPLAZID210, 211
methotrexate sodium (pf) injection solution	NURTEC ODT212
25 mg/ml	0
methotrexate sodium injection solution 25	octreotide acetate
mg/ml 388	octreotide, microspheres
methotrexate sodium oral tablet 2.5 mg . 388	ODOMZO215
methylergonovine oral	OFEV216, 217
methylprednisolone oral tablet 16 mg, 32	OGSIVEO ORAL TABLET 100 MG, 150
mg, 4 mg, 8 mg	MG, 50 MG218
metyrosine	OJEMDA ORAL SUSPENSION FOR
mifepristone oral tablet 300 mg	RECONSTITUTION219
modafinil oral tablet 100 mg, 200 mg 193	OJEMDA ORAL TABLET 400 MG/WEEK
MODEYSO	(100 MG X 4), 500 MG/WEEK (100 MG
177	X 5), 600 MG/WEEK (100 MG X 6)219
	OJJAARA220
	Out 11 11(1 1

OMNITROPE127, 128	PLENAMINE INTRAVENOUS
ondansetron hcl oral solution 4 mg/5 ml 389	PARENTERAL SOLUTION 15 %389
ondansetron hcl oral tablet 4 mg, 8 mg 389	POMALYST237
ondansetron oral tablet, disintegrating 4 mg,	posaconazole oral tablet, delayed release
8 mg 389	(dr/ec)238, 239
ONUREG221	premasol 10 % intravenous parenteral
OPIPZA ORAL FILM 10 MG, 2 MG, 5 MG	solution 10 %
	PREVYMIS ORAL PELLETS IN PACKET
ORGOVYX	240, 241
ORKAMBI ORAL GRANULES IN	PREVYMIS ORAL TABLET 240, 241
PACKET	PROCRIT
ORKAMBI ORAL TABLET 224	PROGRAF ORAL GRANULES IN
ORSERDU ORAL TABLET 345 MG, 86	PACKET 0.2 MG, 1 MG389
·	PROLASTIN-C INTRAVENOUS
MG	SOLUTION16
OTEZLA STARTER ORAL	
	PROLIA
TABLETS, DOSE PACK 10 MG (4)- 20	PULMOZYME244
MG (51), 10 MG (4)-20 MG (4)-30 MG	pyrimethamine245
(47)	Q
OZEMPIC SUBCUTANEOUS PEN	QINLOCK246
INJECTOR 0.25 MG OR 0.5 MG (2	QULIPTA247
MG/3 ML), 1 MG/DOSE (4 MG/3 ML),	R
2 MG/DOSE (8 MG/3 ML) 123	RABAVERT (PF) INTRAMUSCULAR
P	SUSPENSION FOR
PANRETIN 227	RECONSTITUTION 2.5 UNIT389
pazopanib228, 229	RALDESY 248, 249
PEMAZYRE230	RECOMBIVAX HB (PF)
penicillamine oral tablet	INTRAMUSCULAR SUSPENSION 10
pentamidine inhalation recon soln 300 mg	MCG/ML, 40 MCG/ML, 5 MCG/0.5 ML
	389
perampanel oral tablet 10 mg, 12 mg, 2 mg,	RECOMBIVAX HB (PF)
4 mg, 6 mg, 8 mg 117	INTRAMUSCULAR SYRINGE 10
pimecrolimus	MCG/ML, 5 MCG/0.5 ML389
PIQRAY ORAL TABLET 200 MG/DAY	REPATHA 250, 251
(200 MG X 1), 250 MG/DAY (200 MG	REPATHA PUSHTRONEX 250, 251
X1-50 MG X1), 300 MG/DAY (150 MG	REPATHA SURECLICK 250, 251
X 2) 234	RETACRIT96, 97
pirfenidone oral capsule	RETEVMO ORAL TABLET 120 MG, 160
pirfenidone oral tablet 801 mg	MG, 40 MG, 80 MG252, 253
PLEGRIDY INTRAMUSCULAR 236	REVCOVI
PLEGRIDY SUBCUTANEOUS PEN	REVUFORJ ORAL TABLET 110 MG, 160
INJECTOR 125 MCG/0.5 ML, 63	MG, 25 MG255
MCG/0.5 ML- 94 MCG/0.5 ML 236	REXULTI ORAL TABLET27
PLEGRIDY SUBCUTANEOUS SYRINGE	REZDIFFRA
125 MCG/0.5 ML, 63 MCG/0.5 ML- 94	REZLIDHIA258
•	REZUROCK
MCG/0.5 ML	KEZUKUCK239

riluzole	SOLTAMOX281
RINVOQ ORAL TABLET EXTENDED	SOMAVERT282
RELEASE 24 HR 15 MG, 30 MG, 45	sorafenib283
MG 261	SPRITAM ORAL TABLET FOR
roflumilast	SUSPENSION 1,000 MG, 250 MG, 500
ROMVIMZA	MG, 750 MG284
ROZLYTREK ORAL CAPSULE 100 MG,	STELARA SUBCUTANEOUS
200 MG	SOLUTION338
ROZLYTREK ORAL PELLETS IN	STELARA SUBCUTANEOUS SYRINGE
PACKET	45 MG/0.5 ML, 90 MG/ML338
RUBRACA265, 266	STIVARGA285, 286
rufinamide oral suspension	STRENSIQ
rufinamide oral tablet 200 mg, 400 mg 267	SUCRAID
RYBELSUS	sunitinib malate291
RYDAPT	SYMLINPEN 120292
S	SYMLINPEN 60
sajazir5	SYMPAZAN61
sapropterin	SYNAREL
SCEMBLIX ORAL TABLET 100 MG, 20	T
MG, 40 MG273	TABLOID294
SECUADO	TABRECTA295
SELARSDI SUBCUTANEOUS SYRINGE	
	tacrolimus oral capsule 0.5 mg, 1 mg, 5 mg
45 MG/0.5 ML, 90 MG/ML 338	
SIGNIFOR	tacrolimus topical
sildenafil (pulmonary arterial hypertension)	tadalafil (pulm. hypertension)298
oral tablet	tadalafil oral tablet 5 mg
SIMLANDI(CF) AUTOINJECTOR	TAFINLAR ORAL CAPSULE 299, 300
SUBCUTANEOUS AUTO-INJECTOR,	TAFINLAR ORAL TABLET FOR
KIT 40 MG/0.4 ML, 80 MG/0.8 ML 6	SUSPENSION299, 300
SIMLANDI(CF) SUBCUTANEOUS	TAGRISSO301
SYRINGE KIT 20 MG/0.2 ML, 40	TALZENNA ORAL CAPSULE 0.1 MG,
MG/0.4 ML, 80 MG/0.8 ML 6	0.25 MG, 0.35 MG, 0.5 MG, 0.75 MG, 1
sirolimus oral solution 1 mg/ml 389	MG302, 303
sirolimus oral tablet 0.5 mg, 1 mg, 2 mg 389	TASIGNA ORAL CAPSULE 150 MG, 200
SIRTURO	MG, 50 MG304
SKYRIZI SUBCUTANEOUS PEN	tasimelteon
INJECTOR 278	tazarotene topical cream 0.1 %307
SKYRIZI SUBCUTANEOUS SYRINGE	tazarotene topical gel307
278	TAZVERIK308
SKYRIZI SUBCUTANEOUS WEARABLE	TEPMETKO309
INJECTOR 180 MG/1.2 ML (150	teriflunomide310
MG/ML), 360 MG/2.4 ML (150 MG/ML)	teriparatide subcutaneous pen injector 20
278	mcg/dose (560mcg/2.24ml)311
SODIUM OXYBATE279, 280	testosterone cypionate
sodium phenylbutyrate 232	testosterone enanthate
SOFOSBUVIR-VELPATASVIR 10	testosterone transdermal gel 314, 315

testosterone transdermal gel in metered-dose	V
pump 20.25 mg/1.25 gram (1.62 %) 314,	VALCHLOR339
315	VALTOCO340
testosterone transdermal gel in packet 1 %	VANFLYTA341
(25 mg/2.5gram), 1 % (50 mg/5 gram),	VEMLIDY342
1.62 % (20.25 mg/1.25 gram), 1.62 %	VENCLEXTA ORAL TABLET 10 MG,
(40.5 mg/2.5 gram)314, 315	100 MG, 50 MG343
testosterone transdermal solution in metered	VENCLEXTA STARTING PACK343
pump w/app314, 315	VERQUVO344
tetrabenazine oral tablet 12.5 mg, 25 mg316,	VERSACLOZ345
317	VERZENIO
THALOMID ORAL CAPSULE 100 MG,	vigabatrin
50 MG318, 319	vigadrone
TIBSOVO320, 321	VITRAKVI ORAL CAPSULE 100 MG, 25
tobramycin in 0.225 % nacl	MG350
tolvaptan323, 324	VITRAKVI ORAL SOLUTION350
tolvaptan (polycys kidney dis) oral tablet 15	VIZIMPRO351
mg, 30 mg325, 326	VONJO
tolvaptan (polycys kidney dis) oral tablets,	VORANIGO ORAL TABLET 10 MG, 40
sequential325, 326	MG
•	voriconazole intravenous20
topiramate oral solution	
travasol 10 % intravenous parenteral solution 10 %	voriconazole oral suspension for
	reconstitution
tretinoin topical	voriconazole oral tablet
tridacaine ii	VOWST
trientine oral capsule 250 mg	VRAYLAR ORAL CAPSULE27
TRIKAFTA ORAL TABLETS,	VUMERITY359
SEQUENTIAL	W
TRINTELLIX	WELIREG
TROPHAMINE 10 % INTRAVENOUS	WINREVAIR361
PARENTERAL SOLUTION 10 % 389	X
TRULICITY 123	XALKORI ORAL CAPSULE 362, 363
TRUQAP	XALKORI ORAL PELLET 150 MG, 20
TUKYSA ORAL TABLET 150 MG, 50	MG, 50 MG
MG332, 333	XATMEP ORAL SOLUTION 2.5 MG/ML
TURALIO ORAL CAPSULE 125 MG 334	389
TYENNE AUTOINJECTOR 335	XCOPRI MAINTENANCE PACK60
TYENNE SUBCUTANEOUS 335	XCOPRI ORAL TABLET 100 MG, 150
U	MG, 200 MG, 25 MG, 50 MG60
UPTRAVI ORAL 337	XCOPRI TITRATION PACK60
USTEKINUMAB SUBCUTANEOUS	XDEMVY364
SOLUTION 336	XELJANZ ORAL SOLUTION365
USTEKINUMAB SUBCUTANEOUS	XELJANZ ORAL TABLET365
SYRINGE 45 MG/0.5 ML, 90 MG/ML	XELJANZ XR365
	XERMELO366
	XGEVA 367, 368

XIFAXAN ORAL TABLET 200 MG, 550	Y
MG369, 370	YESINTEK SUBCUTANEOUS
XOLAIR SUBCUTANEOUS AUTO-	SOLUTION338
INJECTOR 150 MG/ML, 300 MG/2 ML,	YESINTEK SUBCUTANEOUS SYRINGE
75 MG/0.5 ML	45 MG/0.5 ML, 90 MG/ML338
XOLAIR SUBCUTANEOUS RECON	YUPELRI INHALATION SOLUTION
SOLN 371	FOR NEBULIZATION 175 MCG/3 ML
XOLAIR SUBCUTANEOUS SYRINGE	389
150 MG/ML, 300 MG/2 ML, 75 MG/0.5	${f Z}$
ML 371	ZARXIO 377, 378
XOSPATA 372	ZEJULA ORAL TABLET 100 MG, 200
XPOVIO ORAL TABLET 100 MG/WEEK	MG, 300 MG379
(50 MG X 2), 40 MG/WEEK (10 MG X	ZELBORAF380
4), 40 MG/WEEK (40 MG X 1), 40MG	ZEPOSIA381
TWICE WEEK (40 MG X 2), 60	ZEPOSIA STARTER KIT (28-DAY)381
MG/WEEK (60 MG X 1), 60MG TWICE	ZEPOSIA STARTER PACK (7-DAY)381
WEEK (120 MG/WEEK), 80 MG/WEEK	ZOLINZA382
(40 MG X 2), 80MG TWICE WEEK (160	ZONISADE383
MG/WEEK)373, 374	ZTALMY384
XTANDI ORAL CAPSULE375, 376	ZURZUVAE ORAL CAPSULE 20 MG, 25
XTANDI ORAL TABLET 40 MG, 80 MG	MG, 30 MG385
375, 376	ZYDELIG386
	ZYKADIA387

